


**CUMULATIVE
SUPPLEMENT 10
October 2011**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Cumulative Supplement 10

October 2011

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**CUMULATIVE SUPPLEMENT 10
October 2011**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALCON INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON LABORATORIES INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON RESEARCH LTD (ALCON RES)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
JOHNSON AND JOHNSON PHARMACEUTICAL (JOHNSON AND JOHNSON)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
MCNEIL PEDIATRICS (MCNEIL PED)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO BIOTECH PRODUCTS LP (ORTHO BIOTECH)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)

ORTHO MCNEIL JANSSEN
PHARMACEUTICAL INC
(ORTHO MCNEIL JANSSEN)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

ORTHO MCNEIL JANSSEN
PHARMACEUTICAL INC
(ORTHO MCNEIL JANSSEN)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

PADDOCK LABORATORIES INC
(PADDOCK LABS)

PADDOCK LABORATORIES LLC
(PADDOCK LLC)

SHIONOGI PHARMA INC
(SHIONOGI PHARMA)

SHIONOGI INC
(SHIONOGI INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001

LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2010</u>	<u>MAR 2011</u>	<u>JUN 2011</u>	<u>SEPT 2011</u>	<u>DEC 2011</u>
DRUG PRODUCTS LISTED	13838	14029	14309	14271	
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)	2468 (17.2%)	2452 (17.2%)	
MULTISOURCE	11267 (81.4%)	11463 (81.7%)	11752 (82.1%)	11743 (82.3%)	
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)	11592 (81.0%)	11573 (81.1%)	
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)	160 (1.1%)	170 (1.2%)	
EXCEPTIONS ¹	89 (0.6%)	89 (0.6%)	89 (0.6%)	76 (0.5%)	
NEW MOLECULAR ENTITIES					
APPROVED	8	6	8	6	
NUMBER OF APPLICANTS	752	768	784	801	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The

application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 31ST EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

1-1

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+	CENTOCOR ORTHO	250MG	N202379	001	Apr 28, 2011	Apr	NEWA
+	JANSSEN BIOTECH	250MG	N202379	001	Apr 28, 2011	Aug	CAHN

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	STRIDES ARCOLAB LTD	25MG	A090912	001	Jul 27, 2011	Jul	NEWA
AB		50MG	A090912	002	Jul 27, 2011	Jul	NEWA
AB		100MG	A090912	003	Jul 27, 2011	Jul	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011	Aug	NEWA
---------------	------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN
AA		500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

>A>	AB	+	WATSON LABS INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Oct	CAHN
>D>	AB	+	WATSON PHARMS	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Oct	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN
----	-------------------	-------------------	---------	-----	--------------	-----	------

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006	Aug	DISC
------------------------	-------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>A>	AA	@ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001		Aug	DISC
		VINTAGE PHARMS	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011	Oct	NEWA

SUSPENSION; ORAL

CAPITAL AND CODEINE

@ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001		Aug	DISC
------------------------	--------------------	---------	-----	--	-----	------

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ WATSON LABS	300MG;15MG	A089997	001	Dec 28, 1994	Aug	DISC
@	300MG;30MG	A089998	001	Dec 28, 1994	Aug	DISC
@	300MG;60MG	A089999	001	Dec 28, 1994	Aug	DISC
@ WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003	Jul	DISC
@	300MG;30MG	A040443	002	Jan 22, 2003	Jul	DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ WATSON LABS FLORIDA 300MG;60MG

A040443 003 Jan 22, 2003 Jul DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA BOCA PHARMA 325MG/15ML;7.5MG/15ML

A040894 001 Jul 19, 2011 Jul NEWA

AA + MIKART 325MG/15ML;7.5MG/15ML

A040482 001 Sep 25, 2003 Jul CTEC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA BOCA PHARMA 300MG;5MG

A090415 001 Jan 24, 2011 Feb CTEC

AB 300MG;5MG

A090415 001 Jan 24, 2011 Jan NEWA

AA 300MG;7.5MG

A090415 002 Jan 24, 2011 Feb CTEC

AB 300MG;7.5MG

A090415 002 Jan 24, 2011 Jan NEWA

AA 300MG;10MG

A090415 003 Jan 24, 2011 Feb CTEC

AB 300MG;10MG

A090415 003 Jan 24, 2011 Jan NEWA

AA + MIKART 300MG;5MG

A040658 001 Jan 19, 2006 Mar CRLD

AA 300MG;5MG

A040658 001 Jan 19, 2006 Feb CTEC

AA + 300MG;7.5MG

A040556 002 Mar 24, 2006 Feb CTEC

AA + 300MG;10MG

A040556 001 Jun 23, 2004 Feb CTEC

@ RANBAXY 500MG;5MG

A040825 001 Aug 16, 2007 May DISC

@ 500MG;10MG

A040824 001 Aug 16, 2007 May DISC

@ RANBAXY LABS LTD 325MG;10MG

A040826 001 Aug 16, 2007 May DISC

@ 750MG;7.5MG

A040822 001 Aug 16, 2007 May DISC

@ WATSON LABS 500MG;2.5MG

A040123 003 Mar 04, 1996 Aug DISC

@ 500MG;7.5MG

A040123 004 Mar 04, 1996 Aug DISC

@ 650MG;7.5MG

A040123 001 Mar 04, 1996 Aug DISC

@ 650MG;10MG

A040123 002 Mar 04, 1996 Aug DISC

@ WATSON LABS FLORIDA 500MG;5MG

A040493 001 May 28, 2003 Jul DISC

@ 750MG;7.5MG

A040494 001 May 28, 2003 Jul DISC

LORTAB

AA UCB INC 500MG;5MG

A087722 001 Jul 09, 1982 Jan CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

@ ACTAVIS TOTOWA 500MG;5MG

A040199 001 Dec 30, 1998 Jul DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

@ ACTAVIS TOTOWA 325MG;5MG

A040203 001 Mar 15, 1999 Jul DISC

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

@ MYLAN 650MG;65MG

A083978 001 Aug DISC

@ VINTAGE PHARMS 650MG;65MG

A040507 001 Jul 30, 2003 Mar DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

@ XANODYNE PHARM 650MG;100MG

N017122 002 Jan DISC

DARVOCET-N 50

@ XANODYNE PHARM 325MG;50MG

N017122 001 Jan DISC

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

@ CORNERSTONE 325MG;100MG

A076743 001 May 07, 2004 Mar DISC

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	@ CORNERSTONE	500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC
	@ MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Apr	DISC
AB		650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN
+	MYLAN	650MG;100MG	A070145	001	Jun 12, 1985	Aug	CRLD
	@ TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC
	@ VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC
	@	650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC
	@ WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007	Aug	DISC
	@	650MG;100MG	A077677	002	Mar 16, 2007	Aug	DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

>A>	AB	HERITAGE PHARMS INC	500MG	A090779	001	Jul 14, 2011	Oct	CAHN
>D>	AB	INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Oct	CAHN
	AB		500MG	A090779	001	Jul 14, 2011	Jul	NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

	@ ACTAVIS MID ATLANTIC	2%	A087146	001		Aug	DISC
--	------------------------	----	---------	-----	--	-----	------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993	Jun	CAHN
---	-----------------	-----------	---------	-----	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

	@ ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997	Aug	DISC
AB	MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN

CREAM; TOPICAL

ZOVIRAX

+	VALEANT INTL	5%	N021478	001	Dec 30, 2002	Jul	CAHN
---	--------------	----	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

ZOVIRAX

+	VALEANT INTL	5%	N018604	001	Mar 29, 1982	Jul	CAHN
---	--------------	----	---------	-----	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

	@ ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997	Aug	DISC
	@	800MG	A074870	002	Jun 05, 1997	Aug	DISC
AB	MYLAN	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
AB		800MG	A074976	002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	+	APP PHARMS	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Aug	CRLD
		@ HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997	Aug	DISC
		@	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC
		ZOVIRAX						
		@ GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N018603	001	Oct 22, 1982	Aug	DISC
		@	EQ 1GM BASE/VIAL	N018603	002	Jun 29, 1989	Aug	DISC

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	MEDA PHARMS	5%;1%	N022436	001	Jul 31, 2009	May	CTNA
+	VALEANT INTL	5%;1%	N022436	001	Jul 31, 2009	Aug	CAHN

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@	BAXTER HLTHCARE	3MG/ML	A076501	001	Jun 16, 2004	Sep	DISC
---	-----------------	--------	---------	-----	--------------	-----	------

ALBENDAZOLE

TABLET; ORAL

ALBENZA

+	COREPHARMA	200MG	N020666	001	Jun 11, 1996	Jun	CAHN
---	------------	-------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

	@	ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995	Aug	DISC
AN		RTEDOSE CORP	EQ 0.083% BASE	A077839	001	Dec 16, 2008	Jul	CAHN
AN		WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Aug	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

>A>		SPRAY, METERED; INHALATION						
>A>		COMBIVENT RESPIMAT						
>A>	+	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011	Oct	NEWA

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+	ALLERGAN	0.25%	N022134	001	Jul 28, 2010	Jun	CAHN
---	----------	-------	---------	-----	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

ACLOVATE

AB	+	NYCOMED US	0.05%	N018702	001	Dec 14, 1982	Mar	CAHN
----	---	------------	-------	---------	-----	--------------	-----	------

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN D5-W

@	HOSPIRA	5ML/100ML;5GM/100ML	A083263	001		Aug	DISC
---	---------	---------------------	---------	-----	--	-----	------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB		MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
AB			EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
	@	SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
	@		EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
	@		EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
	@		EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC
	@		EQ 70MG BASE	A075871	005	Apr 22, 2009	Mar	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	APOTEX INC	10MG	A079013	001	Jul 18, 2011	Jul	NEWA
AB	MYLAN	10MG	A079014	001	Jul 18, 2011	Jul	NEWA
AB	SUN PHARMA GLOBAL	10MG	A079057	001	Jul 18, 2011	Jul	NEWA
AB	TEVA PHARMS	10MG	A079056	001	Jul 18, 2011	Jul	NEWA
AB	TORRENT PHARMS	10MG	A079054	001	Jul 18, 2011	Jul	NEWA
UROXATRAL							
AB	+ SANOFI AVENTIS US	10MG	N021287	001	Jun 12, 2003	Jul	CFTG

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
AB		300MG	A090637	002	Mar 16, 2011	Feb	NEWA

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

AP	+ MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Jul	CAHN
----	-----------------------	--------------------	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Sep	NEWA
AB		1MG	A078469	002	Sep 29, 2011	Sep	NEWA
AB		2MG	A078469	003	Sep 29, 2011	Sep	NEWA
AB		3MG	A078469	004	Sep 29, 2011	Sep	NEWA
AB	AUROBINDO PHARMA USA	0.5MG	A090871	001	Jun 07, 2011	May	NEWA
AB		1MG	A090871	002	Jun 07, 2011	May	NEWA
AB		2MG	A090871	003	Jun 07, 2011	May	NEWA
AB		3MG	A090871	004	Jun 07, 2011	May	NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	May	CAHN
		0.25MG	N020700	002	Nov 19, 1996	May	CAHN
		0.5MG	N020700	003	Nov 19, 1996	May	CAHN
+		1MG	N020700	004	Nov 19, 1996	May	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	100MG	A077659	001	Feb 23, 2006	Jul	DISC
---	----------------	-------	---------	-----	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997	Aug	DISC
---	---------	---------------------	---------	-----	--------------	-----	------

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 11.4%

@ HOSPIRA 11.4% (11.4GM/100ML) N017957 003 Aug 09, 1982 Aug DISC

NOVAMINE 15%

@ HOSPIRA 15% (15GM/100ML) N017957 004 Nov 28, 1986 Aug DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

@ HOSPIRA 3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML N019683 001 Nov 07, 1988 Aug DISC

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

@ HOSPIRA 4.25%;36.8MG/100ML;20GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML N019683 002 Nov 07, 1988 Aug DISC

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

@ HOSPIRA 4.25%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML N019683 003 Nov 07, 1988 Aug DISC

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

@ HOSPIRA 3.5%;25GM/100ML N019681 001 Nov 01, 1988 Aug DISC

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 3.5%;5GM/100ML N019681 002 Nov 01, 1988 Aug DISC

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA 4.25%;10GM/100ML N019681 004 Nov 01, 1988 Aug DISC

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

@ HOSPIRA 4.25%;20GM/100ML N019681 005 Nov 01, 1988 Aug DISC

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

@ HOSPIRA 4.25%;25GM/100ML N019681 003 Nov 01, 1988 Aug DISC

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

@ HOSPIRA 5%;25GM/100ML N019681 006 Nov 01, 1988 Aug DISC

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML N019682 001 Nov 01, 1988 Aug DISC

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA 4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML N019682 002 Nov 01, 1988 Aug DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

NEXTERONE

>A>	AP	BAXTER HLTHCARE	50MG/ML	N022325 001	Dec 24, 2008	Oct	CAHN
>A>	+		150MG/100ML (1.5MG/ML)	N022325 002	Nov 16, 2010	Oct	CAHN
>A>	+		360MG/200ML (1.8MG/ML)	N022325 003	Nov 16, 2010	Oct	CAHN
>D>	AP	PRISM PHARMS	50MG/ML	N022325 001	Dec 24, 2008	Oct	CAHN
>D>	+		150MG/100ML (1.5MG/ML)	N022325 002	Nov 16, 2010	Oct	CAHN
>D>	+		360MG/200ML (1.8MG/ML)	N022325 003	Nov 16, 2010	Oct	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552 001	Apr 08, 2009	Apr	CAHN
AB		EQ 5MG BASE	A078552 002	Apr 08, 2009	Apr	CAHN
AB		EQ 10MG BASE	A078552 003	Apr 08, 2009	Apr	CAHN
	@ GEDEON RICHTER USA	EQ 2.5MG BASE	A077333 001	Jul 17, 2007	Jul	DISC
	@	EQ 5MG BASE	A077333 002	Jul 17, 2007	Jul	DISC
	@	EQ 10MG BASE	A077333 003	Jul 17, 2007	Jul	DISC
AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771 001	Apr 12, 2011	Mar	NEWA
AB		EQ 5MG BASE	A077771 002	Apr 12, 2011	Mar	NEWA
AB		EQ 10MG BASE	A077771 003	Apr 12, 2011	Mar	NEWA
AB	PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007	May	CAHN
AB		EQ 5MG BASE	A078131 002	Sep 04, 2007	May	CAHN
AB		EQ 10MG BASE	A078131 003	Sep 04, 2007	May	CAHN
AB	SECAN PHARMS	EQ 5MG BASE	A090752 001	Apr 15, 2011	Apr	NEWA
AB		EQ 10MG BASE	A090752 002	Apr 15, 2011	Apr	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	DR REDDYS LABS INC	EQ 5MG BASE;40MG	A090149 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090149 002	Jul 05, 2011	Jun	NEWA
AB	LUPIN PHARMS	EQ 5MG BASE;40MG	A078466 005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A078466 006	Jul 05, 2011	Jun	NEWA
AB	MYLAN	EQ 5MG BASE;40MG	A079047 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A079047 002	Jul 05, 2011	Jun	NEWA
AB	TEVA PHARMS	EQ 5MG BASE;40MG	A077179 005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A077179 006	Jul 05, 2011	Jun	NEWA
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090364 002	Jul 05, 2011	Jun	NEWA
	LOTREL					
AB	NOVARTIS	EQ 5MG BASE;40MG	N020364 007	Apr 11, 2006	Jan	CFTG
AB	+	EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058 001		Feb	CDFR
AB		500MG	A062058 002		Feb	CDFR

FOR SUSPENSION; ORAL

AMOXIL

AB	DR REDDYS LABS INC	200MG/5ML	N050760 001	Apr 15, 1999	Sep	CMFD
AB		400MG/5ML	N050760 002	Apr 15, 1999	Sep	CMFD

TABLET; ORAL

AMOXIL

AB	DR REDDYS LABS INC	500MG	N050754 002	Jul 10, 1998	Sep	CMFD
AB		875MG	N050754 001	Jul 10, 1998	Sep	CMFD

TABLET, CHEWABLE; ORAL

AMOXIL

AB	DR REDDYS LABS INC	125MG	N050542 002		Sep	CMFD
AB		200MG	N050761 001	Apr 15, 1999	Sep	CMFD
AB		250MG	N050542 001		Sep	CMFD
AB		400MG	N050761 002	Apr 15, 1999	Sep	CMFD

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	SHIONOGI INC	775MG	N050813	001	Jan 23, 2008	Aug	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

	@ RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003	Aug	DISC
--	--------------------	-------	---------	-----	--------------	-----	------

	@	400MG	A065080	001	Aug 11, 2003	Aug	DISC
--	---	-------	---------	-----	--------------	-----	------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Feb	NEWA
---	-----------------	--	---------	-----	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '125'

AB	DR REDDYS LABS INC	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Sep	CAHN
----	--------------------	-------------------------------	---------	-----	--------------	-----	------

AUGMENTIN '200'

AB	DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Sep	CMFD
----	--------------------	------------------------------	---------	-----	--------------	-----	------

AUGMENTIN '250'

AB	+ DR REDDYS LABS INC	250MG/5ML;EQ 62.5MG BASE/5ML	N050575	002	Aug 06, 1984	Sep	CAHN
----	----------------------	------------------------------	---------	-----	--------------	-----	------

AUGMENTIN '400'

AB	DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Sep	CMFD
----	--------------------	----------------------------	---------	-----	--------------	-----	------

AUGMENTIN ES-600

AB	DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Sep	CMFD
----	--------------------	------------------------------	---------	-----	--------------	-----	------

TABLET; ORAL

AUGMENTIN '250'

AB	DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Sep	CAHN
----	--------------------	---------------------	---------	-----	--------------	-----	------

AUGMENTIN '500'

AB	DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Sep	CAHN
----	--------------------	---------------------	---------	-----	--------------	-----	------

AUGMENTIN '875'

AB	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Sep	CAHN
----	--------------------	---------------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

AUGMENTIN '125'

AB	DR REDDYS LABS INC	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	Sep	CMFD
----	--------------------	-----------------------	---------	-----	--------------	-----	------

AUGMENTIN '200'

AB	DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Sep	CMFD
----	--------------------	----------------------	---------	-----	--------------	-----	------

AUGMENTIN '250'

AB	DR REDDYS LABS INC	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	Sep	CMFD
----	--------------------	----------------------	---------	-----	--------------	-----	------

AUGMENTIN '400'

AB	DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Sep	CMFD
----	--------------------	--------------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

AUGMENTIN XR

AB	+ DR REDDYS LABS INC	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Sep	CAHN
----	----------------------	--------------------	---------	-----	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	@ MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003	Sep	DISC
--	--------------------	-----------------------------	---------	-----	--------------	-----	------

	@	1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003	Sep	DISC
--	---	---------------------------------	---------	-----	--------------	-----	------

	@	2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003	Sep	DISC
--	---	-------------------------	---------	-----	--------------	-----	------

	@	3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003	Sep	DISC
--	---	---------------------------------	---------	-----	--------------	-----	------

	@	3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003	Sep	DISC
--	---	-----------------------------	---------	-----	--------------	-----	------

	@	5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003	Sep	DISC
--	---	-----------------	---------	-----	--------------	-----	------

	@	7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Sep	DISC
--	---	-------------------------	---------	-----	--------------	-----	------

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	+	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Jun	CRLD
		FUNGIZONE						
		@ APOTHECON	50MG/VIAL	A060517	001		Jun	DISC
		INJECTABLE, LIPID COMPLEX; INJECTION						
		AMPHOTEC						
	+	ALDOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Jul	CAHN
	+		100MG/VIAL	N050729	002	Nov 22, 1996	Jul	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	Apr	CAIN
AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349	001	Sep 20, 2010	Apr	CAIN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	Apr	CAIN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010	Apr	CAIN
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339	001	Sep 20, 2010	Apr	CAIN

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

		DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	Jul	CTEC
		PRINCIPEN						
		@ APOTHECON	EQ 125MG BASE/5ML	A061394	002		Jul	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB		SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010	Feb	CAHN
AB		SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011	Jul	NEWA
		@ SYNTHON PHARMS	1MG	A078322	001	Jun 28, 2010	Jul	DISC

ARGATROBAN

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Jun	NEWA
+	SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May	NEWA

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

	@ SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	May	DISC
--	----------	----------------------	---------	-----	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

+	MERCK SHARP DOHME	EQ 10MG BASE	N022117	002	Aug 13, 2009	Aug	CAHN
---	-------------------	--------------	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

>A>	AA	+	WATSON LABS INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Oct	CAHN
>D>	AA	+	WATSON PHARMS	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Oct	CAHN

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ ACTAVIS ELIZABETH 325MG;50MG;40MG

A086710 002 Aug 23, 1983 Aug DISC

@ PURACAP PHARM 325MG;50MG;40MG

A087048 002 Dec 09, 1983 Jun CAHN

FIORINAL

>A> @ WATSON LABS INC 325MG;50MG;40MG

N017534 003 Apr 16, 1986 Oct CAHN

>D> @ WATSON PHARMS 325MG;50MG;40MG

N017534 003 Apr 16, 1986 Oct CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE

>A> AB + WATSON LABS INC 325MG;50MG;40MG;30MG

N019429 003 Oct 26, 1990 Oct CAHN

>D> AB + WATSON PHARMS 325MG;50MG;40MG;30MG

N019429 003 Oct 26, 1990 Oct CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB MIRROR PHARMS 325MG;200MG

A040832 001 Jan 07, 2010 Mar CAHN

AB PROSAM LABS 325MG;200MG

A040252 001 Dec 10, 1997 Feb CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB MIRROR PHARMS 325MG;200MG;16MG

A040860 001 Jan 07, 2010 Mar CAHN

AB PROSAM LABS 325MG;200MG;16MG

A040283 001 Dec 29, 1998 Feb CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA COASTAL PHARMS 325MG;4.8355MG

A091670 001 Mar 16, 2011 Feb NEWA

AA WATSON LABS 325MG;4.8355MG

A090084 001 Mar 22, 2011 Mar NEWA

PERCODAN

AA + ENDO PHARMS 325MG;4.8355MG

N007337 007 Aug 05, 2005 Feb CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB MYLAN 25MG

A074126 003 Aug 26, 1998 Feb CAHN

AB 50MG

A074126 001 Mar 23, 1994 Feb CAHN

AB 100MG

A074126 002 Mar 23, 1994 Feb CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@ ACTAVIS ELIZABETH 10MG

A078940 001 Aug 30, 2010 Aug DISC

@ 18MG

A078940 002 Aug 30, 2010 Aug DISC

@ 25MG

A078940 003 Aug 30, 2010 Aug DISC

@ 40MG

A078940 004 Aug 30, 2010 Aug DISC

@ 60MG

A078940 005 Aug 30, 2010 Aug DISC

@ 80MG

A078940 006 Aug 30, 2010 Aug DISC

@ 100MG

A078940 007 Aug 30, 2010 Aug DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB GLENMARK GENERICS 250MG;100MG

A091211 001 Jan 12, 2011 Jan NEWA

TABLET; ORAL

MALARONE

AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000	Jan	CFTG
----	---	-----------------	-------------	---------	-----	--------------	-----	------

ATROPINE

INJECTABLE; INJECTION

ATROPINE

@ SOLVAY

EQ 2MG SULFATE/0.7ML

A071295 001 Jan 30, 1987 Jul CAHN

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

>D>	+	BIONICHE PHARMA	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991	Oct	DISC
>D>	+		0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Oct	CAHN
>A>		@ MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991	Oct	DISC
>A>	+		0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Oct	CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

@ MEDA PHARMS

EQ 0.125MG BASE/SPRAY

N022203 001 Oct 15, 2008 Aug DISC

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

TAKEDA PHARMS

40MG

N200796 001 Feb 25, 2011 Feb NEWA

+

80MG

N200796 002 Feb 25, 2011 Feb NEWA

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

AB APOTEX CORP

EQ 250MG BASE

A065507 001 Jul 13, 2011 Jul NEWA

AB

EQ 500MG BASE

A065509 001 Jul 13, 2011 Jul NEWA

AB

EQ 600MG BASE

A065508 001 Jul 13, 2011 Jul NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP BEDFORD

1GM/VIAL

A065286 001 Mar 23, 2011 Mar NEWA

AP

2GM/VIAL

A065286 002 Mar 23, 2011 Mar NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

+ FERA PHARMS

500 UNITS/GM

A061212 001

Feb CAHN

+ NYCOMED US

500 UNITS/GM

A061212 001

Jan CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT FERA PHARMS

400 UNITS/GM;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

A060764 002

Feb CAHN

AT NYCOMED US

400 UNITS/GM;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

A060764 002

Jan CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Feb	CAHN
AT	NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Feb	CAHN
+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	CNS THERAPS INC	0.05MG/ML	N022462 001	Nov 19, 2010	Feb	CTEC
AP		0.5MG/ML	N022462 002	Nov 19, 2010	Feb	CTEC
AP		2MG/ML	N022462 003	Nov 19, 2010	Feb	CTEC

LLORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075 003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075 001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075 002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	PRINSTON INC	5MG	A076118 001	Feb 11, 2004	Aug	CAHN
AB		10MG	A076118 002	Feb 11, 2004	Aug	CAHN
AB		20MG	A076118 003	Feb 11, 2004	Aug	CAHN
AB		40MG	A076118 004	Feb 11, 2004	Aug	CAHN
AB	PRINSTON PHARM LLC	5MG	A076118 001	Feb 11, 2004	May	CAHN
AB		10MG	A076118 002	Feb 11, 2004	May	CAHN
AB		20MG	A076118 003	Feb 11, 2004	May	CAHN
AB		40MG	A076118 004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Feb	CAHN
AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Feb	CAHN
AB		20MG;12.5MG	A076612 003	Feb 11, 2004	Feb	CAHN
AB		20MG;25MG	A076612 004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010	Feb	CAHN
----	----------	--------	-------------	--------------	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

@ ACTAVIS TOTOWA 0.5MG
 @ 1MG
 @ 2MG

A040699 001 Feb 14, 2008 Jul DISC
 A040705 001 Feb 14, 2008 Jul DISC
 A040706 001 Feb 14, 2008 Jul DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB STI PHARMA LLC EQ 0.1% BASE

A070052 001 Jul 31, 1985 Apr CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ ACTAVIS TOTOWA 5MG
 @ 10MG
 @ 25MG

A040552 001 Oct 28, 2004 Jul DISC
 A040553 001 Oct 28, 2004 Jul DISC
 A040554 001 Oct 28, 2004 Jul DISC

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB ROXANE 50MG

A078285 001 Mar 24, 2011 Mar NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

>A> + APTALIS PHARMA US 140MG;125MG;125MG
 >D> + AXCAN 140MG;125MG;125MG
 + 140MG;125MG;125MG

N050786 001 Sep 28, 2006 Oct CAHN
 N050786 001 Sep 28, 2006 Oct CAHN
 N050786 001 Sep 28, 2006 Jun CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

>D> AB ACTAVIS ELIZABETH 2.5MG;6.25MG
 >A> @ 2.5MG;6.25MG
 >D> AB 5MG;6.25MG
 >A> @ 5MG;6.25MG
 >D> AB 10MG;6.25MG
 >A> @ 10MG;6.25MG

A075672 001 Sep 25, 2000 Oct DISC
 A075672 001 Sep 25, 2000 Oct DISC
 A075672 002 Sep 25, 2000 Oct DISC
 A075672 002 Sep 25, 2000 Oct DISC
 A075672 003 Sep 25, 2000 Oct DISC
 A075672 003 Sep 25, 2000 Oct DISC

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ SCHERING 200MG

N202258 001 May 13, 2011 May NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ HOSPIRA 50MG/ML

N019030 001 Apr 29, 1986 Jun DISC

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN 200MG/100ML
 + 400MG/100ML
 @ HOSPIRA 200MG/100ML
 @ 400MG/100ML

N019121 002 Apr 29, 1986 Aug CTEC
 N019121 003 Apr 29, 1986 Aug CTEC
 N019008 002 Apr 29, 1986 Aug DISC
 N019008 003 Apr 29, 1986 Aug DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+	ISTA PHARMS INC	0.09%	N021664	002	Oct 16, 2010	Mar	CRLD
	BROMFENAC SODIUM						
	COASTAL PHARMS	0.09%	A201211	001	May 11, 2011	Apr	NEWA
	XIBROM						
	@ ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Mar	DISC

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB	MYLAN	3MG	A090410	001	May 16, 2011	May	NEWA
	ENTOCORT EC						
AB	+ ASTRAZENECA	3MG	N021324	001	Oct 02, 2001	May	CFTG

BUPIVACAINE

>A> INJECTABLE, LIPOSOMAL; INJECTION

>A> EXPAREL

>A>	+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Oct	NEWA
>A>	+		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Oct	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

>A>	AP	SAGENT STRIDES	0.25%	A091503	001	Oct 18, 2011	Oct	NEWA
>A>	AP		0.5%	A091503	002	Oct 18, 2011	Oct	NEWA
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE						
>A>	AP	SAGENT STRIDES	0.25%	A091487	002	Oct 18, 2011	Oct	NEWA
>A>	AP		0.5%	A091487	001	Oct 18, 2011	Oct	NEWA
>A>	AP		0.75%	A091487	003	Oct 18, 2011	Oct	NEWA

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

	@ AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003	Jun	CAHN
--	------------------------	--	---------	-----	--------------	-----	------

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

	VALEANT INTL	174MG	N022108	001	Apr 23, 2008	Jun	CAHN
+		348MG	N022108	002	Apr 23, 2008	Jun	CAHN
		522MG	N022108	003	Apr 23, 2008	Jun	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	May	NEWA
AB2		150MG	A091520	001	Jun 09, 2011	May	NEWA
AB1		150MG	A091459	002	Jun 09, 2011	May	NEWA
AB1		200MG	A091459	003	Jun 09, 2011	May	NEWA
AB1	WATSON LABS FLORIDA	100MG	A079095	001	Mar 24, 2009	May	CAHN
AB2		150MG	A079094	001	Mar 24, 2009	May	CAHN
AB1		150MG	A079095	002	Mar 24, 2009	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1		WATSON LABS FLORIDA	200MG	A079095 003	Mar 24, 2009	May	CAHN
		WELLBUTRIN XL					
AB3	+	VALEANT INTL	150MG	N021515 001	Aug 28, 2003	Jul	CAHN
AB3			300MG	N021515 002	Aug 28, 2003	Jul	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

	@	BRISTOL MYERS SQUIBB	5MG	N018731 001	Sep 29, 1986	Aug	DISC
--	---	----------------------	-----	-------------	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

	@	ACTAVIS TOTOWA	5MG	A075388 001	May 09, 2002	Jul	DISC
	@		10MG	A075388 002	May 09, 2002	Jul	DISC
	@		15MG	A075388 003	May 09, 2002	Jul	DISC
	@		30MG	A078302 001	Dec 17, 2007	Jul	DISC

BUSULFAN

TABLET; ORAL

MYLERAN

>A>	+	ASPEN GLOBAL	2MG	N009386 001		Oct	CAHN
>D>	+	GLAXOSMITHKLINE	2MG	N009386 001		Oct	CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT		G AND W LABS INC	0.005%	A078468 001	Mar 24, 2011	Mar	NEWA
----	--	------------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

SOLUTION; ORAL

PHOSLYRA

	+	FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581 001	Apr 18, 2011	Apr	NEWA
--	---	-----------------	----------------------	-------------	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB		PADDOCK LABS	EQ 169MG CALCIUM	A091561 001	Apr 13, 2011	Mar	NEWA
----	--	--------------	------------------	-------------	--------------	-----	------

ELIPHOS

AB	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502 001	Nov 25, 2008	Mar	CTEC
----	---	---------------	------------------	-------------	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB		PRINSTON INC	12.5MG	A074477 001	Feb 13, 1996	Aug	CAHN
AB			25MG	A074477 002	Feb 13, 1996	Aug	CAHN
AB			50MG	A074477 003	Feb 13, 1996	Aug	CAHN
AB			100MG	A074477 004	Feb 13, 1996	Aug	CAHN
AB		PRINSTON PHARM LLC	12.5MG	A074477 001	Feb 13, 1996	May	CAHN
AB			25MG	A074477 002	Feb 13, 1996	May	CAHN
AB			50MG	A074477 003	Feb 13, 1996	May	CAHN
AB			100MG	A074477 004	Feb 13, 1996	May	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		NOSTRUM	100MG	A076697 001	May 20, 2011	May	NEWA
AB			200MG	A076697 002	May 20, 2011	May	NEWA
AB			300MG	A076697 003	May 20, 2011	May	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

AB	SHIRE	100MG	N020712 003	Sep 30, 1997	May	CFTG
AB		200MG	N020712 001	Sep 30, 1997	May	CFTG
AB	+	300MG	N020712 002	Sep 30, 1997	May	CFTG

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

@	JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988	Jan	CAHN
---	------------------	-------	-------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB	MERCK SHARP DOHME	10MG;100MG	N017555 001		Jan	CAHN
AB		25MG;100MG	N017555 003		Jan	CAHN
AB	+	25MG;250MG	N017555 002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

AB	MERCK SHARP DOHME	25MG;100MG	N019856 002	Dec 24, 1992	Jan	CAHN
AB	+	50MG;200MG	N019856 001	May 30, 1991	Jan	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

AA	RIVERS EDGE PHARMS	4MG	A090756 001	May 27, 2011	May	NEWA
----	--------------------	-----	-------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

>A>	AP	ONCO THERAPIES LTD	50MG/5ML (10MG/ML)	A091063 001	Nov 09, 2011	Oct	NEWA
>A>	AP		150MG/15ML (10MG/ML)	A091063 002	Nov 09, 2011	Oct	NEWA
>A>	AP		450MG/45ML (10MG/ML)	A091063 003	Nov 09, 2011	Oct	NEWA
>A>	AP		600MG/60ML (10MG/ML)	A091063 004	Nov 09, 2011	Oct	NEWA
		@ SAGENT PHARMS	50MG/5ML (10MG/ML)	A077096 001	Jun 14, 2005	Sep	CAHN
		@	150MG/15ML (10MG/ML)	A077096 002	Jun 14, 2005	Sep	CAHN
		@	450MG/45ML (10MG/ML)	A077096 003	Jun 14, 2005	Sep	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	MIRROR PHARMS	350MG	A040823 001	Oct 22, 2008	Mar	CAHN
AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN

CEFACLO

FOR SUSPENSION; ORAL

CEFACLO

@	FACTA FARMA	EQ 125MG BASE/5ML	A062206 001		Aug	CAHN
@		EQ 187MG BASE/5ML	A062206 003	Apr 20, 1988	Aug	CAHN
@		EQ 250MG BASE/5ML	A062206 002		Aug	CAHN
@		EQ 375MG BASE/5ML	A062206 004	Apr 20, 1988	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL

CEFACLO

+	TEVA	EQ 500MG BASE	A065058 002	Sep 04, 2002	Jul	CRLD
@	WORLD GEN	EQ 500MG BASE	A065057 001	Jan 05, 2001	Jul	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Jan	CAHN
AP	STERI PHARMA	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991	Jul	CMFD
AP		EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991	Jul	CMFD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007	Jan	CAHN
	MAXIPIME					
AP	+ HOSPIRA INC	EQ 500MG BASE/VIAL	N050679 001	Jan 18, 1996	Aug	CAHN
AP	+	EQ 1GM BASE/VIAL	N050679 002	Jan 18, 1996	Aug	CAHN
AP	+	EQ 2GM BASE/VIAL	N050679 003	Jan 18, 1996	Aug	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290 001	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065290 002	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293 001	Aug 10, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290 003	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293 002	Aug 10, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292 001	Aug 10, 2006	Jan	CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

>D>	+ APP PHARMS	EQ 1GM BASE/VIAL	A065374 001	Aug 09, 2007	Oct	CTEC
>A>	AP +	EQ 1GM BASE/VIAL	A065374 001	Aug 09, 2007	Oct	CTEC
>D>	+	EQ 2GM BASE/VIAL	A065374 002	Aug 09, 2007	Oct	CTEC
>A>	AP +	EQ 2GM BASE/VIAL	A065374 002	Aug 09, 2007	Oct	CTEC
>D>	+	EQ 10GM BASE/VIAL	A065375 001	Aug 09, 2007	Oct	CTEC
>A>	AP +	EQ 10GM BASE/VIAL	A065375 001	Aug 09, 2007	Oct	CTEC
>A>	AP WEST-WARD PHARM CORP	EQ 1GM BASE/VIAL	A091031 001	Oct 26, 2011	Oct	NEWA
>A>	AP	EQ 2GM BASE/VIAL	A091031 002	Oct 26, 2011	Oct	NEWA
>A>	AP	EQ 10GM BASE/VIAL	A091030 001	Oct 26, 2011	Oct	NEWA

CEFOXITIN

INJECTABLE; INJECTION

CEFOXITIN

AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Aug	NEWA
AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Aug	NEWA

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006	Jan	CAHN
----	-------------	------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CEFOXITIN

AP	HOSPIRA INC	EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006	Jan	CAHN
	MEFOXIN					
	@ MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	N050517 001		Aug	CAHN
	@	EQ 2GM BASE/VIAL	N050517 002		Aug	CAHN
	@	EQ 10GM BASE/VIAL	N050517 003		Aug	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	+ SANDOZ	EQ 200MG BASE	A065462 002	May 28, 2008	Jan	CRLD
	VANTIN					
	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992	Jan	DISC
	@	EQ 200MG BASE	N050674 002	Aug 07, 1992	Jan	DISC

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME IN DEXTROSE CONTAINER

	B BRAUN	EQ 1GM BASE	N050823 001	Jun 13, 2011	Jun	NEWA
+		EQ 2GM BASE	N050823 002	Jun 13, 2011	Jun	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230 001	Aug 02, 2005	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A065230 002	Aug 02, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065230 003	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065230 004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION

CEFTRIAXONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168 001	May 17, 2005	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ALKEM LABS LTD	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	CAHN
AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	CAHN
AB	APOTEX	EQ 250MG BASE	A065069 001	Oct 02, 2002	Jun	CAHN
AB		EQ 500MG BASE	A065069 002	Oct 02, 2002	Jun	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB	FACTA FARMA	EQ 250MG BASE	A062118 001		Aug	CAHN
AB		EQ 500MG BASE	A062118 002		Aug	CAHN

KEFLEX

AB	SHIONOGI INC	EQ 250MG BASE	N050405 002		Aug	CAHN
	@	EQ 333MG BASE	N050405 004	May 12, 2006	Aug	CAHN
AB		EQ 500MG BASE	N050405 003		Aug	CAHN
	+	EQ 750MG BASE	N050405 005	May 12, 2006	Aug	CAHN

FOR SUSPENSION; ORAL

CEPHALEXIN

	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117 001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117 002		Jan	CAHN
AB	+	EQ 250MG BASE/5ML	A062117 003		Jan	CAHN
	@ FACTA FARMA	EQ 100MG BASE/ML	A062117 001		Aug	CAHN
AB		EQ 125MG BASE/5ML	A062117 002		Aug	CAHN
AB	+	EQ 250MG BASE/5ML	A062117 003		Aug	CAHN

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

	@ RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003	Aug	DISC
	@	EQ 250MG BASE	A065100 001	Sep 11, 2003	Aug	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

	@ ACTAVIS MID ATLANTIC	5MG/5ML	A078617 001	Feb 02, 2010	Aug	DISC
AA	PERRIGO R AND D	5MG/5ML	A078398 001	Jun 17, 2008	Aug	CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE

AB	APOTEX INC	30MG	A091260 001	Aug 25, 2011	Aug	NEWA
	EVOXAC					
AB	+	DAIICHI SANKYO CO	N020989 002	Jan 11, 2000	Aug	CFTG

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	LYNE	0.12%	A074291 001	Dec 28, 1995	Feb	CAHN
----	------	-------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011	Jan	NEWA
AA		EQ 300MG BASE	A090612 001	Jan 21, 2011	Jan	NEWA

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP	SUN PHARMA GLOBAL	EQ 500MG BASE/VIAL	A091546 001	Jul 26, 2011	Jul	NEWA
----	-------------------	--------------------	-------------	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

ZUTRIPRO

+	CYPRESS PHARM	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439 001	Jun 08, 2011	Jun	NEWA
---	---------------	----------------------------	-------------	--------------	-----	------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@	ACTAVIS TOTOWA	250MG	A088928 001	May 08, 1987	Jul	DISC
@		500MG	A040113 001	Sep 29, 1995	Jul	DISC
@	OHM LABS	250MG	A081298 001	Dec 29, 1993	Aug	DISC
@		500MG	A081299 001	Dec 29, 1993	Aug	DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996	Apr	CRLD
CHOLESTYRAMINE LIGHT							
AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996	Apr	CRLD
QUESTRAN							
	@	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640 001		Apr	DISC
	@		EQ 4GM RESIN/SCOOPFUL	N016640 003		Apr	DISC
QUESTRAN LIGHT							
	@	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Apr	DISC
	@		EQ 4GM RESIN/SCOOPFUL	N019669 003	Dec 05, 1988	Apr	DISC
AB	+		EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT		TARO	1%	A090269 001	Feb 23, 2011	Feb	NEWA
----	--	------	----	-------------	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@	ACTAVIS TOTOWA	100MG	A077028 002	Nov 26, 2004	Jul	DISC
---	----------------	-------	-------------	--------------	-----	------

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	HOSPIRA	EQ 6MG BASE/ML	A074269 001	Dec 27, 1994	Aug	DISC
---	---------	----------------	-------------	--------------	-----	------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	TEVA PHARMS	200MG/100ML	A077138 001	Mar 18, 2008	Aug	DISC
@		400MG/200ML	A077138 002	Mar 18, 2008	Aug	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

@	DEPOMED INC	EQ 500MG BASE	N021744 001	May 19, 2005	May	DISC
---	-------------	---------------	-------------	--------------	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166 002	Nov 27, 2007	Jun	CMFD
AB		425.2MG;EQ 574.9MG BASE	A078166 001	Nov 27, 2007	Jun	CMFD

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

>D>	@ BRISTOL MYERS	10MG/VIAL	N018057 001		Oct	CAHN
>D>	@	50MG/VIAL	N018057 002		Oct	CAHN
	@	50MG/VIAL	N018057 002		Jun	DISC
>A>	@ CORDEN PHARMA	10MG/VIAL	N018057 001		Oct	CAHN
>A>	@	50MG/VIAL	N018057 002		Oct	CAHN

PLATINOL-AQ

>D>	@ BRISTOL MYERS	0.5MG/ML	N018057 003	Jul 18, 1984	Oct	CAHN
>D>	@	1MG/ML	N018057 004	Nov 08, 1988	Oct	CAHN
>A>	@ CORDEN PHARMA	0.5MG/ML	N018057 003	Jul 18, 1984	Oct	CAHN
>A>	@	1MG/ML	N018057 004	Nov 08, 1988	Oct	CAHN

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	MYLAN	EQ 10MG BASE	A077042 001	Nov 05, 2004	Apr	CAHN
AB		EQ 20MG BASE	A077042 002	Nov 05, 2004	Apr	CAHN
AB		EQ 40MG BASE	A077042 003	Nov 05, 2004	Apr	CAHN

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP	ONCO THERAPIES LTD	1MG/ML	A200510 001	Oct 06, 2011	Sep	NEWA
----	--------------------	--------	-------------	--------------	-----	------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

@ ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075 001	Oct 31, 1993	Aug	DISC
------------------------	-------------------	-------------	--------------	-----	------

CLINDAMYCIN

INJECTABLE; INJECTION

CLINDAMYCIN

AP	SAGENT STRIDES	EQ 150MG BASE/ML	A090108 001	Sep 30, 2011	Sep	NEWA
AP		EQ 150MG BASE/ML	A090109 001	Sep 30, 2011	Sep	NEWA

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	MATRIX LABS LTD	EQ 75MG BASE	A091225 001	May 31, 2011	May	NEWA
AB		EQ 150MG BASE	A091225 002	May 31, 2011	May	NEWA
AB		EQ 300MG BASE	A091225 003	May 31, 2011	May	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

BT	+ GALDERMA LABS LP	EQ 1% BASE	N050782 001	Nov 27, 2000	Mar	CRLD
----	--------------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ ACTAVIS MID ATLANTIC EQ 1% BASE

A062811 001 Sep 01, 1988 Aug DISC

@ COREPHARMA EQ 1% BASE

A064108 001 Sep 27, 1996 Apr CAHN

>A> CLOBAZAM

>A> TABLET; ORAL

>A> ONFI

>A> LUNDBECK INC 5MG

N202067 001 Oct 21, 2011 Oct NEWA

>A> 10MG

N202067 002 Oct 21, 2011 Oct NEWA

>A> + 20MG

N202067 003 Oct 21, 2011 Oct NEWA

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX

AB + STIEFEL LABS INC 0.05%

N021142 001 May 26, 2000 May CAHN

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ ACTAVIS MID ATLANTIC 0.05%

A074139 001 Aug 03, 1994 Aug DISC

@ COREPHARMA 0.05%

A075338 001 Feb 09, 2001 Apr CAHN

CLOBETASOL PROPIONATE (EMOLLIENT)

@ COREPHARMA 0.05%

A075733 001 Aug 22, 2001 Apr CAHN

TEMOVATE

AB1 + NYCOMED US 0.05%

N019322 001 Dec 27, 1985 Aug CAHN

GEL; TOPICAL

TEMOVATE

AB + NYCOMED US 0.05%

N020337 001 Apr 29, 1994 Aug CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

@ ACTAVIS MID ATLANTIC 0.05%

A074128 001 Aug 03, 1994 Aug DISC

@ COREPHARMA 0.05%

A075057 001 Aug 12, 1998 Apr CAHN

TEMOVATE

AB + NYCOMED US 0.05%

N019323 001 Dec 27, 1985 Aug CAHN

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB ACTAVIS MID ATLANTIC 0.05%

A078854 001 Jun 07, 2011 May NEWA

CLOBEX

AB + GALDERMA LABS 0.05%

N021644 001 Feb 05, 2004 May CFTG

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

@ ACTAVIS MID ATLANTIC 0.05%

A074331 001 Dec 15, 1995 Aug DISC

AT NYCOMED US 0.05%

A075391 001 Feb 08, 1999 Apr CAHN

TEMOVATE

AT + NYCOMED US 0.05%

N019966 001 Feb 22, 1990 Aug CAHN

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

AT PADDOCK LABS 0.05%

A090898 001 Jun 16, 2011 May NEWA

CLOBEX

AT + GALDERMA LABS LP 0.05%

N021835 001 Oct 27, 2005 Jun CTEC

+

0.05%

N021835 001 Oct 27, 2005 May CFTG

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+ PROMIUS PHARMA LLC 0.1%

N017765 001 Jun CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	MALLINCKRODT LLC	25MG	N019906 001	Dec 29, 1989	Aug	CAHN
AB	+	50MG	N019906 002	Dec 29, 1989	Aug	CAHN
AB		75MG	N019906 003	Dec 29, 1989	Aug	CAHN

CLONIDINE

SUSPENSION, EXTENDED RELEASE; ORAL

CLONIDINE

@ TRIS PHARMA INC EQ 0.09MG BASE/ML

N022499 001 Dec 03, 2009 Sep DISC

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE

@ TRIS PHARMA INC EQ 0.17MG BASE

N022500 001 Dec 03, 2009 Sep DISC

@ EQ 0.26MG BASE

N022500 002 Dec 03, 2009 Sep DISC

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	APP PHARMS	1MG/10ML (0.1MG/ML)	A200673 001	Jul 08, 2011	Jun	NEWA
AP		5MG/10ML (0.5MG/ML)	A200673 002	Jul 08, 2011	Jun	NEWA
AP	HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A200300 001	Jan 26, 2011	Jul	CAHN
AP		5MG/10ML (0.5MG/ML)	A200300 002	Jan 26, 2011	Jul	CAHN
AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300 001	Jan 26, 2011	Jan	NEWA
AP		5MG/10ML (0.5MG/ML)	A200300 002	Jan 26, 2011	Jan	NEWA

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

+ ROXANE 30MG/5ML

N202245 001 Jun 30, 2011 Jun NEWA

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB	MIRROR PHARMS	0.5MG;500MG	A040618 001	May 13, 2008	Mar	CAHN
----	---------------	-------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750 001		Jun CAHN
----	---	----------------------	-------------	-------------	--	----------

CRIZOTINIB

CAPSULE; ORAL

XALKORI

PFIZER 200MG

N202570 001 Aug 26, 2011 Aug NEWA

+ 250MG

N202570 002 Aug 26, 2011 Aug NEWA

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

>A>	AA	PACK PHARMS LLC	100MG/5ML	A202583 001	Oct 27, 2011	Oct NEWA
-----	----	-----------------	-----------	-------------	--------------	----------

GASTROCROM

>D>	+	AZUR PHARMA	100MG/5ML	N020479 001	Feb 29, 1996	Oct CTEC
-----	---	-------------	-----------	-------------	--------------	----------

>A>	AA	+	100MG/5ML	N020479 001	Feb 29, 1996	Oct CTEC
-----	----	---	-----------	-------------	--------------	----------

SOLUTION; INHALATION

CROMOLYN SODIUM

@ ACTAVIS MID ATLANTIC 10MG/ML

A075067 001 Jul 19, 1999 Aug DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB ANESTA AG 15MG

N021777 001 Feb 01, 2007 Apr CFTG

AB + 30MG

N021777 002 Feb 01, 2007 Apr CFTG

CYCLOBENZAPRINE HYDROCHLORIDE

AB MYLAN 15MG

A090738 001 Apr 18, 2011 Apr NEWA

AB 30MG

A090738 002 Apr 18, 2011 Apr NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB JUBILANT CADISTA 5MG

A077563 001 Apr 19, 2006 Jan CAHN

AB 10MG

A077563 002 Apr 19, 2006 Jan CAHN

AB KVK TECH 5MG

A078048 001 Feb 28, 2011 Feb NEWA

AB 10MG

A078048 002 Feb 28, 2011 Feb NEWA

AB PROSAM LABS 5MG

A077291 001 Feb 03, 2006 Feb CAHN

AB 10MG

A077209 001 Oct 04, 2005 Feb CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP + BAXTER HLTHCARE 500MG/VIAL

A040745 001 May 21, 2008 Aug CRLD

AP + 1GM/VIAL

A040745 002 May 21, 2008 Aug CRLD

AP + 2GM/VIAL

A040745 003 May 21, 2008 Aug CRLD

CYTOXAN

AP BAXTER HLTHCARE 500MG/VIAL

N012142 003 Aug CRLD

AP 1GM/VIAL

N012142 004 Aug 30, 1982 Aug CRLD

AP 2GM/VIAL

N012142 005 Aug 30, 1982 Aug CRLD

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

@ ACTAVIS TOTOWA 25MG

A076686 001 Oct 24, 2005 Jul DISC

@ 50MG

A076686 002 Oct 24, 2005 Jul DISC

@ 100MG

A076686 003 Oct 24, 2005 Jul DISC

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

REV-EYES

>D> @ ANGELINI 0.5%

N019849 001 Dec 31, 1990 Oct CAHN

>A> @ FERA PHARMS 0.5%

N019849 001 Dec 31, 1990 Oct CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

WARNER CHILCOTT LLC EQ 7.5MG BASE

N021513 001 Dec 22, 2004 May CAHN

+ EQ 15MG BASE

N021513 002 Dec 22, 2004 May CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

@ TIBOTEC EQ 300MG BASE

N021976 001 Jun 23, 2006 May DISC

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

+ GALEN (UK) EQ 2MG BASE/ML N050704 002 Apr 08, 1996 Jun CAHN

>A> DEFERIPRONE

>A> TABLET; ORAL

>A> FERRIPROX

>A> + APOPHARMA INC 500MG N021825 001 Oct 14, 2011 Oct NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@ COREPHARMA 75MG

N050261 001 May CAHN

AB 150MG N050261 002 May CAHN

AB + 300MG N050261 003 May CAHN

DEMECLOCYCLINE HYDROCHLORIDE

AB VERSAPHARM 150MG A065389 001 Dec 01, 2008 May CAHN

AB 300MG A065389 002 Dec 01, 2008 May CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB ACTAVIS TOTOWA 50MG

A071588 001 Jun 05, 1987 Aug CAHN

DESLOMATADINE

TABLET; ORAL

DESLOMATADINE

AB DR REDDYS LABS LTD 5MG

A078365 001 Mar 08, 2011 Feb NEWA

DESLOMATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

AB + SCHERING 5MG;240MG N021605 001 Mar 03, 2005 Apr CFTG

DESLOMATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB DR REDDYS LABS LTD 5MG;240MG A078366 001 Apr 26, 2011 Apr NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

STIMATE

@ CSL BEHRING 0.15MG/SPRAY

N020355 001 Mar 07, 1994 May DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB VINTAGE 0.15MG;0.03MG

A076675 001 Feb 25, 2011 Feb NEWA

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB VERSAPHARM 0.05%

A090727 001 Mar 10, 2011 Feb NEWA

OINTMENT; TOPICAL

TOPICORT

+ TARO PHARMS NORTH 0.05%

N018594 001 Jan 17, 1985 May CMFD

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011	Jun	NEWA
AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA

TABLET; ORAL

DEXAMETHASONE

BP	PAR PHARM	0.5MG	A088148	001	Apr 28, 1983	Aug	CMFD
BP		0.75MG	A088160	001	Apr 28, 1983	Aug	CMFD
BP		1.5MG	A088237	001	Apr 28, 1983	Aug	CMFD
BP		4MG	A088238	001	Apr 28, 1983	Aug	CMFD
BP	+	6MG	A088481	001	Nov 28, 1983	Sep	CRLD
BP		6MG	A088481	001	Nov 28, 1983	Aug	CMFD
BP	ROXANE	0.5MG	A084611	001		Aug	CTEC
BP		0.75MG	A084613	001		Aug	CTEC
BP		1MG	A088306	001	Sep 15, 1983	Aug	CTEC
BP		2MG	A087916	001	Aug 26, 1982	Aug	CTEC
BP		4MG	A084612	001		Aug	CTEC
BP	+	6MG	A088316	001	Sep 15, 1983	Aug	CTEC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	PFIZER	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	May	CAHN
AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	May	CAHN
	@ TEVA PARENTERAL	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990	Aug	DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

NOVARTIS

25MG

N021802 008 Apr 21, 2011 May NEWA

35MG

N021802 007 Apr 21, 2011 May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

>A>	AP	MYLAN INSTITUTIONAL	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Oct	NEWA
>A>	AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Oct	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	COREPHARMA	5MG	N017078	001		Jun	CAHN
AB		10MG	N017078	002		Jun	CAHN
AB	+	15MG	N017078	003		Jun	CAHN

TABLET; ORALDEXTROAMPHETAMINE SULFATE

>A>		MIKART	2.5MG	A090533 001	Oct 25, 2011	Oct	NEWA
>A>	AA		5MG	A090533 002	Oct 25, 2011	Oct	NEWA
>A>			7.5MG	A090533 003	Oct 25, 2011	Oct	NEWA
>A>	AA		10MG	A090533 004	Oct 25, 2011	Oct	NEWA
>A>			15MG	A090533 005	Oct 25, 2011	Oct	NEWA
>A>			20MG	A090533 006	Oct 25, 2011	Oct	NEWA
>A>			30MG	A090533 007	Oct 25, 2011	Oct	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORALPROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575 001	Feb 08, 2011	Jan	NEWA
----	--	---------------	---------------------	-------------	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDEINJECTABLE; INJECTIONDEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634 004		Jun	CAHN
----	--	-----------------	----------------------	-------------	--	-----	------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634 001		Jun	CAHN
----	--	-----------------	-----------------------	-------------	--	-----	------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634 003		Jun	CAHN
----	--	-----------------	-----------------------	-------------	--	-----	------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634 002		Jun	CAHN
----	--	-----------------	-----------------------	-------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUSINJECTABLE; INJECTIONIONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML ;146MG/100ML;207MG/100ML	N019514 001	May 08, 1986	Aug	DISC
---	---------	---	-------------	--------------	-----	------

DIAZEPAMTABLET; ORALDIAZEPAM

@	ACTAVIS ELIZABETH	2MG	A070781 001	Mar 19, 1986	Aug	DISC
@		5MG	A070706 001	Mar 19, 1986	Aug	DISC
@		10MG	A070707 001	Mar 19, 1986	Aug	DISC

DICLOFENAC SODIUMTABLET, EXTENDED RELEASE; ORALDICLOFENAC SODIUM

AB		VALEANT INTL	100MG	A075492 001	Feb 11, 2000	Apr	CAHN
----	--	--------------	-------	-------------	--------------	-----	------

DICYCLOMINE HYDROCHLORIDECAPSULE; ORALBENTYL

>A>	AB	+	APTALIS PHARMA US	10MG	N007409 003	Oct 15, 1984	Oct	CAHN
>D>	AB	+	AXCAN	10MG	N007409 003	Oct 15, 1984	Oct	CAHN

INJECTABLE; INJECTIONBENTYL

>A>	AP	+	APTALIS PHARMA US	10MG/ML	N008370 001	Oct 15, 1984	Oct	CAHN
>D>	AP	+	AXCAN	10MG/ML	N008370 001	Oct 15, 1984	Oct	CAHN

BENTYL PRESERVATIVE FREE

>A>	AP	+	APTALIS PHARMA US	10MG/ML	N008370 002	Oct 15, 1984	Oct	CAHN
>D>	AP	+	AXCAN	10MG/ML	N008370 002	Oct 15, 1984	Oct	CAHN

SYRUP; ORAL

BENTYL

>A>	AA	+	APTALIS PHARMA US	10MG/5ML	N007961	002	Oct 15, 1984	Oct	CAHN
>D>	AA	+	AXCAN	10MG/5ML	N007961	002	Oct 15, 1984	Oct	CAHN

TABLET; ORAL

BENTYL

>A>	AB	+	APTALIS PHARMA US	20MG	N007409	001	Oct 15, 1984	Oct	CAHN
>D>	AB	+	AXCAN	20MG	N007409	001	Oct 15, 1984	Oct	CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

	AA		LANNETT HOLDINGS INC	25MG	A200177	001	Jul 18, 2011	Jul	NEWA
--	----	--	----------------------	------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDE

>A>	AB		LANNETT HOLDINGS INC	75MG	A091680	001	Oct 24, 2011	Oct	NEWA
-----	----	--	----------------------	------	---------	-----	--------------	-----	------

TENUATE DOSPAN

>D>		+	WATSON PHARMS	75MG	N012546	001		Oct	CFTG
>A>	AB	+		75MG	N012546	001		Oct	CFTG

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

		+	ALCON PHARMS LTD	0.05%	N022212	001	Jun 23, 2008	May	CAHN
--	--	---	------------------	-------	---------	-----	--------------	-----	------

DIGOXIN

TABLET; ORAL

DIGOXIN

		@	ACTAVIS TOTOWA	0.125MG	A040282	001	Dec 23, 1999	Jul	DISC
		@		0.25MG	A040282	002	Dec 23, 1999	Jul	DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

	AB3		VALEANT INTL	120MG	N020062	001	Aug 10, 1992	Jun	CAHN
	AB3			180MG	N020062	002	Dec 27, 1991	Jun	CAHN
	AB3			240MG	N020062	003	Dec 27, 1991	Jun	CAHN
>D>	AB3	+		300MG	N020062	004	Dec 27, 1991	Oct	CRLD
>A>	AB3			300MG	N020062	004	Dec 27, 1991	Oct	CRLD
	AB3	+		300MG	N020062	004	Dec 27, 1991	Jun	CAHN
>D>	BC	+		360MG	N020062	005	Aug 24, 1999	Oct	CTEC
>A>	AB3	+		360MG	N020062	005	Aug 24, 1999	Oct	CTEC
	BC	+		360MG	N020062	005	Aug 24, 1999	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

>A>	AB3		SUN PHARMA GLOBAL	120MG	A090492	001	Oct 28, 2011	Oct	NEWA
>A>	AB3			180MG	A090492	002	Oct 28, 2011	Oct	NEWA
>A>	AB3			240MG	A090492	003	Oct 28, 2011	Oct	NEWA
>A>	AB3			300MG	A090492	004	Oct 28, 2011	Oct	NEWA
>A>	AB3			360MG	A090492	005	Oct 28, 2011	Oct	NEWA
	AB3		VALEANT INTL	120MG	A075116	001	Dec 23, 1999	Apr	CAHN
	AB3			180MG	A075116	002	Dec 23, 1999	Apr	CAHN
	AB3			240MG	A075116	003	Dec 23, 1999	Apr	CAHN
	AB3			300MG	A075116	004	Dec 23, 1999	Apr	CAHN

TIAZAC

	AB4		VALEANT INTL	120MG	N020401	001	Sep 11, 1995	Jun	CAHN
	AB4			180MG	N020401	002	Sep 11, 1995	Jun	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

TIAZAC

AB4	VALEANT INTL	240MG	N020401 003	Sep 11, 1995	Jun	CAHN
AB4		300MG	N020401 004	Sep 11, 1995	Jun	CAHN
AB4		360MG	N020401 005	Sep 11, 1995	Jun	CAHN
AB4	+	420MG	N020401 006	Oct 16, 1998	Jun	CAHN

TABLET; ORAL

CARDIZEM

AB	VALEANT INTL	30MG	N018602 001	Nov 05, 1982	Jun	CAHN
AB		60MG	N018602 002	Nov 05, 1982	Jun	CAHN
AB		90MG	N018602 003	Dec 08, 1986	Jun	CAHN
AB	+	120MG	N018602 004	Dec 08, 1986	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

AB	MYLAN	30MG	A072838 004	Nov 05, 1992	Aug	CMS1
AB		60MG	A072838 003	Nov 05, 1992	Aug	CMS1
AB		90MG	A072838 002	Nov 05, 1992	Aug	CMS1

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

AB	VALEANT INTL	120MG	N021392 001	Feb 06, 2003	Jun	CAHN
AB		180MG	N021392 002	Feb 06, 2003	Jun	CAHN
AB		240MG	N021392 003	Feb 06, 2003	Jun	CAHN
AB		300MG	N021392 004	Feb 06, 2003	Jun	CAHN
AB		360MG	N021392 005	Feb 06, 2003	Jun	CAHN
AB	+	420MG	N021392 006	Feb 06, 2003	Jun	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

@	HOSPIRA	5MG/ML	A074601 001	Dec 19, 1997	Aug	DISC
---	---------	--------	-------------	--------------	-----	------

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

AB	ODYSSEY PHARMS	250MG	A088482 001	Dec 08, 1983	Mar	CTEC
AB	+	500MG	A088483 001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

AB	SIGMAPHARM LABS LLC	250MG	A091619 001	Mar 28, 2011	Mar	NEWA
AB		500MG	A091619 002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB	MYLAN	EQ 125MG VALPROIC ACID	A090407 001	Mar 28, 2011	Mar	NEWA
----	-------	------------------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB	AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554 001	Apr 21, 2011	Apr	NEWA
AB		EQ 250MG VALPROIC ACID	A090554 002	Apr 21, 2011	Apr	NEWA
AB		EQ 500MG VALPROIC ACID	A090554 003	Apr 21, 2011	Apr	NEWA
AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163 001	Apr 05, 2011	Mar	NEWA
AB		EQ 250MG VALPROIC ACID	A079163 002	Apr 05, 2011	Mar	NEWA
AB		EQ 500MG VALPROIC ACID	A079163 003	Apr 05, 2011	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080 001	Feb 25, 2011	Feb	NEWA
----	---------------------	------------------------	-------------	--------------	-----	------

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

AP	+	HOSPIRA	EQ 12.5MG BASE/ML	A074292 001	Feb 16, 1995	Aug	CRLD
		@ TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206 001	Oct 19, 1993	Aug	DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534 001	May 03, 2011	May	NEWA
+		80MG/VIAL	N022534 002	May 03, 2011	May	NEWA

DOCETAXEL

		ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jun	NEWA
			80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jun	NEWA
AP	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Jun	CTEC
	+		20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Mar	NEWA
AP	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Jun	CTEC
	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Mar	NEWA
AP	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Jun	CTEC
	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Mar	NEWA
AP		SANDOZ	20MG/2ML (10MG/ML)	N201525 001	Jun 29, 2011	Jun	NEWA
AP			160MG/16ML (10MG/ML)	N201525 003	Jun 29, 2011	Jun	NEWA
AP		SANDOZ INC	80MG/8ML (10MG/ML)	N201525 002	Jun 29, 2011	Jun	NEWA
		TAXOTERE					
		@ SANOFI AVENTIS US	40MG/ML	N020449 001	May 14, 1996	Mar	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB		ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011	Aug	NEWA
AB			10MG	A201335 002	Aug 29, 2011	Aug	NEWA
AB		ACTAVIS PHARMA	5MG	A090551 001	May 31, 2011	May	NEWA
AB			10MG	A090551 002	May 31, 2011	May	NEWA
AB		APOTEX	5MG	A078841 001	Jun 02, 2011	May	NEWA
AB			10MG	A078841 002	Jun 02, 2011	May	NEWA
AB		AUROBINDO	5MG	A090056 001	May 31, 2011	May	NEWA
AB			10MG	A090056 002	May 31, 2011	May	NEWA
AB		CIPLA LTD	5MG	A077518 001	May 31, 2011	May	NEWA
AB			10MG	A077518 002	May 31, 2011	May	NEWA
AB		DR REDDYS LABS LTD	5MG	A201001 001	May 31, 2011	May	NEWA
AB			10MG	A201001 002	May 31, 2011	May	NEWA
AB		HIKMA PHARMS	5MG	A090247 001	May 31, 2011	May	NEWA
AB			10MG	A090247 002	May 31, 2011	May	NEWA
AB		HUAHAI US INC	5MG	A200292 001	May 31, 2011	May	NEWA
AB			10MG	A200292 002	May 31, 2011	May	NEWA
AB		JUBILANT LIFE	5MG	A090768 001	May 31, 2011	May	NEWA
AB			10MG	A090768 002	May 31, 2011	May	NEWA
AB		MATRIX LABS LTD	5MG	A090521 001	May 31, 2011	May	NEWA
AB			10MG	A090521 002	May 31, 2011	May	NEWA
AB		PLIVA HRVATSKA DOO	5MG	A090425 001	May 31, 2011	May	NEWA
AB			10MG	A090425 002	May 31, 2011	May	NEWA
AB		ROXANE	5MG	A078662 001	May 31, 2011	May	NEWA

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ROXANE	10MG	A078662	002	May 31, 2011	May	NEWA
AB	SANDOZ	5MG	A090290	001	May 31, 2011	May	NEWA
AB		10MG	A090290	002	May 31, 2011	May	NEWA
AB	SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May	NEWA
AB		10MG	A090493	002	May 31, 2011	May	NEWA
AB	TEVA	5MG	A077344	001	May 31, 2011	May	NEWA
AB		10MG	A077344	002	May 31, 2011	May	NEWA
AB	TORRENT PHARMS	5MG	A090686	001	May 31, 2011	May	NEWA
AB		10MG	A090686	002	May 31, 2011	May	NEWA
AB	WOCKHARDT	5MG	A091267	001	May 31, 2011	May	NEWA
AB		10MG	A091267	002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

	@ MUTUAL PHARM	5MG	A077975	002	Dec 11, 2009	Sep	DISC
	@	10MG	A077975	001	Dec 11, 2009	Sep	DISC
AB	SANDOZ	5MG	A091198	001	May 10, 2011	Apr	NEWA
AB		10MG	A091198	002	May 10, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011	Apr	NEWA
AB		10MG	A090175	002	May 10, 2011	Apr	NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

	@ ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000	Aug	DISC
	@	EQ 2MG BASE	A075574	002	Oct 18, 2000	Aug	DISC
	@	EQ 4MG BASE	A075574	003	Oct 18, 2000	Aug	DISC
	@	EQ 8MG BASE	A075574	004	Oct 18, 2000	Aug	DISC

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

AB	ROXANE	0.5MCG	A091433	001	Sep 23, 2011	Sep	NEWA
AB	HECTOROL						
AB	GENZYME CORP	0.5MCG	N020862	002	Apr 23, 2004	Sep	CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

>A>	AP	ONCO THERAPIES LTD	10MG/VIAL	A200170	001	Oct 28, 2011	Oct	NEWA
>A>	AP		50MG/VIAL	A200170	002	Oct 28, 2011	Oct	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
AB	MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
AB	+ PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
AB	+	EQ 150MG BASE	A065055	003	Jul 15, 2005	Jan	CTEC

TABLET; ORAL

DOXYCYCLINE

	@ MUTUAL PHARM	EQ 50MG BASE	A065471	001	Apr 17, 2009	Sep	DISC
	@	EQ 75MG BASE	A065471	002	Apr 17, 2009	Sep	DISC
	@	EQ 100MG BASE	A065471	003	Apr 17, 2009	Sep	DISC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	WATSON LABS FLORIDA	EQ 50MG BASE	A062031 002	Oct 13, 1982	May	CAHN
AB		EQ 100MG BASE	A062031 001		May	CAHN

DRONABINOL

CAPSULE; ORAL

DRONABINOL

AB	INSYS THERAP	2.5MG	A078501 001	Aug 19, 2011	Aug	NEWA
AB		5MG	A078501 002	Aug 19, 2011	Aug	NEWA
AB		10MG	A078501 003	Aug 19, 2011	Aug	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

LORYNA

AB	SANDOZ	3MG;0.02MG	A079221 001	Mar 28, 2011	Mar	NEWA
----	--------	------------	-------------	--------------	-----	------

TABLET; ORAL-28

SYEDA

AB	SANDOZ	3MG;0.03MG	A090114 001	Mar 28, 2011	Mar	NEWA
----	--------	------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE

@ ORTHO JANSSEN

1%

N018751 001	Dec 23, 1982	Jul	CAHN
-------------	--------------	-----	------

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

@ HOSPIRA

10MG/ML

A040131 001	Feb 24, 1998	Aug	DISC
-------------	--------------	-----	------

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

>A>	GLAXOSMITHKLINE	EQ 12.5MG ACID	N022291 004	Oct 20, 2011	Oct	NEWA
-----	-----------------	----------------	-------------	--------------	-----	------

EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+ GILEAD SCIENCES INC 200MG;25MG;300MG

N202123 001	Aug 10, 2011	Aug	NEWA
-------------	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

AB	VALEANT INTL	2.5MG	N018998 005	Jul 26, 1988	Jun	CAHN
AB		5MG	N018998 001	Dec 24, 1985	Jun	CAHN
AB		10MG	N018998 002	Dec 24, 1985	Jun	CAHN
AB	+	20MG	N018998 003	Dec 24, 1985	Jun	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB	VALEANT INTL	5MG;12.5MG	N019221 003	Jul 12, 1995	Jun	CAHN
AB	+	10MG;25MG	N019221 001	Oct 31, 1986	Jun	CAHN

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

SANOFI AVENTIS US 300MG/3ML (100MG/ML)

N020164 009 Jan 23, 2003 Feb CDFR

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	AMPHASTAR PHARM	30MG/0.3ML (100MG/ML)	A076684 001	Sep 19, 2011	Sep	NEWA
AP		40MG/0.4ML (100MG/ML)	A076684 002	Sep 19, 2011	Sep	NEWA
AP		60MG/0.6ML (100MG/ML)	A076684 003	Sep 19, 2011	Sep	NEWA
AP		80MG/0.8ML (100MG/ML)	A076684 004	Sep 19, 2011	Sep	NEWA
AP		100MG/ML (100MG/ML)	A076684 005	Sep 19, 2011	Sep	NEWA
AP		120MG/0.8ML (150MG/ML)	A076684 006	Sep 19, 2011	Sep	NEWA
AP		150MG/ML (150MG/ML)	A076684 007	Sep 19, 2011	Sep	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565 001	Oct 16, 2003	Feb	CFTG
----	---	----------	-------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

>A>	AT	APOTEX	0.05%	A090919 001	Oct 31, 2011	Oct	NEWA
	AT	CYPRESS PHARM	0.05%	A090870 001	Mar 14, 2011	Feb	NEWA
>A>	AT	PHARMAFORCE	0.05%	A090951 001	Oct 31, 2011	Oct	NEWA
>A>	AT	SUN PHARM INDS	0.05%	A091626 001	Oct 31, 2011	Oct	NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

AP	+	DENTSPLY PHARM	0.005MG/ML;4%	N021383 001		Aug	CFTG
----	---	----------------	---------------	-------------	--	-----	------

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		SEPTODONT INC	0.005MG/ML;4%	A078959 001	Aug 30, 2011	Aug	NEWA
----	--	---------------	---------------	-------------	--------------	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		MUSTAFA NEVSAT	200MG/100ML (2MG/ML)	A090266 002	Apr 15, 2011	Apr	NEWA
AP			50MG/25ML (2MG/ML)	A090266 001	Apr 15, 2011	Apr	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

+ ACTELION EQ 1.5MG BASE/VIAL

N022260 001 Jun 27, 2008 Aug CTNA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS INC	250MG	A062746 001	Dec 22, 1986	Jan	CAHN
----	--	------------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

E-GLADES

AT		COREPHARMA	2%	A065009 001	Mar 18, 2002	Apr	CAHN
----	--	------------	----	-------------	--------------	-----	------

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	+	FERA PHARMS	0.5%	A062447 001	Sep 26, 1983	Feb	CAHN
AT	+	NYCOMED US	0.5%	A062447 001	Sep 26, 1983	Jan	CAHN

SOLUTION; TOPICAL

ERYDERM

@ ARBOR PHARMS INC	2%	A062290 001		Jan	CAHN
--------------------	----	-------------	--	-----	------

ERYTHROMYCIN

@ COREPHARMA	2%	A064127 001	Feb 14, 1997	Apr	CAHN
--------------	----	-------------	--------------	-----	------

SWAB; TOPICAL

ERYCETTE

@ ORTHO JANSSEN	2%	N050594 001	Feb 15, 1985	Jul	CAHN
-----------------	----	-------------	--------------	-----	------

ERYTHROMYCIN

@ COREPHARMA	2%	A064128 001	Jul 03, 1996	Apr	CAHN
--------------	----	-------------	--------------	-----	------

TABLET; ORAL

ERYTHROMYCIN

ARBOR PHARMS INC	250MG	A061621 001		Jan	CAHN
------------------	-------	-------------	--	-----	------

+	500MG	A061621 002		Jan	CAHN
---	-------	-------------	--	-----	------

TABLET, COATED PARTICLES; ORAL

PCE

ARBOR PHARMS INC	333MG	N050611 001	Sep 09, 1986	Jan	CAHN
------------------	-------	-------------	--------------	-----	------

+	500MG	N050611 002	Aug 22, 1990	Jan	CAHN
---	-------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

@ ARBOR PHARMS INC	250MG	A060272 001		Jan	CAHN
--------------------	-------	-------------	--	-----	------

@	333MG	A060272 002		Jan	CAHN
---	-------	-------------	--	-----	------

ERY-TAB

+	ARBOR PHARMS INC	250MG	A062298 001		Jan	CAHN
---	------------------	-------	-------------	--	-----	------

+		333MG	A062298 003	Mar 29, 1982	Jan	CAHN
---	--	-------	-------------	--------------	-----	------

+		500MG	A062298 002		Jan	CAHN
---	--	-------	-------------	--	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207 001		Jan	CAHN
----	------------------	-------------------	-------------	--	-----	------

ERYPED

AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207 003	Mar 30, 1987	Jan	CAHN
----	------------------	-------------------	-------------	--------------	-----	------

+		EQ 400MG BASE/5ML	N050207 002		Jan	CAHN
---	--	-------------------	-------------	--	-----	------

SUSPENSION; ORAL

E.E.S. 200

AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639 001		Jan	CAHN
----	------------------	-------------------	-------------	--	-----	------

E.E.S. 400

AB	+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639 002		Jan	CAHN
----	---	------------------	-------------------	-------------	--	-----	------

PEDIAMYCIN

AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304 001		Jan	CAHN
----	------------------	-------------------	-------------	--	-----	------

PEDIAMYCIN 400

AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304 002		Jan	CAHN
----	------------------	-------------------	-------------	--	-----	------

TABLET; ORAL

E.E.S. 400

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061905 002	Aug 12, 1982	Jan	CAHN
----	---	------------------	---------------	-------------	--------------	-----	------

@		EQ 400MG BASE	A061905 001		Jan	CAHN
---	--	---------------	-------------	--	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061904 001		Jan	CAHN
----	---	------------------	---------------	-------------	--	-----	------

TABLET, CHEWABLE; ORAL

E.E.S.

@ ARBOR PHARMS INC	EQ 200MG BASE	N050297 002		Jan	CAHN
--------------------	---------------	-------------	--	-----	------

ERYPED

@ ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988	Jan	CAHN
--------------------	---------------	-------------	--------------	-----	------

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

@ ARBOR PHARMS INC	EQ 125MG BASE	A060359 002	Jan	CAHN
+	EQ 250MG BASE	A060359 001	Aug	CRLD
	EQ 250MG BASE	A060359 001	Jan	CAHN
@	EQ 500MG BASE	A060359 003	Aug	DISC
+	EQ 500MG BASE	A060359 003	Jan	CAHN

ESTRADIOL

TABLET; ORAL

ESTRACE

@ BRISTOL MYERS SQUIBB	0.5MG	A081295 001	Jun 30, 1993	Aug	DISC
------------------------	-------	-------------	--------------	-----	------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907 002	Dec 28, 2006	Mar	CTEC
	ESTRADIOL AND NORETHINDRONE ACETATE					
AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324 002	Jun 09, 2011	May	NEWA

ESTROPIPATE

CREAM; VAGINAL

OGEN

@ PHARMACIA AND UPJOHN	1.5MG/GM	A084710 001		Apr	DISC
------------------------	----------	-------------	--	-----	------

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

>D>	AB	LUPIN LTD	1MG	A091124 001	Sep 13, 2011	Oct	DISC
>A>		@	1MG	A091124 001	Sep 13, 2011	Oct	DISC
	AB		1MG	A091124 001	Sep 13, 2011	Aug	NEWA
>D>	AB		2MG	A091124 002	Sep 13, 2011	Oct	DISC
>A>		@	2MG	A091124 002	Sep 13, 2011	Oct	DISC
	AB		2MG	A091124 002	Sep 13, 2011	Aug	NEWA
>D>	AB		3MG	A091124 003	Sep 13, 2011	Oct	DISC
>A>		@	3MG	A091124 003	Sep 13, 2011	Oct	DISC
	AB		3MG	A091124 003	Sep 13, 2011	Aug	NEWA
		@ TEVA	1MG	A091169 001	May 23, 2011	Jun	DISC
	AB		1MG	A091169 001	May 23, 2011	May	NEWA
		@	2MG	A091169 002	May 23, 2011	Jun	DISC
	AB		2MG	A091169 002	May 23, 2011	May	NEWA
		@	3MG	A091169 003	May 23, 2011	Jun	DISC
	AB		3MG	A091169 003	May 23, 2011	May	NEWA
		@ WOCKHARDT LTD	1MG	A091165 001	Jul 14, 2011	Jul	NEWA
		@	2MG	A091165 002	Jul 14, 2011	Jul	NEWA
		@	3MG	A091165 003	Jul 14, 2011	Jul	NEWA
	LUNESTA						
>D>	AB	SUNOVION PHARMS INC	1MG	N021476 001	Dec 15, 2004	Oct	CTEC
>A>			1MG	N021476 001	Dec 15, 2004	Oct	CTEC
	AB		1MG	N021476 001	Dec 15, 2004	Aug	CTEC
			1MG	N021476 001	Dec 15, 2004	Jun	CTEC
	AB		1MG	N021476 001	Dec 15, 2004	May	CFTG
>D>	AB		2MG	N021476 002	Dec 15, 2004	Oct	CTEC
>A>			2MG	N021476 002	Dec 15, 2004	Oct	CTEC

TABLET; ORAL

LUNESTA

AB		SUNOVION PHARMS INC	2MG	N021476	002	Dec 15, 2004	Aug	CTEC
			2MG	N021476	002	Dec 15, 2004	Jun	CTEC
AB			2MG	N021476	002	Dec 15, 2004	May	CFTG
>D>	AB	+	3MG	N021476	003	Dec 15, 2004	Oct	CTEC
>A>		+	3MG	N021476	003	Dec 15, 2004	Oct	CTEC
	AB	+	3MG	N021476	003	Dec 15, 2004	Aug	CTEC
		+	3MG	N021476	003	Dec 15, 2004	Jun	CTEC
	AB	+	3MG	N021476	003	Dec 15, 2004	May	CFTG

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A>	AB	LUPIN LTD	0.02MG,0.01MG;0.1MG,N/A	A091674	001	Oct 26, 2011	Oct	NEWA
>A>	AB	WATSON LABS	0.02MG,0.01MG;0.1MG,N/A	A200407	001	Oct 25, 2011	Oct	NEWA
	AB		0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

	AB	WATSON LABS	0.03MG,0.01MG;0.15MG,N/A	A078834	001	May 31, 2011	May	NEWA
		LOSEASONIQUE						
>D>		TEVA WOMENS	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Oct	CFTG
>A>	AB		0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Oct	CFTG
			0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Aug	CAHN

LYBREL

AB	+	WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	CFTG
----	---	------------------	---------------	---------	-----	--------------	-----	------

SEASONIQUE

AB	+	TEVA WOMENS	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	May	CFTG
----	---	-------------	--------------------------	---------	-----	--------------	-----	------

TABLET; ORAL-21

ALESSE

		@ AKRIMAX PHARMS	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Jul	CAHN
		@ WYETH PHARMS	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Aug	CAHN

TRIPHASIL-21

		@ WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N019192	001	Nov 01, 1984	Aug	CAHN
--	--	----------------	---	---------	-----	--------------	-----	------

TABLET; ORAL-28

ALESSE

		@ AKRIMAX PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Jul	CAHN
		@ WYETH PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Aug	CAHN

ORSYTHIA

AB1		VINTAGE PHARMS	0.02MG;0.1MG	A077099	001	May 11, 2011	Apr	NEWA
-----	--	----------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

BRIELLYN

AB		GLENMARK GENERICS	0.035MG;0.4MG	A090538	001	Mar 22, 2011	Mar	NEWA
----	--	-------------------	---------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

	+	WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan	CRLD
AB		WATSON LABS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	Sep	NEWA
	+	WATSON LABS INC	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jun	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LO LOESTRIN FE

	+	WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May	CRLD
--	---	--------------------	-----------------------	---------	-----	--------------	-----	------

TABLET; ORAL-28									
GILDESS FE 1.5/30									
AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jan	CTNA		
GILDESS FE 1/20									
AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Jan	CTNA		
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>									
TABLET; ORAL									
NORGESTIMATE AND ETHINYL ESTRADIOL									
AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Jun	NEWA		
TABLET; ORAL-28									
NORGESTIMATE AND ETHINYL ESTRADIOL									
AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb	NEWA		
<u>ETHINYL ESTRADIOL; NORGESTREL</u>									
TABLET; ORAL-21									
OVRAL									
	@ WYETH PHARMS	0.05MG;0.5MG	N016672	001		Aug	CAHN		
TABLET; ORAL-28									
LO/OVRAL-28									
AB	WYETH PHARMS	0.03MG;0.3MG	N017802	001		Aug	CAHN		
OVRAL-28									
	@ WYETH PHARMS	0.05MG;0.5MG	N016806	001		Aug	CAHN		
<u>ETHOSUXIMIDE</u>									
CAPSULE; ORAL									
ETHOSUXIMIDE									
AB	VERSAPHARM	250MG	A040686	001	May 28, 2008	May	CAHN		
<u>ETODOLAC</u>									
CAPSULE; ORAL									
ETODOLAC									
	@ MYLAN	200MG	A075071	001	Sep 30, 1998	Feb	CAHN		
	@	300MG	A075071	002	Sep 30, 1998	Feb	CAHN		
TABLET; ORAL									
ETODOLAC									
	@ ACTAVIS ELIZABETH	400MG	A074819	001	Feb 28, 1997	Aug	DISC		
	@	500MG	A074819	002	Apr 28, 1998	Sep	NEWA		
	@ MYLAN	400MG	A075012	001	Sep 30, 1998	Feb	CAHN		
	@	500MG	A075012	002	Sep 30, 1998	Feb	CAHN		
<u>ETONOGESTREL</u>									
IMPLANT; IMPLANTATION									
NEXPLANON									
+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011	May	NEWA		
<u>ETRAVIRINE</u>									
TABLET; ORAL									
INTELENCE									
	TIBOTEC	100MG	N022187	001	Jan 18, 2008	Jan	CRLD		
+		200MG	N022187	002	Dec 22, 2010	Jan	NEWA		

EXEMESTANE

TABLET; ORAL

AROMASIN

AB	+	PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999	Mar	CFTG
----	---	----------------------	------	---------	-----	--------------	-----	------

EXEMESTANE

AB		ROXANE	25MG	A077431	001	Apr 01, 2011	Mar	NEWA
----	--	--------	------	---------	-----	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

>A>		MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Oct	CAHN
>A>			10MG;20MG	N021687	002	Jul 23, 2004	Oct	CAHN
>A>			10MG;40MG	N021687	003	Jul 23, 2004	Oct	CAHN
>A>	+		10MG;80MG	N021687	004	Jul 23, 2004	Oct	CAHN
>D>		MSP SINGAPORE	10MG;10MG	N021687	001	Jul 23, 2004	Oct	CAHN
>D>			10MG;20MG	N021687	002	Jul 23, 2004	Oct	CAHN
>D>			10MG;40MG	N021687	003	Jul 23, 2004	Oct	CAHN
>D>	+		10MG;80MG	N021687	004	Jul 23, 2004	Oct	CAHN

EZOGABINE

TABLET; ORAL

POTIGA

VALEANT PHARMS

+

50MG	N022345	001	Jun 10, 2011	Jun	NEWA
200MG	N022345	002	Jun 10, 2011	Jun	NEWA
300MG	N022345	003	Jun 10, 2011	Jun	NEWA
400MG	N022345	004	Jun 10, 2011	Jun	NEWA

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB		APOTEX	125MG	A091480	001	Jul 22, 2011	Jul	NEWA
AB			250MG	A091480	002	Jul 22, 2011	Jul	NEWA
AB			500MG	A091480	003	Jul 22, 2011	Jul	NEWA
AB		AUROBINDO PHARMA LTD	125MG	A091114	001	Mar 21, 2011	Mar	NEWA
AB			250MG	A091114	002	Mar 21, 2011	Mar	NEWA
AB			500MG	A091114	003	Mar 21, 2011	Mar	NEWA
AB		MYLAN	125MG	A201333	001	Mar 24, 2011	Mar	NEWA
AB			250MG	A201333	002	Mar 24, 2011	Mar	NEWA
AB			500MG	A201333	003	Mar 24, 2011	Mar	NEWA
AB		ROXANE	125MG	A090128	001	Mar 21, 2011	Mar	NEWA
AB			250MG	A090128	002	Mar 21, 2011	Mar	NEWA
AB			500MG	A090128	003	Mar 21, 2011	Mar	NEWA
AB		WATSON LABS	125MG	A078278	001	Mar 21, 2011	Mar	NEWA
AB			250MG	A078278	002	Mar 21, 2011	Mar	NEWA
AB			500MG	A078278	003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

@ HOSPIRA

AP		PFIZER	10MG/ML	A075870	001	Nov 23, 2001	Aug	DISC
			10MG/ML	A078641	001	Jun 25, 2008	May	CAHN

FAMOTIDINE PRESERVATIVE FREE

AP		PFIZER	10MG/ML	A078642	001	Jun 25, 2008	May	CAHN
----	--	--------	---------	---------	-----	--------------	-----	------

PEPCID

@ MERCK

10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC
---------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

PEPCID PRESERVATIVE FREE

@ MERCK 10MG/ML

N019510 004 Nov 04, 1986 Jan DISC

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

@ MERCK 0.4MG/ML

N020249 001 Feb 18, 1994 Jan DISC

TABLET; ORAL

FAMOTIDINE

@ ACTAVIS ELIZABETH 20MG

A075650 001 Sep 14, 2001 Aug DISC

@ 40MG

A075650 002 Sep 14, 2001 Aug DISC

AB ALEMBIC PHARMS LTD 20MG

A078916 001 May 22, 2009 Jul CAHN

AB 40MG

A078916 002 May 22, 2009 Jul CAHN

AB MYLAN 20MG

A075457 001 Apr 18, 2001 Feb CAHN

AB 40MG

A075457 002 Apr 18, 2001 Feb CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+ HORIZON PHARMA 26.6MG;800MG

N022519 001 Apr 23, 2011 Apr NEWA

FELBAMATE

TABLET; ORAL

FELBAMATE

AB AMNEAL PHARMS 400MG

A201680 001 Sep 13, 2011 Aug NEWA

AB 600MG

A201680 002 Sep 13, 2011 Aug NEWA

FELBATOL

AB MEDA PHARMS 400MG

N020189 001 Jul 29, 1993 Aug CFTG

AB + 600MG

N020189 002 Jul 29, 1993 Aug CFTG

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>A> AB ENDO PHARMS 2.5MG

A200815 001 Oct 28, 2011 Oct NEWA

>A> AB 5MG

A200815 002 Oct 28, 2011 Oct NEWA

>A> AB 10MG

A200815 003 Oct 28, 2011 Oct NEWA

FENOFIBRATE

CAPSULE; ORAL

LIPOFEN

@ CIPHER PHARMS INC 100MG

N021612 002 Jan 11, 2006 Sep DISC

TABLET; ORAL

FENOGLIDE

SHORE THERAP 40MG

N022118 001 Aug 10, 2007 Feb CAHN

+ 120MG

N022118 002 Aug 10, 2007 Feb CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB MALLINCKRODT INC 100MCG/HR

A077154 004 Feb 09, 2011 Jan NEWA

FENTANYL-25

AB MALLINCKRODT INC 25MCG/HR

A077154 001 Feb 09, 2011 Jan NEWA

FENTANYL-50

AB MALLINCKRODT INC 50MCG/HR

A077154 002 Feb 09, 2011 Jan NEWA

FENTANYL-75

AB MALLINCKRODT INC 75MCG/HR

A077154 003 Feb 09, 2011 Jan NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

ARCHIMEDES

100MCG

N022569 001 Jun 30, 2011 Jun NEWA

+

400MCG

N022569 002 Jun 30, 2011 Jun NEWA

TABLET; SUBLINGUAL

ABSTRAL

PROSTRAKAN INC

EQ 0.1MG BASE

N022510 001 Jan 07, 2011 Jan NEWA

EQ 0.2MG BASE

N022510 002 Jan 07, 2011 Jan NEWA

EQ 0.3MG BASE

N022510 003 Jan 07, 2011 Jan NEWA

+

EQ 0.4MG BASE

N022510 004 Jan 07, 2011 Jan NEWA

EQ 0.6MG BASE

N022510 005 Jan 07, 2011 Jan NEWA

EQ 0.8MG BASE

N022510 006 Jan 07, 2011 Jan NEWA

FIDAXOMICIN

TABLET; ORAL

DIFICID

+

OPTIMER PHARMS

200MG

N201699 001 May 27, 2011 May NEWA

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB

SUN PHARMA GLOBAL

1MG

A090508 001 Oct 03, 2011 Sep NEWA

AB

5MG

A090507 001 Aug 16, 2011 Aug NEWA

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB

AMNEAL PHARM

50MG

A078423 001 Mar 07, 2011 Feb NEWA

AB

100MG

A078423 002 Mar 07, 2011 Feb NEWA

AB

150MG

A078423 003 Mar 07, 2011 Feb NEWA

AB

200MG

A078423 004 Mar 07, 2011 Feb NEWA

AB

MYLAN

50MG

A076042 001 Jul 29, 2004 Feb CAHN

AB

100MG

A076042 002 Jul 29, 2004 Feb CAHN

AB

150MG

A076042 003 Jul 29, 2004 Feb CAHN

AB

200MG

A076042 004 Jul 29, 2004 Feb CAHN

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

AB

VALEANT

250MG

N017001 001 Jun CFTG

AB

+

500MG

N017001 002 Jun CFTG

FLUCYTOSINE

AB

SIGMAPHARM LABS LLC

250MG

A201566 001 Jun 28, 2011 Jun NEWA

AB

500MG

A201566 002 Jun 28, 2011 Jun NEWA

FLUDARABINE PHOSPHATE

TABLET; ORAL

OFORTA

+

SANOFI AVENTIS US

10MG

N022273 001 Dec 18, 2008 Apr CMFD

@

10MG

N022273 001 Dec 18, 2008 Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	Feb	CTEC
AP		PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	Feb	NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB		WEST-WARD PHARM CORP	0.1MG	A091302	001	Jul 22, 2011	Jul	NEWA
----	--	----------------------	-------	---------	-----	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP		PFIZER	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	May	CAHN
AP			1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	May	CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

>D>		@ G AND W LABS	0.025%	A089525	001	Jul 26, 1988	Oct	CMFD
>A>	AT		0.025%	A089525	001	Jul 26, 1988	Oct	CMFD

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N012787	004		Jun	CAHN
AT	+		0.025%	N012787	002		Jun	CAHN
AT	+		0.025%	N012787	005		Jun	CAHN

SYNALAR-HP

@ MEDIMETRIKS PHARMS

0.2%	N016161	002		Jun	CAHN
------	---------	-----	--	-----	------

OIL; TOPICAL

DERMA-SMOOTH/FS

>D>	+	HILL DERMAC	0.01%	N019452	002	Nov 09, 2005	Oct	CFTG
>D>	+		0.01%	N019452	001	Feb 03, 1988	Oct	CFTG
>A>	AT	+	0.01%	N019452	001	Feb 03, 1988	Oct	CFTG
>A>	AT	+	0.01%	N019452	002	Nov 09, 2005	Oct	CFTG
>A>		FLUOCINOLONE ACETONIDE						
>A>	AT	IDENTI PHARMS INC	0.01%	A201759	001	Oct 17, 2011	Oct	NEWA
>A>	AT		0.01%	A201764	001	Oct 17, 2011	Oct	NEWA

OIL/DROPS; OTIC

DERMOTIC

>D>	+	HILL DERMAC	0.01%	N019452	003	Nov 09, 2005	Oct	CFTG
>A>	AT	+	0.01%	N019452	003	Nov 09, 2005	Oct	CFTG
>A>		FLUOCINOLONE ACETONIDE						
>A>	AT	IDENTI PHARMS INC	0.1%	A091306	001	Oct 17, 2011	Oct	NEWA

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

>D>		@ G AND W LABS	0.025%	A089524	001	Jul 26, 1988	Oct	CMFD
>A>	AT		0.025%	A089524	001	Jul 26, 1988	Oct	CMFD

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.025%	N013960	001		Jun	CAHN
----	---	--------------------	--------	---------	-----	--	-----	------

SOLUTION; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N015296	001		Jun	CAHN
----	---	--------------------	-------	---------	-----	--	-----	------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

@ MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700 001	Aug	CAHN
----------------------	-------------------------	-------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	SANDOZ	2.5GM/50ML (50MG/ML)	A091299 001	May 02, 2011	Apr	NEWA
AP		5GM/100ML (50MG/ML)	A091299 002	May 02, 2011	Apr	NEWA
	@ VALEANT	500MG/10ML (50MG/ML)	N012209 001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223 001	Mar 19, 2009	Apr	CAHN
AB1		EQ 20MG BASE	A090223 002	Mar 19, 2009	Apr	CAHN
AB		EQ 40MG BASE	A090223 003	Mar 19, 2009	Apr	CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>A>	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133 001	Oct 06, 2011	Oct	NEWA
-----	---------------------	--------------	-------------	--------------	-----	------

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

>D>	@ WATSON PHARMS	0.025%	N012806 003		Oct	CMFD
>A>		0.025%	N012806 003		Oct	CMFD
	@	0.025%	N012806 003		Jul	DISC
	@	0.05%	N012806 002		Jul	DISC

OINTMENT; TOPICAL

CORDRAN

@ WATSON PHARMS	0.025%	N012806 004	Jun	DISC
@	0.05%	N012806 001	Jun	DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

>D>	DALMANE					
>D>	AB VALEANT PHARM INTL	15MG	N016721 001		Oct	DISC
>A>	@	15MG	N016721 001		Oct	DISC
>D>	AB +	30MG	N016721 002		Oct	DISC
>A>	@	30MG	N016721 002		Oct	DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	MYLAN	125MG	A076224 001	May 09, 2003	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

LOTION; TOPICAL

CUTIVATE

AB	+ NYCOMED US	0.05%	N021152 001	Mar 31, 2005	Apr	CFTG
	FLUTICASONE PROPIONATE					
AB	GLENMARK GENERICS	0.05%	A090759 001	May 02, 2011	Apr	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN	50MG	A075950 001	Oct 15, 2001	Feb	CAHN
@	100MG	A075950 002	Oct 15, 2001	Feb	CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	+	AMNEAL PHARM	1MG	A040625 001	Jul 21, 2005	Apr	CAHN
AA		JUBILANT CADISTA	1MG	A040514 001	Jun 14, 2005	Jan	CAHN
		@ MUTUAL PHARM	1MG	A040582 001	Jul 18, 2005	Sep	DISC

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

AP	+	GLAXOSMITHKLINE	2.5MG/0.5ML	N021345 001	Dec 07, 2001	Jun	CFTG
AP	+		5MG/0.4ML	N021345 002	May 28, 2004	Jun	CFTG
AP	+		7.5MG/0.6ML	N021345 003	May 28, 2004	Jun	CFTG
AP	+		10MG/0.8ML	N021345 004	May 28, 2004	Jun	CFTG

FONDAPARINUX SODIUM

AP		DR REDDYS LABS LTD	2.5MG/0.5ML	A091316 001	Jul 11, 2011	Jun	NEWA
AP			5MG/0.4ML	A091316 002	Jul 11, 2011	Jun	NEWA
AP			7.5MG/0.6ML	A091316 003	Jul 11, 2011	Jun	NEWA
AP			10MG/0.8ML	A091316 004	Jul 11, 2011	Jun	NEWA

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

@ NOVARTIS	0.0085MG/INH	N021592 001	Dec 15, 2006	Jun	DISC
------------	--------------	-------------	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB		AUROBINDO PHARMA LTD	10MG	A091163 001	Mar 30, 2011	Mar	NEWA
AB			20MG	A091163 002	Mar 30, 2011	Mar	NEWA
AB			40MG	A091163 003	Mar 30, 2011	Mar	NEWA

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		EMCURE PHARMS USA	10MG;12.5MG	A079025 001	Sep 17, 2010	Jul	CAHN
AB			20MG;12.5MG	A079025 002	Sep 17, 2010	Jul	CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	+	APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052 001	Aug 06, 2007	Apr	CRLD
AP		PFIZER	EQ 50MG PNENYTOIN NA/ML	A078476 001	Mar 18, 2008	May	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB		MARKSANS PHARMA	100MG	A090007 001	Jul 21, 2011	Jul	NEWA
AB			300MG	A090007 002	Jul 21, 2011	Jul	NEWA

CAPSULE; ORAL

GABAPENTIN

AB	MARKSANS PHARMA	400MG	A090007 003	Jul 21, 2011	Jul	NEWA
AB	MATRIX LABS LTD	100MG	A090158 001	Feb 14, 2011	Jan	NEWA
AB		300MG	A090158 002	Feb 14, 2011	Jan	NEWA
AB		400MG	A090158 003	Feb 14, 2011	Jan	NEWA
AB	MYLAN	100MG	A090158 001	Feb 14, 2011	May	CAHN
AB		300MG	A090158 002	Feb 14, 2011	May	CAHN
AB		400MG	A090158 003	Feb 14, 2011	May	CAHN

SOLUTION; ORAL

GABAPENTIN

AA	HI TECH PHARMA	250MG/5ML	A078974 001	Feb 18, 2011	Feb	NEWA
----	----------------	-----------	-------------	--------------	-----	------

NEURONTIN

AA	+ PARKE DAVIS	250MG/5ML	N021129 001	Mar 02, 2000	Feb	CFTG
----	---------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

GABAPENTIN

AB	AUROBINDO PHARMA LTD	600MG	A200651 001	Oct 06, 2011	Sep	NEWA
AB		800MG	A200651 002	Oct 06, 2011	Sep	NEWA
AB	HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011	Jul	NEWA
AB		800MG	A078782 002	Jul 21, 2011	Jul	NEWA
AB	ZYDUS PHARMS USA INC	600MG	A078926 001	Feb 11, 2011	Jan	NEWA
AB		800MG	A078926 002	Feb 11, 2011	Jan	NEWA

GRALISE

BX	+ ABBOTT PRODS	300MG	N022544 001	Jan 28, 2011	Jan	NEWA
BX	+	600MG	N022544 002	Jan 28, 2011	Jan	NEWA
BX	+ DEPOMED INC	300MG	N022544 001	Jan 28, 2011	Jul	CAHN
BX	+	600MG	N022544 002	Jan 28, 2011	Jul	CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

+	GLAXO GRP LTD	600MG	N022399 001	Apr 06, 2011	Apr	NEWA
---	---------------	-------	-------------	--------------	-----	------

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011	Mar	NEWA
+		6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011	Mar	NEWA
+		9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011	Mar	NEWA
+		18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011	Mar	NEWA
+		39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB	MYLAN	EQ 8MG BASE	A090900 001	Jan 24, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090900 002	Jan 24, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090900 003	Jan 24, 2011	Jan	NEWA
AB	SUN PHARMA GLOBAL	EQ 8MG BASE	A090178 001	Feb 02, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090178 002	Feb 02, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090178 003	Feb 02, 2011	Jan	NEWA
	RAZADYNE ER					
AB	+ JANSSEN PHARMS	EQ 8MG BASE	N021615 001	Apr 01, 2005	Jul	CAHN
AB		EQ 16MG BASE	N021615 002	Apr 01, 2005	Jul	CAHN
AB		EQ 24MG BASE	N021615 003	Apr 01, 2005	Jul	CAHN

SOLUTION; ORAL

RAZADYNE

AA	+	JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	Jul	CAHN
----	---	----------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

	@	ACTAVIS ELIZABETH	EQ 4MG BASE	A077585	001	Sep 15, 2009	Aug	DISC
	@		EQ 8MG BASE	A077585	002	Sep 15, 2009	Aug	DISC
	@		EQ 12MG BASE	A077585	003	Sep 15, 2009	Aug	DISC
AB		APOTEX INC	EQ 4MG BASE	A077781	001	Sep 27, 2011	Sep	NEWA
AB			EQ 8MG BASE	A077781	002	Sep 27, 2011	Sep	NEWA
AB			EQ 12MG BASE	A077781	003	Sep 27, 2011	Sep	NEWA
AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957	001	Mar 29, 2011	Mar	NEWA
AB			EQ 8MG BASE	A090957	002	Mar 29, 2011	Mar	NEWA
AB			EQ 12MG BASE	A090957	003	Mar 29, 2011	Mar	NEWA
AB		ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898	001	Feb 17, 2011	Jan	NEWA
AB			EQ 8MG BASE	A078898	002	Feb 17, 2011	Jan	NEWA
AB			EQ 12MG BASE	A078898	003	Feb 17, 2011	Jan	NEWA

RAZADYNE

AB	+	JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001	Jul	CAHN
AB			EQ 8MG BASE	N021169	002	Feb 28, 2001	Jul	CAHN
AB			EQ 12MG BASE	N021169	003	Feb 28, 2001	Jul	CAHN

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT		APOTEX CORP	0.3%	A079084	001	Aug 19, 2011	Aug	NEWA
		ZYMAR						
AT	+	ALLERGAN	0.3%	N021493	001	Mar 28, 2003	Aug	CFTG

GEFITINIB

TABLET; ORAL

IRESSA

	@	ASTRAZENECA	250MG	N021399	001	May 05, 2003	Sep	DISC
--	---	-------------	-------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Aug	NEWA
+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Aug	NEWA
+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Aug	NEWA
+		EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD

GEMCITABINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Jul	NEWA
AP		ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Jul	NEWA
AP		APP PHARMS	EQ 2GM BASE/VIAL	A090242	003	May 16, 2011	May	NEWA
AP		DR REDDYS LABS LTD	EQ 200MG BASE/VIAL	A091365	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A091365	002	Jul 25, 2011	Jul	NEWA
AP		FRESENIUS KABI ONCOL	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	May	NEWA
AP		HOSPIRA	EQ 200MG BASE/VIAL	A078339	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078339	002	Jul 25, 2011	Jul	NEWA
AP	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Jul	CTEC

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	May	CTNA
AP		ONCO THERAPIES LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	Jul	NEWA
AP		SUN PHARMA GLOBAL	EQ 200MG BASE/VIAL	A078433	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078433	002	Jul 25, 2011	Jul	NEWA
AP		TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA
AP		WATSON LABS	EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Jul	NEWA
		GEMZAR						
AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN
----	--	------------	-------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT		NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN
----	--	-------------	--------------	---------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB		MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
AB			2MG	A077486	002	Feb 10, 2006	Feb	CAHN
AB			4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB		MYLAN	5MG	A074438	001	Jun 20, 1995	Aug	CAHN
AB			10MG	A074438	002	Jun 20, 1995	Aug	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	+	TEVA PHARMS	5MG;500MG	A077270	003	Oct 28, 2005	Aug	CRLD
AB		ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
AB			2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
AB			5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA

METAGLIP

@ BRISTOL MYERS SQUIBB 2.5MG;250MG

N021460 001 Oct 21, 2002 Aug DISC

@ 2.5MG;500MG

N021460 002 Oct 21, 2002 Aug DISC

@ 5MG;500MG

N021460 003 Oct 21, 2002 Aug DISC

GLUTAMINE

FOR SOLUTION; ORAL
NUTRESTORE

+ EMMAUS MEDCL 5GM/PACKET N021667 001 Jun 10, 2004 May CAHN

GLYBURIDE

TABLET; ORAL

GLYBURIDE

@ ACTAVIS TOTOWA

1.5MG

A075947 001 Nov 14, 2002 Jul DISC

@

3MG

A075947 002 Nov 14, 2002 Jul DISC

@

6MG

A075947 003 Nov 14, 2002 Jul DISC

AB HERITAGE PHARMS INC

1.25MG

A090937 001 Feb 28, 2011 May CAHN

AB

2.5MG

A090937 002 Feb 28, 2011 May CAHN

AB

5MG

A090937 003 Feb 28, 2011 May CAHN

AB INDICUS PHARMA

1.25MG

A090937 001 Feb 28, 2011 Feb NEWA

AB

2.5MG

A090937 002 Feb 28, 2011 Feb NEWA

AB

5MG

A090937 003 Feb 28, 2011 Feb NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP HIKMA FARMACEUTICA

0.2MG/ML

A090963 001 Sep 21, 2011 Sep NEWA

TABLET; ORAL

GLYCOPYRROLATE

>A> AA

BOCA PHARMA

1MG

A090020 001 Oct 19, 2011 Oct NEWA

>A> AA

2MG

A090020 002 Oct 19, 2011 Oct NEWA

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL
SANCUSO

+ PROSTRAKAN INC

3.1MG/24HR

N022198 001 Sep 12, 2008 Jun CAHN

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@ ELORAC

125MG

A061996 001 Jan CAHN

@

250MG

A061996 002 Jan CAHN

FULVICIN P/G 165

@ ELORAC

165MG

A061996 003 Apr 06, 1982 Jan CAHN

FULVICIN P/G 330

@ ELORAC

330MG

A061996 004 Apr 06, 1982 Jan CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

@ ACTAVIS MID ATLANTIC

0.05%

A077109 001 Jun 14, 2005 Aug DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP PFIZER

EQ 5MG BASE/ML

A078347 001 Sep 14, 2009 May CAHN

AP SAGENT PHARMS

EQ 5MG BASE/ML

A200742 001 Sep 02, 2011 Aug NEWA

AP

EQ 5MG BASE/ML

A091637 001 Sep 02, 2011 Aug NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	PFIZER	1,000 UNITS/ML	N201370 001	Jul 21, 2011	Jul	NEWA
		5,000 UNITS/ML	N201370 002	Jul 21, 2011	Jul	NEWA
		10,000 UNITS/ML	N201370 003	Jul 21, 2011	Jul	NEWA
AP	SANDOZ	1,000 UNITS/ML	A091682 001	Jun 08, 2011	May	NEWA
AP		5,000 UNITS/ML	A091659 001	Jun 08, 2011	May	NEWA
AP		5,000 UNITS/ML	A091682 002	Jun 08, 2011	May	NEWA
AP		10,000 UNITS/ML	A201002 001	Jun 08, 2011	May	NEWA
	HEPARIN SODIUM PRESERVATIVE FREE					
	PFIZER	1,000 UNITS/ML	N201370 004	Jul 21, 2011	Jul	NEWA

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	GE HEALTHCARE	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
---	---------------	------------	-------------	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AB	NOVEL LABS INC	1.5MG;5MG	A091528 001	Apr 20, 2011	Apr	NEWA
	TUSSIGON					
AB	+ KING PHARMS	1.5MG;5MG	A088508 001	Jul 30, 1985	Apr	CTEC

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

+	AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jul	CAHN
---	-----------	--------------	-------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA	HETERO LABS UNIT III	10MG	A040901 001	Sep 12, 2008	Jul	CAHN
AA		25MG	A040901 002	Sep 12, 2008	Jul	CAHN
AA		50MG	A040901 003	Sep 12, 2008	Jul	CAHN
AA		100MG	A040901 004	Sep 12, 2008	Jul	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG	A200645 001	Nov 30, 2010	Apr	CAHN
AB	JUBILANT CADISTA	12.5MG	A078391 001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	@ ACTAVIS ELIZABETH	25MG	A085054 002		Aug	DISC
	@	50MG	A085208 001		Aug	DISC
AB	JUBILANT CADISTA	25MG	A040809 001	Sep 04, 2007	Jan	CAHN
AB		50MG	A040809 002	Sep 04, 2007	Jan	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

	@ SANOFI AVENTIS	12.5MG;75MG	N020758 001	Sep 30, 1997	Jun	CAHN
+		12.5MG;150MG	N020758 002	Sep 30, 1997	Sep	CRLD

TABLET; ORAL

AVALIDE

	SANOFI AVENTIS	12.5MG;150MG	N020758 002	Sep 30, 1997	Jun	CAHN
		12.5MG;300MG	N020758 003	Aug 31, 1998	Sep	CRLD
+		12.5MG;300MG	N020758 003	Aug 31, 1998	Aug	CRLD
		12.5MG;300MG	N020758 003	Aug 31, 1998	Jun	CAHN
@		25MG;300MG	N020758 004	Mar 15, 2005	Aug	DISC
+		25MG;300MG	N020758 004	Mar 15, 2005	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;10MG	A076230 001	Jul 01, 2002	Aug	CAHN
AB		12.5MG;20MG	A076230 002	Jul 01, 2002	Aug	CAHN
AB		25MG;20MG	A076230 003	Jul 01, 2002	Aug	CAHN
AB	PRINSTON PHARM LLC	12.5MG;10MG	A076230 001	Jul 01, 2002	May	CAHN
AB		12.5MG;20MG	A076230 002	Jul 01, 2002	May	CAHN
AB		25MG;20MG	A076230 003	Jul 01, 2002	May	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180 001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180 002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180 003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A201356 001	Apr 20, 2011	Apr	NEWA
AB		12.5MG;20MG	A201356 002	Apr 20, 2011	Apr	NEWA
AB		25MG;20MG	A201356 003	Apr 20, 2011	Apr	NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

REZIRA

+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442 001	Jun 08, 2011	Jun	NEWA
---	---------------	------------------	-------------	--------------	-----	------

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

AT	CROWN LABS	1%	A080706 006		Sep	CAHN
----	------------	----	-------------	--	-----	------

LOTION; TOPICAL

ALA-CORT

AT	CROWN LABS	1%	A083201 001		Sep	CAHN
----	------------	----	-------------	--	-----	------

ALA-SCALP

	CROWN LABS	2%	A083231 001		Sep	CAHN
--	------------	----	-------------	--	-----	------

SOLUTION; TOPICAL

TEXACORT

+	STAYMA	2.5%	A081271 001	Apr 17, 1992	Aug	CAHN
---	--------	------	-------------	--------------	-----	------

+	TIBER LABS	2.5%	A081271 001	Apr 17, 1992	May	CAHN
---	------------	------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCORTISONE

AB	COREPHARMA	5MG	A040646 001	Mar 30, 2007	Apr	CAHN
AB		10MG	A040646 002	Mar 30, 2007	Apr	CAHN
AB		20MG	A040646 003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

@ FERA PHARMS	0.5%	A080828 001	Mar	CAHN
---------------	------	-------------	-----	------

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

@ HOSPIRA	EQ 250MG BASE/VIAL	A085930 001	Aug	DISC
-----------	--------------------	-------------	-----	------

@	EQ 500MG BASE/VIAL	A085931 001	Aug	DISC
---	--------------------	-------------	-----	------

@	EQ 1GM BASE/VIAL	A085932 001	Aug	DISC
---	------------------	-------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

HYDROFLUMETHIAZIDE

@ PAR PHARM	50MG	A088850 001	May 31, 1985	May	DISC
-------------	------	-------------	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	ELITE LABS	8MG	A076723 001	Oct 18, 2005	Feb	CAHN
----	------------	-----	-------------	--------------	-----	------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

@ MERCK SANTE SAS	2.5GM/VIAL (5GM/KIT)	N022041 002	Dec 15, 2006	Sep	DISC
-------------------	----------------------	-------------	--------------	-----	------

+	5GM/VIAL (5GM/KIT)	N022041 001	Apr 08, 2011	Sep	CMFD
---	--------------------	-------------	--------------	-----	------

@	5GM/VIAL (5GM/KIT)	N022041 001	Apr 08, 2011	Apr	DISC
---	--------------------	-------------	--------------	-----	------

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

@ PHARMICS	1%	N000004 004	Jan	CAHN
------------	----	-------------	-----	------

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+	KV PHARM	1250MG/5ML (250MG/ML)	N021945 001	Feb 03, 2011	Feb	NEWA
---	----------	-----------------------	-------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ ACTAVIS TOTOWA	10MG	A040600 001	Dec 28, 2004	Jul	DISC
------------------	------	-------------	--------------	-----	------

@	25MG	A040602 001	Dec 28, 2004	Jul	DISC
---	------	-------------	--------------	-----	------

@	50MG	A040604 001	Dec 28, 2004	Jul	DISC
---	------	-------------	--------------	-----	------

AB	HETERO LABS UNIT III	10MG	A040805 001	May 29, 2008	Jul	CAHN
----	----------------------	------	-------------	--------------	-----	------

AB		25MG	A040805 002	May 29, 2008	Jul	CAHN
----	--	------	-------------	--------------	-----	------

AB		50MG	A040805 003	May 29, 2008	Jul	CAHN
----	--	------	-------------	--------------	-----	------

IBUPROFEN

TABLET; ORAL

IBUPROHM

@ OHM LABS	400MG	A070469 001	Aug 29, 1985	Aug	DISC
------------	-------	-------------	--------------	-----	------

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

@ FOREST LABS 400MG;5MG

N021378 001 Nov 26, 2004 Aug DISC

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

AB + ACTAVIS ELIZABETH 400MG;5MG

A078769 001 Jan 04, 2008 Aug CRLD

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

+ SHIRE ORPHAN THERAP EQ 30MG BASE/3ML (EQ 10MG
BASE/ML)

N022150 001 Aug 25, 2011 Aug NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP SANDOZ 1MG/ML

A091293 001 Mar 29, 2011 Mar NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP BEDFORD LABS 1GM/20ML(50MG/ML)

A076619 001 Jun 29, 2011 Jun NEWA

AP 3GM/60ML(50MG/ML)

A076619 002 Jun 29, 2011 Jun NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

NOVARTIS

2MG

N022192 002 May 06, 2009 Jan CAHN

4MG

N022192 003 May 06, 2009 Jan CAHN

6MG

N022192 004 May 06, 2009 Jan CAHN

8MG

N022192 005 May 06, 2009 Jan CAHN

10MG

N022192 006 May 06, 2009 Jan CAHN

ILOPROST

SOLUTION; INHALATION

VENTAVIS

@ ACTELION PHARMS LTD 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004 Jun DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ ACTAVIS TOTOWA 10MG

A040753 001 Feb 28, 2008 Jul DISC

@ 25MG

A040752 001 Feb 28, 2008 Jul DISC

@ 50MG

A040751 001 Feb 28, 2008 Jul DISC

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB TARO 5%

A200173 001 Apr 15, 2011 Apr NEWA

AB TEVA PHARMS USA 5%

A200481 001 Apr 18, 2011 Apr NEWA

AB TOLMAR 5%

A091044 001 Feb 28, 2011 Feb NEWA

ZYCLARA

+ GRACEWAY 2.5%

N022483 002 Jul 15, 2011 Jul NEWA

INDACATEROL MALEATE

POWDER; INHALATION
ARCAPTA NEOHALER

+	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Jul	NEWA
---	----------	---------------	---------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	HETERO DRUGS LTD	25MG	A091240	001	Apr 12, 2011	Mar	NEWA
AB		50MG	A091240	002	Apr 12, 2011	Mar	NEWA
AB	HETERO LABS UNIT III	25MG	A091240	001	Apr 12, 2011	Jul	CAHN
AB		50MG	A091240	002	Apr 12, 2011	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	+	SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA
----	---	--------	------	---------	-----	--------------	-----	------

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA
---	-----------------	----------------------	---------	-----	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

@	HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-200 IN PLASTIC CONTAINER

@	HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250

@	HOSPIRA	51%	A075005	001	Feb 24, 1998	Aug	DISC
---	---------	-----	---------	-----	--------------	-----	------

@		51%	A074898	002	Dec 30, 1997	Feb	DISC
---	--	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250 IN PLASTIC CONTAINER

@	HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300

@	HOSPIRA	61%	A075005	002	Feb 24, 1998	Aug	DISC
---	---------	-----	---------	-----	--------------	-----	------

@		61%	A074898	003	Dec 30, 1997	Feb	DISC
---	--	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300 IN PLASTIC CONTAINER

@	HOSPIRA	61%	A074637	001	Apr 03, 1997	Aug	DISC
---	---------	-----	---------	-----	--------------	-----	------

@		61%	A074636	003	Dec 30, 1997	Feb	DISC
---	--	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370

@	HOSPIRA	76%	A075005	003	Feb 24, 1998	Aug	DISC
---	---------	-----	---------	-----	--------------	-----	------

@		76%	A074898	004	Dec 30, 1997	Feb	DISC
---	--	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370 IN PLASTIC CONTAINER

@	HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

@	ACTAVIS MID ATLANTIC	0.02%	A075111	001	Apr 22, 1999	Aug	DISC
---	----------------------	-------	---------	-----	--------------	-----	------

AN		RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul	CAHN
----	--	---------------	-------	---------	-----	--------------	-----	------

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	BIONICHE PHARMA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	NEWA
----	-----------------	--------------------	---------	-----	--------------	-----	------

AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	NEWA
----	--	---------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTIONIRINOTECAN HYDROCHLORIDE

AP	X-GEN PHARMS	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Jul	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Jul	CAHN

IRON SUCROSEINJECTABLE; INTRAVENOUSVENOFERLUITPOLDEQ 50MG BASE/2.5ML (EQ 20MG
BASE/ML)

N021135 002 Mar 20, 2005 Apr CMFD

ISOSORBIDE DINITRATETABLET; ORALISORDIL

AB	VALEANT INTL	5MG	N012093 007	Jul 29, 1988	Jun	CAHN
AB		10MG	N012093 002	Jul 29, 1988	Jun	CAHN
AB		20MG	N012093 006	Jul 29, 1988	Jun	CAHN
AB	+	30MG	N012093 005	Jul 29, 1988	Jun	CAHN
	+	40MG	N012093 001	Jul 29, 1988	Jun	CAHN

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORALISOSORBIDE MONONITRATE

AB	TORRENT PHARMS	30MG	A200270 001	Jun 03, 2011	May	NEWA
AB		60MG	A200495 001	Jun 03, 2011	May	NEWA
AB		120MG	A200495 002	Jun 03, 2011	May	NEWA

ISRADIPINECAPSULE; ORALISRADIPINE

AB	MIKAH PHARMA	2.5MG	A077169 001	Apr 24, 2006	Feb	CAHN
AB		5MG	A077169 002	Apr 24, 2006	Feb	CAHN

ITRACONAZOLEINJECTABLE; INJECTIONSPORANOX

@ ORTHO MCNEIL JANSSEN 10MG/ML

N020966 001 Mar 30, 1999 May DISC

TABLET; ORALONMEL

+ STIEFEL LABS INC 200MG

N022484 001 Apr 29, 2010 May CTNA

KETOCONAZOLEAEROSOL, FOAM; TOPICALEXTINA

AT	+	STIEFEL LABS INC	2%	N021738 001	Jun 12, 2007	Aug	CFTG
----	---	------------------	----	-------------	--------------	-----	------

KETOCONAZOLE

AT		PERRIGO ISRAEL	2%	A091550 001	Aug 25, 2011	Aug	NEWA
----	--	----------------	----	-------------	--------------	-----	------

GEL; TOPICALXOLEGEL

+ AQUA PHARMS 2%

N021946 001 Jul 28, 2006 May CAHN

KETOROLAC TROMETHAMINEINJECTABLE; INJECTIONKETOROLAC TROMETHAMINE

AP	PFIZER	15MG/ML	A078299 001	Jul 16, 2007	May	CAHN
AP		30MG/ML	A078299 002	Jul 16, 2007	May	CAHN

SPRAY, METERED; NASAL

SPRIX

+	LUITPOLD	15.75MG/SPRAY	N022382	001	May 14, 2010	May	CAHN
---	----------	---------------	---------	-----	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

AB	+	VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	May	CFTG
----	---	---------------	-------------	---------	-----	--------------	-----	------

LAMIVUDINE AND ZIDOVUDINE

AB		TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011	May	NEWA
----	--	-------------	-------------	---------	-----	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB		ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Mar	NEWA
AB			100MG	A078669	002	Apr 08, 2011	Mar	NEWA
AB			150MG	A078669	003	Apr 08, 2011	Mar	NEWA
AB			200MG	A078669	004	Apr 08, 2011	Mar	NEWA
AB		ALEMBIC LTD	25MG	A090607	001	Jan 13, 2011	Jan	NEWA
AB			100MG	A090607	002	Jan 13, 2011	Jan	NEWA
AB			150MG	A090607	003	Jan 13, 2011	Jan	NEWA
AB			200MG	A090607	004	Jan 13, 2011	Jan	NEWA
AB		ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011	Apr	CAHN
AB			100MG	A090607	002	Jan 13, 2011	Apr	CAHN
AB			150MG	A090607	003	Jan 13, 2011	Apr	CAHN
AB			200MG	A090607	004	Jan 13, 2011	Apr	CAHN
AB		HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	Apr	NEWA
AB			100MG	A078134	002	Apr 19, 2011	Apr	NEWA
AB			150MG	A078134	003	Apr 19, 2011	Apr	NEWA
AB			200MG	A078134	004	Apr 19, 2011	Apr	NEWA
AB		UNICHEM LABS LTD	25MG	A090170	001	Oct 06, 2011	Sep	NEWA
AB			100MG	A090170	002	Oct 06, 2011	Sep	NEWA
AB			150MG	A090170	003	Oct 06, 2011	Sep	NEWA
AB			200MG	A090170	004	Oct 06, 2011	Sep	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB		JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Feb	NEWA
AB			25MG	A200220	002	Feb 28, 2011	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

		SMITHKLINE BEECHAM	250MG	N022115	006	Jun 21, 2011	Sep	NEWA
--	--	--------------------	-------	---------	-----	--------------	-----	------

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT		ALCON RES	0.005%	A091449	001	Mar 22, 2011	Mar	NEWA
AT		APOTEX	0.005%	A077697	001	Mar 22, 2011	Mar	NEWA
AT		BAUSCH AND LOMB	0.005%	A201006	001	Mar 22, 2011	Mar	NEWA
AT		LUITPOLD	0.005%	A200925	001	Mar 22, 2011	May	CAHN
AT		MYLAN	0.005%	A201786	001	Mar 22, 2011	Mar	NEWA
AT		PADDOCK LABS	0.005%	A090887	001	Jul 19, 2011	Jul	NEWA
AT		PHARMAFORCE	0.005%	A200925	001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+	PHARMACIA AND UPJOHN	0.005%	N020597	001	Jun 05, 1996	Mar	CFTG
----	---	----------------------	--------	---------	-----	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	ACCORD HLTHCARE	2.5MG	A090934	001	Jun 03, 2011	May	NEWA
AB	ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	Aug	CAHN
AB	AMIDE PHARM	2.5MG	A090292	001	Jul 13, 2011	Jul	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A091191	001	Jun 03, 2011	May	NEWA
AB	ENDO PHARMS	2.5MG	A090789	001	Jun 03, 2011	May	NEWA
AB	FRESENIUS KABI ONCOL	2.5MG	A090491	001	Jun 03, 2011	May	NEWA
AB	IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011	May	NEWA
AB	INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011	May	NEWA
AB	KUDCO IRELAND	2.5MG	A091098	001	Jun 03, 2011	May	NEWA
AB	NATCO PHARMA LTD	2.5MG	A200161	001	Jun 03, 2011	May	NEWA
AB	ROXANE	2.5MG	A090838	001	Jun 03, 2011	May	NEWA
AB	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011	May	NEWA
	@ SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011	Jun	DISC
AB		2.5MG	A090196	001	Jun 03, 2011	May	NEWA
AB	TEVA PHARMS	2.5MG	A090289	001	Jun 03, 2011	May	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

	@ GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC
	LUPRON DEPOT						
+	ABBOTT ENDOCRINE	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CAHN
+		30MG/VIAL	N020517	002	May 30, 1997	Jun	CAHN
		45MG/VIAL	N020517	003	Jun 17, 2011	Jun	NEWA
	LUPRON DEPOT-PED						
+	ABBOTT ENDOCRINE	11.25MG/VIAL	N020263	007	Aug 15, 2011	Aug	NEWA
+		30MG/VIAL	N020263	008	Aug 15, 2011	Aug	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug	CAHN
AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug	CAHN
AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

>A>	AP	HIKMA FARMACEUTICA	500MG/5ML(100MG/ML)	A090981	001	Oct 13, 2011	Oct	NEWA
	AP	INNOPHARMA LLC	500MG/ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	NEWA

SOLUTION; ORAL

LEVETIRACETAM

	AA	APOTEX	100MG/ML	A090187	001	Aug 05, 2011	Jul	NEWA
>A>	AA	LUPIN LTD	100MG/ML	A090893	001	Oct 17, 2011	Oct	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
AB		500MG	A090843	002	Feb 14, 2011	Jan	NEWA
AB		750MG	A090843	003	Feb 14, 2011	Jan	NEWA
AB		1GM	A090843	004	Feb 14, 2011	Jan	NEWA
AB	AJANTA PHARMA	250MG	A201293	001	Jun 14, 2011	May	NEWA
AB		500MG	A201293	002	Jun 14, 2011	May	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	AJANTA PHARMA	750MG	A201293 003	Jun 14, 2011	May	NEWA
AB		1GM	A201293 004	Jun 14, 2011	May	NEWA
AB	BRECKENRIDGE PHARM	250MG	A090511 001	Aug 18, 2011	Aug	NEWA
AB		500MG	A090511 002	Aug 18, 2011	Aug	NEWA
AB		750MG	A090511 003	Aug 18, 2011	Aug	NEWA
AB		1GM	A090511 004	Aug 18, 2011	Aug	NEWA

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

AB	UCB INC	500MG	N022285 001	Sep 12, 2008	Aug	CFTG
AB	+	750MG	N022285 002	Feb 12, 2009	Aug	CFTG

LEVETIRACETAM

AB	ACTAVIS ELIZABETH	500MG	A091557 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091557 002	Sep 12, 2011	Aug	NEWA
AB	ANCHEN PHARMS	500MG	A091360 001	Oct 04, 2011	Sep	NEWA
AB		750MG	A091360 002	Oct 04, 2011	Sep	NEWA
AB	APOTEX INC	500MG	A091261 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091261 002	Sep 12, 2011	Aug	NEWA
AB	LUPIN LTD	500MG	A091399 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091399 002	Sep 12, 2011	Aug	NEWA
AB	MUTUAL PHARM CO INC	500MG	A091285 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091285 002	Sep 12, 2011	Aug	NEWA
AB	PAR PHARM	500MG	A091291 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091291 002	Sep 12, 2011	Aug	NEWA
AB	TEVA PHARMS	500MG	A091430 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091430 002	Sep 12, 2011	Aug	NEWA
AB	WATSON LABS FLORIDA	500MG	A091093 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091093 002	Sep 12, 2011	Aug	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

>A> LEVOCETIRIZINE DIHYDROCHLORIDE

>A>	AA	SYNTHON PHARMS	2.5MG/5ML	A091263 001	Nov 07, 2011	Oct	NEWA
-----	----	----------------	-----------	-------------	--------------	-----	------

XYZAL

>D>	+	UCB INC	2.5MG/5ML	N022157 001	Jan 28, 2008	Oct	CFTG
>A>	AA	+	2.5MG/5ML	N022157 001	Jan 28, 2008	Oct	CFTG

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	DR REDDYS LABS LTD	5MG	A090392 001	Feb 24, 2011	Feb	NEWA
AB	GLENMARK GENERICS	5MG	A090385 001	Feb 24, 2011	Feb	NEWA
AB	TEVA PHARMS	5MG	A090199 001	Aug 22, 2011	Aug	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

AP	+	ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996	Jun	CFTG
AP	+		EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996	Jun	CFTG
		LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+	ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635 002	Dec 20, 1996	Jun	CFTG
AP	+		EQ 500MG/100ML (EQ 5MG/ML)	N020635 003	Dec 20, 1996	Jun	CFTG
AP	+		EQ 750MG/150ML (EQ 5MG/ML)	N020635 005	Dec 20, 1996	Jun	CFTG

LEVOFLOXACIN

AP	AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001	Jun 20, 2011	Jun	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A091644 002	Jun 20, 2011	Jun	NEWA
AP	SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011	Jun	NEWA

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	SAGENT PHARMS	EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011	Jun	NEWA
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343 001	Jul 07, 2011	Jun	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A090343 002	Jul 07, 2011	Jun	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A090343 003	Jul 07, 2011	Jun	NEWA
AP	HIKMA FARMACEUTICA	EQ 250MG/50ML (EQ 5MG/ML)	A091375 001	Sep 16, 2011	Sep	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091375 002	Sep 16, 2011	Sep	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091375 003	Sep 16, 2011	Sep	NEWA

SOLUTION; ORAL

LEVAQUIN

AA	+ ORTHO MCNEIL JANSSEN	250MG/10ML	N021721 001	Oct 21, 2004	Jun	CFTG
----	------------------------	------------	-------------	--------------	-----	------

LEVOFLOXACIN

AA	HI TECH PHARMA	250MG/10ML	A091678 001	Jun 20, 2011	Jun	NEWA
----	----------------	------------	-------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT	HI TECH PHARMA	0.5%	A076826 001	Feb 10, 2011	Jan	NEWA
----	----------------	------	-------------	--------------	-----	------

TABLET; ORAL

LEVAQUIN

AB	ORTHO MCNEIL JANSSEN	250MG	N020634 001	Dec 20, 1996	Jun	CFTG
AB		500MG	N020634 002	Dec 20, 1996	Jun	CFTG
AB	+	750MG	N020634 003	Sep 08, 2000	Jun	CFTG

LEVOFLOXACIN

AB	APOTEX INC	250MG	A090787 001	Sep 29, 2011	Sep	NEWA
AB		500MG	A090787 002	Sep 29, 2011	Sep	NEWA
AB		750MG	A090787 003	Sep 29, 2011	Sep	NEWA
AB	AUROBINDO PHARMA LTD	250MG	A201043 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A201043 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A201043 003	Jun 20, 2011	Jun	NEWA
AB	DR REDDYS LABS INC	250MG	A076710 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076710 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A076710 003	Jun 20, 2011	Jun	NEWA
AB	GLENMARK GENERICS	250MG	A200250 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A200250 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A200250 003	Jun 20, 2011	Jun	NEWA
AB	LUPIN	250MG	A078424 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A078424 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A078424 003	Jun 20, 2011	Jun	NEWA
AB	MYLAN	250MG	A076276 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076276 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A077097 001	Jun 20, 2011	Jun	NEWA
AB	SANDOZ	250MG	A077438 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A077438 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A077438 003	Jun 20, 2011	Jun	NEWA
AB	TEVA	250MG	A076361 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076361 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A076361 003	Jun 20, 2011	Jun	NEWA
AB	TORRENT PHARMS	250MG	A090722 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A090722 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A090722 003	Jun 20, 2011	Jun	NEWA
AB	WOCKHARDT	250MG	A090367 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A090367 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A090367 003	Jun 20, 2011	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 20, 2011	Apr	NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 20, 2011	Apr	NEWA

SOLUTION; IV (INFUSION)

FUSILEV

>A>	+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 29, 2011	Oct	CMS1
	+		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 20, 2011	May	CDFR
>A>	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 29, 2011	Oct	CMS1
	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 20, 2011	May	CDFR

LEVONORGESTREL

TABLET; ORAL

PLAN B

	@ TEVA WOMENS	0.75MG	N021045 001	Jul 28, 1999	Feb	CAHN
AB	+	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ VALEANT PHARM INTL

2MG

N008720 001 Dec 19, 1991 Mar DISC

LEVORPHANOL TARTRATE

ROXANE

2MG

A074278 001 Mar 31, 2000 Mar CTEC

LEVOTHYROXINE SODIUM

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

+	APP PHARMS	100MCG/VIAL	N202231 001	Jun 24, 2011	Jun	NEWA
+		200MCG/VIAL	N202231 002	Jun 24, 2011	Jun	NEWA
+		500MCG/VIAL	N202231 003	Jun 24, 2011	Jun	NEWA

TABLET; ORAL

LEVO-T

AB1, AB2, AB3	ALARA PHARM	0.025MG	N021342 001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.05MG	N021342 002	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.075MG	N021342 003	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.088MG	N021342 004	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.1MG	N021342 005	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.112MG	N021342 006	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.125MG	N021342 007	Mar 01, 2002	Feb	CTEC

TABLET; ORAL

LEVO-T

AB1,	ALARA PHARM	0.137MG	N021342 012	Dec 08, 2003	Feb	CTEC
AB2,						
AB3						
AB1,		0.15MG	N021342 008	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.175MG	N021342 009	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.2MG	N021342 010	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1, +		0.3MG	N021342 011	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT	NOVOCOL INC	5%	A040911 001	May 23, 2011	May	NEWA
----	-------------	----	-------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	HI TECH PHARMA	2%	A040837 001	Mar 23, 2011	Mar	NEWA
----	----------------	----	-------------	--------------	-----	------

XYLOCAINE

AT	+ OAK PHARMS	2%	N008816 001		Aug	CAHN
----	--------------	----	-------------	--	-----	------

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

@ ACTAVIS MID ATLANTIC

2%

A086578 001		Aug	DISC
-------------	--	-----	------

SOLUTION; TOPICAL

PEDIATRIC LTA KIT

@ HOSPIRA

2%

A085995 001		Aug	DISC
-------------	--	-----	------

SYSTEM; INTRADERMAL

ZINGO

@ POWDER PHARMS

0.5MG

N022114 001	Aug 16, 2007	Jun	CAHN
-------------	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB	+ OAK PHARMS	2.5%;2.5%	N019941 001	Dec 30, 1992	Aug	CAHN
----	--------------	-----------	-------------	--------------	-----	------

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+ BOEHRINGER INGELHEIM 5MG

N201280 001	May 02, 2011	May	NEWA
-------------	--------------	-----	------

LINDANE

LOTION; TOPICAL

LINDANE

>D>	@ OLTA PHARMS	1%	A087313 001		Oct	CMFD
-----	---------------	----	-------------	--	-----	------

>A>	AT	1%	A087313 001		Oct	CMFD
-----	----	----	-------------	--	-----	------

>D>	+ WOCKHARDT	1%	A088190 001	Aug 16, 1984	Oct	CTEC
-----	-------------	----	-------------	--------------	-----	------

>A>	AT	+ 1%	A088190 001	Aug 16, 1984	Oct	CTEC
-----	----	------	-------------	--------------	-----	------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	PRINSTON INC	2.5MG	A076180 001	Jul 01, 2002	Aug	CAHN
AB		5MG	A076180 002	Jul 01, 2002	Aug	CAHN
AB		10MG	A076180 003	Jul 01, 2002	Aug	CAHN
AB		20MG	A076164 001	Jul 01, 2002	Aug	CAHN
AB		30MG	A076164 002	Jul 01, 2002	Aug	CAHN
AB		40MG	A076164 003	Jul 01, 2002	Aug	CAHN
AB	PRINSTON PHARM LLC	2.5MG	A076180 001	Jul 01, 2002	May	CAHN
AB		5MG	A076180 002	Jul 01, 2002	May	CAHN
AB		10MG	A076180 003	Jul 01, 2002	May	CAHN
AB		20MG	A076164 001	Jul 01, 2002	May	CAHN
AB		30MG	A076164 002	Jul 01, 2002	May	CAHN
AB		40MG	A076164 003	Jul 01, 2002	May	CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	GLENMARK GENERICS	450MG	A091616 001	Feb 14, 2011	Jan	NEWA
----	-------------------	-------	-------------	--------------	-----	------

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AP	TAYLOR	2MG/ML	A075025 001	Jul 23, 1998	Sep	CMFD
----	--------	--------	-------------	--------------	-----	------

TABLET; ORAL

ATIVAN

AB	VALEANT INTL	0.5MG	N017794 001		Jul	CAHN
AB		1MG	N017794 002		Jul	CAHN
AB	+	2MG	N017794 003		Jul	CAHN

LORAZEPAM

@ MUTUAL PHARM

@

@

		0.5MG	A072553 001	Mar 29, 1991	Sep	DISC
		1MG	A072554 001	Mar 29, 1991	Sep	DISC
		2MG	A072555 001	Mar 29, 1991	Sep	DISC

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	25MG	A090428 001	Oct 06, 2010	Apr	CAHN
AB		50MG	A090428 002	Oct 06, 2010	Apr	NEWA
AB		100MG	A090428 003	Oct 06, 2010	Apr	CAHN
AB	HUAHAI US INC	25MG	A091497 001	Jun 06, 2011	May	NEWA
AB		50MG	A091497 002	Jun 06, 2011	May	NEWA
AB		100MG	A091497 003	Jun 06, 2011	May	NEWA
AB	MYLAN	25MG	A091590 001	Oct 06, 2010	Jan	NEWA
AB		50MG	A091590 002	Oct 06, 2010	Jan	NEWA
AB		100MG	A091590 003	Oct 06, 2010	Jan	NEWA
AB	PRINSTON INC	25MG	A091497 001	Jun 06, 2011	Aug	CAHN
AB		50MG	A091497 002	Jun 06, 2011	Aug	CAHN
AB		100MG	A091497 003	Jun 06, 2011	Aug	CAHN

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738 001	Apr 15, 2011	Apr	NEWA
---	-----------------	------	-------------	--------------	-----	------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	LANNETT HOLDINGS INC	EQ 5MG BASE	A090695 001	Sep 26, 2011	Sep	NEWA
AB		EQ 10MG BASE	A090695 002	Sep 26, 2011	Sep	NEWA
AB		EQ 25MG BASE	A090695 003	Sep 26, 2011	Sep	NEWA
AB		EQ 50MG BASE	A090695 004	Sep 26, 2011	Sep	NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

@ HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML	N018406 002	Jul 08, 1982	Aug	DISC
	526MG/100ML; 502MG/100ML				

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451 001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451 002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451 003	Feb 23, 2011	Feb	NEWA
AA	JUBILANT CADISTA	12.5MG	A040659 001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659 002	Jun 04, 2010	Jan	CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	LUPIN LTD	250MG	A091322 001	Jul 22, 2011	Jul	NEWA
----	-----------	-------	-------------	--------------	-----	------

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	MYLAN	7.5MG	A077934 001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077934 002	Jul 20, 2006	Feb	CAHN
AB	PURACAP PHARM	7.5MG	A077938 001	Jul 19, 2006	Jun	CAHN
AB		15MG	A077938 002	Jul 19, 2006	Jun	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

@ SUN PHARMA GLOBAL

5MG

A090058 001 May 05, 2010 May CAHN

@

10MG

A090058 002 May 05, 2010 May CAHN

MEMANTINE HYDROCHLORIDE

>A>

@ TEVA PHARMS

5MG

A090052 001 Oct 25, 2011 Oct NEWA

>A>

@

10MG

A090052 002 Oct 25, 2011 Oct NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BAXTER HLTHCARE CORP	10MG/ML	A081002 001	Jul 30, 1993	May	CAHN
----	----------------------	---------	-------------	--------------	-----	------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA	ALEMBIC PHARMS LTD	200MG	A090122 001	Feb 18, 2009	May	CAHN
AA		400MG	A090122 002	Feb 18, 2009	May	CAHN

TABLET; ORAL

MEPROBAMATE

AA	TARO	200MG	A200998 001	May 23, 2011	May	NEWA
AA		400MG	A200998 002	May 23, 2011	May	NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+	AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999	May	CAHN
---	-------------	----------	-------------	--------------	-----	------

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

>A>	AP	ACS DOBFAR	500MG/VIAL	A091404 001	Oct 26, 2011	Oct	NEWA
>A>	AP		1GM/VIAL	A091404 002	Oct 26, 2011	Oct	NEWA
	AP	SANDOZ	500MG/VIAL	A091201 001	Mar 29, 2011	Mar	NEWA
	AP		1GM/VIAL	A091201 002	Mar 29, 2011	Mar	NEWA
		MERREM					
	AP	+ ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Mar	CTNA
	AP	+	1GM/VIAL	N050706 001	Jun 21, 1996	Mar	CTNA

MESALAMINE

ENEMA; RECTAL

ROWASA

AB	+	MEDA PHARMS	4GM/60ML	N019618 001	Dec 24, 1987	Jun	CAHN
----	---	-------------	----------	-------------	--------------	-----	------

SFROWASA

AB		MEDA PHARMS	4GM/60ML	N019618 002	Jun 20, 2008	Jun	CAHN
----	--	-------------	----------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

ASACOL

+	WARNER CHILCOTT LLC	400MG	N019651 001	Jan 31, 1992	Jun	CAHN
---	---------------------	-------	-------------	--------------	-----	------

ASACOL HD

+	WARNER CHILCOTT LLC	800MG	N021830 001	May 29, 2008	Jun	CAHN
---	---------------------	-------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG	A075973 001	Jan 25, 2002	Feb	CAHN
AB		850MG	A075973 002	Jan 25, 2002	Feb	CAHN
AB		1GM	A075973 003	Jan 25, 2002	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

AB2	ANDRX LABS LLC	500MG	N021574 001	Apr 27, 2004	Jun	CTEC
-----	----------------	-------	-------------	--------------	-----	------

AB	+	1GM	N021574 002	Apr 27, 2004	Jun	CTEC
----	---	-----	-------------	--------------	-----	------

GLUCOPHAGE XR

AB1	BRISTOL MYERS SQUIBB	500MG	N021202 001	Oct 13, 2000	Jun	CTEC
-----	----------------------	-------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

@ ACTAVIS ELIZABETH

		500MG	A076450 001	Oct 01, 2004	Aug	DISC
--	--	-------	-------------	--------------	-----	------

AB1		500MG	A076450 001	Oct 01, 2004	Jun	CTEC
-----	--	-------	-------------	--------------	-----	------

@

		750MG	A076878 001	Apr 13, 2005	Aug	DISC
--	--	-------	-------------	--------------	-----	------

AB1	ALVOGEN	500MG	A078321 001	Apr 17, 2008	Aug	CAHN
-----	---------	-------	-------------	--------------	-----	------

AB		750MG	A078321 002	Apr 17, 2008	Aug	CAHN
----	--	-------	-------------	--------------	-----	------

AB1	AMNEAL PHARMS NY	500MG	A078596 001	Jan 03, 2008	Jun	CTEC
-----	------------------	-------	-------------	--------------	-----	------

AB1	APOTEX	500MG	A076706 001	Dec 14, 2004	Jun	CTEC
-----	--------	-------	-------------	--------------	-----	------

AB		750MG	A076706 002	Dec 29, 2005	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

AB1	IMPAX LABS	500MG	A076249 001	Jul 30, 2004	Jun	CTEC
-----	------------	-------	-------------	--------------	-----	------

AB2	LUPIN LTD	500MG	A090692 001	Jun 29, 2011	Aug	CAHN
-----	-----------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB2	LUPIN LTD	500MG	A090692 001	Jun 29, 2011	Jun	NEWA
AB		1GM	A090692 002	Jun 29, 2011	Aug	CAHN
AB		1GM	A090692 002	Jun 29, 2011	Jun	NEWA
AB1	MYLAN	500MG	A076650 001	Sep 13, 2005	Jun	CTEC
AB1	NEUROSCI INC	500MG	A078321 001	Apr 17, 2008	Jun	CTEC
AB1	NOSTRUM	500MG	A076756 001	Jul 26, 2006	Jun	CTEC
AB1	RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004	Jun	CTEC
AB1	SANDOZ	500MG	A076873 001	Dec 14, 2004	Jun	CTEC
AB1	SUN PHARM INDS (IN)	500MG	A077336 001	Feb 09, 2006	Jun	CTEC
AB1	TEVA	500MG	A076269 001	Jun 18, 2004	Jun	CTEC
AB1	TORRENT PHARM	500MG	A090014 001	Dec 30, 2009	Jun	CTEC
AB1	WATSON LABS FLORIDA	500MG	A076172 001	Jun 16, 2004	Jun	CTEC
AB1	WATSON LABS INC	500MG	A076818 001	Dec 14, 2004	Jun	CTEC
AB1	ZYDUS PHARMS USA	500MG	A077060 001	Apr 20, 2005	Jun	CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Feb	CFTG
AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Feb	CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG;EQ 15MG BASE	A090406 001	Feb 25, 2011	Feb	NEWA
AB		850MG;EQ 15MG BASE	A090406 002	Feb 25, 2011	Feb	NEWA

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

>D>	+	BIONICHE PHARMA	10MG/ML	N021624 001		Oct	CAHN
>A>	+	MYLAN INSTITUTIONAL	10MG/ML	N021624 001		Oct	CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	EMCURE PHARMS USA	5MG	A040734 001	Dec 14, 2007	Jul	CAHN
AB		10MG	A040734 002	Dec 14, 2007	Jul	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>A>	AA	AUSTARPHARMA LLC	500MG	A200958 001	Oct 21, 2011	Oct	NEWA
>A>	AA		750MG	A200958 002	Oct 21, 2011	Oct	NEWA
	AA	LANNETT HOLDINGS INC	500MG	A084756 002	Mar 31, 2003	Jun	CAHN
	AA		750MG	A084756 001		Jun	CAHN
		@ PURACAP PHARM	500MG	A084231 002		Jun	CAHN
		@	750MG	A084471 001		Jun	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

AB	+	NOVARTIS	0.2MG	N006035 003		Apr	CTEC
		METHYLERGONOVINE MALEATE					
AB		NOVEL LABS INC	0.2MG	A091577 001	May 02, 2011	Apr	NEWA

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

>A>	PROGENICS	8MG/0.4ML	N021964 002	Sep 27, 2010	Oct	NEWA
-----	-----------	-----------	-------------	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS ELIZABETH

5MG

A040321 001 Feb 05, 2002 Aug DISC

@

10MG

A040321 002 Feb 05, 2002 Aug DISC

@

20MG

A040321 003 Feb 05, 2002 Aug DISC

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS ELIZABETH

20MG

A075450 001 Dec 21, 2001 Aug DISC

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB JUBILANT CADISTA

4MG

A040189 001 Oct 31, 1997 Jan CAHN

AB

8MG

A040189 002 Oct 31, 1997 Jan CAHN

AB

16MG

A040189 003 Jul 20, 2007 Jan CAHN

AB

32MG

A040189 004 Jul 20, 2007 Jan CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP HEMOFARM

EQ 40MG BASE/VIAL

A040793 001 Nov 25, 2008 Apr CAHN

AP

EQ 125MG BASE/VIAL

A040827 001 Nov 25, 2008 Apr CAHN

@ HOSPIRA

EQ 500MG BASE/VIAL

A089173 001 Aug 18, 1987 Feb DISC

@

EQ 1GM BASE/VIAL

A089174 001 Aug 18, 1987 Feb DISC

METHYLPREDNISOLONE SODIUM SUCCINATE

AP MUSTAFA NEVSAT

EQ 40MG BASE/VIAL

A040888 001 Jul 18, 2011 Jul NEWA

AP

EQ 125MG BASE/VIAL

A040888 002 Jul 18, 2011 Jul NEWA

AP

EQ 500MG BASE/VIAL

A040888 003 Jul 18, 2011 Jul NEWA

AP

EQ 1GM BASE/VIAL

A040888 004 Jul 18, 2011 Jul NEWA

AP

EQ 2GM BASE/VIAL

A040888 005 Jul 18, 2011 Jul NEWA

SOLU-MEDROL

AP + PHARMACIA AND UPJOHN EQ 2GM BASE/VIAL

N011856 007 Feb 27, 1985 Jul CTEC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@ HOSPIRA

EQ 5MG BASE/ML

A073117 001 Jan 17, 1991 Aug DISC

TABLET; ORAL

REGLAN

AB ANI PHARMS

EQ 5MG BASE

N017854 002 May 05, 1987 Aug CAHN

AB

+

EQ 10MG BASE

N017854 001 Aug CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

REGLAN ODT

@ MEDA PHARMS

EQ 5MG BASE

N021793 001 Jun 10, 2005 Aug CAHN

@

EQ 10MG BASE

N021793 002 Jun 10, 2005 Aug CAHN

METRONIDAZOLE

GEL; TOPICAL

METROGEL

AB	+	GALDERMA LABS LP	1%	N021789 001	Jun 30, 2005	Jul	CTEC
----	---	------------------	----	-------------	--------------	-----	------

METRONIDAZOLE

AB		G AND W LABS INC	0.75%	A078178 001	Jan 19, 2011	Jan	NEWA
----	--	------------------	-------	-------------	--------------	-----	------

AB		TOLMAR	1%	A090903 001	Jul 22, 2011	Jul	NEWA
----	--	--------	----	-------------	--------------	-----	------

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+	PFIZER	500MG/100ML	N018353 002		Jun	CAHN
----	---	--------	-------------	-------------	--	-----	------

TABLET; ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	250MG	A079067 001	Mar 13, 2009	May	CAHN
----	--	--------------------	-------	-------------	--------------	-----	------

AB			500MG	A079067 002	Mar 13, 2009	May	CAHN
----	--	--	-------	-------------	--------------	-----	------

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

	@	PFIZER	EQ 500MG BASE/VIAL	N018353 001		Jun	DISC
--	---	--------	--------------------	-------------	--	-----	------

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+		ASTELLAS	100MG/VIAL	N021506 003	Jun 27, 2006	Jan	CRLD
---	--	----------	------------	-------------	--------------	-----	------

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

	@	ORTHO JANSSEN	2%	N017494 001		Jul	CAHN
--	---	---------------	----	-------------	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	@	HOSPIRA	EQ 1MG BASE/ML	A075409 002	Jun 20, 2000	Aug	DISC
--	---	---------	----------------	-------------	--------------	-----	------

MIDOZALAM HYDROCHLORIDE

AP		SAGENT STRIDES	EQ 1MG BASE/ML	A090316 001	May 04, 2011	Apr	NEWA
----	--	----------------	----------------	-------------	--------------	-----	------

AP			EQ 5MG BASE/ML	A090316 002	May 04, 2011	Apr	NEWA
----	--	--	----------------	-------------	--------------	-----	------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+		CYPRESS BIOSCIENCE	50MG	N022256 003	Jan 14, 2009	Aug	CRLD
---	--	--------------------	------	-------------	--------------	-----	------

			100MG	N022256 004	Jan 14, 2009	Aug	CRLD
--	--	--	-------	-------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	@	HOSPIRA	EQ 1MG BASE/ML	A075884 001	May 28, 2002	Feb	DISC
--	---	---------	----------------	-------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

>D>	AB	MEDICIS	EQ 50MG BASE	A065131 001	Apr 16, 2003	Oct	CAHN
-----	----	---------	--------------	-------------	--------------	-----	------

>D>	AB		EQ 75MG BASE	A065131 002	Apr 16, 2003	Oct	CAHN
-----	----	--	--------------	-------------	--------------	-----	------

>D>	AB	+	EQ 100MG BASE	A065131 003	Apr 16, 2003	Oct	CAHN
-----	----	---	---------------	-------------	--------------	-----	------

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	PAR PHARM	EQ 50MG BASE	A065131 001	Apr 16, 2003	Oct	CAHN
>A>	AB		EQ 75MG BASE	A065131 002	Apr 16, 2003	Oct	CAHN
>A>	AB	+	EQ 100MG BASE	A065131 003	Apr 16, 2003	Oct	CAHN

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

@	ACTAVIS ELIZABETH	15MG	A076308 001	Jun 20, 2003	Aug	DISC
@		30MG	A076308 002	Jun 20, 2003	Aug	DISC
@		45MG	A076308 003	Jun 20, 2003	Aug	DISC
@	ACTAVIS TOTOWA	15MG	A076241 001	Jun 25, 2003	Jul	DISC
@		30MG	A076241 002	Jun 25, 2003	Jul	DISC
@		45MG	A076241 003	Jun 25, 2003	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB	ACTAVIS ELIZABETH	15MG	A077959 001	Feb 14, 2011	Jan	NEWA
AB		30MG	A077959 002	Feb 14, 2011	Jan	NEWA
AB		45MG	A077959 003	Feb 14, 2011	Jan	NEWA
@	ACTAVIS TOTOWA	15MG	A076689 001	Aug 31, 2005	Jul	DISC
@		30MG	A076689 002	Aug 31, 2005	Jul	DISC
@		45MG	A076689 003	Aug 31, 2005	Jul	DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	+	HOSPIRA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076871 001	Apr 11, 2006	Aug	CRLD
AP	+		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076871 002	Apr 11, 2006	Aug	CRLD
AP	+		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076871 003	Apr 11, 2006	Aug	CRLD
		NOVANTRONE					
	@	EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297 001	Dec 23, 1987	Aug	DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

>D>		ACTAVIS ELIZABETH	20MG	N020616 001	Jul 03, 1996	Oct	CFTG
>A>	AB		20MG	N020616 001	Jul 03, 1996	Oct	CFTG
>D>	BX		30MG	N020616 004	Mar 09, 2001	Oct	CFTG
>A>	AB		30MG	N020616 004	Mar 09, 2001	Oct	CFTG
>D>			50MG	N020616 002	Jul 03, 1996	Oct	CFTG
>A>	AB		50MG	N020616 002	Jul 03, 1996	Oct	CFTG
>D>	BX		60MG	N020616 005	Mar 09, 2001	Oct	CFTG
>A>	AB		60MG	N020616 005	Mar 09, 2001	Oct	CFTG
>D>			80MG	N020616 006	Oct 27, 2006	Oct	CFTG
>A>	AB		80MG	N020616 006	Oct 27, 2006	Oct	CFTG
>D>	+		100MG	N020616 003	Jul 03, 1996	Oct	CFTG
>A>	AB	+	100MG	N020616 003	Jul 03, 1996	Oct	CFTG
>A>		MORPHINE SULFATE					
>A>	AB	WATSON LABS	20MG	A200812 001	Nov 10, 2011	Oct	NEWA
>A>	AB		30MG	A200812 002	Nov 10, 2011	Oct	NEWA
>A>	AB		50MG	A200812 003	Nov 10, 2011	Oct	NEWA
>A>	AB		60MG	A200812 004	Nov 10, 2011	Oct	NEWA

		CAPSULE, EXTENDED RELEASE; ORAL					
>A>		MORPHINE SULFATE					
>A>	AB	WATSON LABS	80MG	A200812	005	Nov 10, 2011	Oct NEWA
>A>	AB		100MG	A200812	006	Nov 10, 2011	Oct NEWA
		INJECTABLE, LIPOSOMAL; EPIDURAL					
		DEPODUR					
		+ EKR THERAP	10MG/ML (10MG/ML)	N021671	001	May 18, 2004	May CRLD
		@	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004	May DISC
		SOLUTION; ORAL					
		MORPHINE SULFATE					
		LANNETT HOLDINGS INC	20MG/ML	N201517	001	Jun 23, 2011	Jun NEWA
AA		MALLINCKRODT INC	100MG/5ML	A202348	001	Jul 15, 2011	Jul NEWA
AA	+	ROXANE	100MG/5ML	N022195	003	Jan 25, 2010	Aug CTEC
		TABLET, EXTENDED RELEASE; ORAL					
		MORPHINE SULFATE					
>A>	AB	MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011	Oct NEWA
>A>	AB		30MG	A200824	002	Oct 18, 2011	Oct NEWA
>A>	AB		60MG	A200824	003	Oct 18, 2011	Oct NEWA
>A>	AB		100MG	A200824	004	Oct 18, 2011	Oct NEWA
>A>	AB		200MG	A200824	005	Oct 18, 2011	Oct NEWA
		@ WATSON LABS	100MG	A075656	001	Jan 30, 2001	Aug DISC
<u>MUPIROCIN</u>							
		OINTMENT; TOPICAL					
		MUPIROCIN					
AB		GLENMARK PHARMS	2%	A090480	001	Jun 08, 2011	May NEWA
<u>MUPIROCIN CALCIUM</u>							
		CREAM; TOPICAL					
		BACTROBAN					
		+ GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan CDFR
<u>MYCOPHENOLATE MOFETIL</u>							
		CAPSULE; ORAL					
		MYCOPHENOLATE MOFETIL					
>A>	AB	DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011	Oct NEWA
		TABLET; ORAL					
		MYCOPHENOLATE MOFETIL					
>A>	AB	ALKEM LABS LTD	500MG	A091249	001	Nov 04, 2011	Oct NEWA
>D>	AB	DR REDDYS LABS LTD	500MG	A090464	001	Sep 13, 2010	Oct DISC
>A>		@	500MG	A090464	001	Sep 13, 2010	Oct DISC
<u>NABUMETONE</u>							
		TABLET; ORAL					
		NABUMETONE					
		@ ACTAVIS ELIZABETH	500MG	A079093	001	Feb 27, 2009	Aug DISC
		@	750MG	A079093	002	Feb 27, 2009	Aug DISC
AB		LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan NEWA
AB			750MG	A090445	002	Jan 12, 2011	Jan NEWA
AB		WATSON LABS	500MG	A091083	001	Jun 13, 2011	May NEWA
AB			750MG	A091083	002	Jun 13, 2011	May NEWA
<u>NAFCILLIN SODIUM</u>							
		INJECTABLE; INJECTION					
		NAFCILLIN SODIUM					
AP		ACIC FINE CHEMS	EQ 1GM BASE	A090560	001	Oct 03, 2011	Sep NEWA

INJECTABLE; INJECTIONNAFCILLIN SODIUM

AP	ACIC FINE CHEMS	EQ 2GM BASE	A090560 002	Oct 03, 2011	Sep	NEWA
AP	IBI	EQ 1GM BASE/VIAL	A090002 001	Jun 30, 2011	Jun	NEWA
AP		EQ 2GM BASE/VIAL	A090002 002	Jun 30, 2011	Jun	NEWA
AP	INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005 001	Apr 20, 2011	Apr	NEWA
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A062527 004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDETABLET; ORALNALTREXONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A091205 001	Aug 17, 2011	Aug	NEWA
AB	ELITE LABS	50MG	A075274 001	May 26, 1999	Feb	CAHN

NAPROXENTABLET; ORALNAPROXEN

>A>	AB	AUROBINDO PHARMA USA	250MG	A200429 001	Nov 08, 2011	Oct	NEWA
>A>	AB		375MG	A200429 002	Nov 08, 2011	Oct	NEWA
>A>	AB		500MG	A200429 003	Nov 08, 2011	Oct	NEWA
	AB	INVAGEN PHARMS	250MG	A091305 001	Aug 24, 2011	Aug	NEWA
	AB		375MG	A091305 002	Aug 24, 2011	Aug	NEWA
	AB		500MG	A091305 003	Aug 24, 2011	Aug	NEWA
	AB	MARKSANS PHARMA	250MG	A091416 001	Feb 14, 2011	Jan	NEWA
	AB		375MG	A091416 002	Feb 14, 2011	Jan	NEWA
	AB		500MG	A091416 003	Feb 14, 2011	Jan	NEWA

TABLET, DELAYED RELEASE; ORALNAPROXEN

		@ ACTAVIS ELIZABETH	375MG	A074936 001	Feb 24, 1998	Aug	DISC
		@	500MG	A074936 002	Feb 24, 1998	Aug	DISC
	AB	INVAGEN PHARMS	375MG	A091432 001	Sep 19, 2011	Sep	NEWA
	AB		500MG	A091432 002	Sep 19, 2011	Sep	NEWA

NAPROXEN SODIUMTABLET; ORALNAPROXEN SODIUM

>A>	AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A200629 001	Oct 31, 2011	Oct	NEWA
>A>	AB		EQ 500MG BASE	A200629 002	Oct 31, 2011	Oct	NEWA

NARATRIPTANTABLET; ORALNARATRIPTAN

	AB	APOTEX CORP	EQ 1MG BASE	A091373 001	Apr 22, 2011	Apr	NEWA
	AB		EQ 2.5MG BASE	A091373 002	Apr 22, 2011	Apr	NEWA
	AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552 001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDETABLET; ORALNARATRIPTAN

>A>	AB	HERITAGE PHARMS INC	EQ 1MG BASE	A200502 001	Feb 28, 2011	Oct	CAHN
>A>	AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Oct	CAHN
>D>	AB	INDICUS PHARMA	EQ 1MG BASE	A200502 001	Feb 28, 2011	Oct	CAHN
	AB		EQ 1MG BASE	A200502 001	Feb 28, 2011	Feb	NEWA
>D>	AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Oct	CAHN
	AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	WATSON LABS	60MG	A077462 001	Mar 30, 2011	Mar	NEWA
AB		120MG	A077462 002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

+	BOEHRINGER INGELHEIM	400MG	N201152 001	Mar 25, 2011	Mar	NEWA
---	----------------------	-------	-------------	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

@	EKR THERAP	45MG	N020005 002	Feb 21, 1992	May	DISC
---	------------	------	-------------	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	VALEANT INTL	30MG	A075269 001	Dec 04, 2000	Apr	CAHN
AB2		30MG	A075289 002	Feb 06, 2001	Apr	CAHN
AB1		60MG	A075269 002	Dec 04, 2000	Apr	CAHN
AB2		60MG	A075289 001	Sep 27, 2000	Apr	CAHN
AB1		90MG	A076070 001	Aug 16, 2002	Apr	CAHN

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

	NOVARTIS	EQ 150MG BASE	N022068 002	Jun 17, 2010	Aug	NEWA
--	----------	---------------	-------------	--------------	-----	------

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

AB	+	BANNER PHARMACAPS	30MG	A076740 001	Jan 17, 2008	Sep	CRLD
AB		BARR LABS INC	30MG	A077811 001	May 02, 2007	Sep	CRLD

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001 001	Jan 26, 2011	Jan	NEWA	
AB		17MG	A091001 002	Jan 26, 2011	Jan	NEWA	
AB		25.5MG	A091001 003	Jan 26, 2011	Jan	NEWA	
AB		34MG	A091001 004	Jan 26, 2011	Jan	NEWA	
	SULAR						
AB	+	SHIONOGI PHARMA	8.5MG	N020356 008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356 007	Jan 02, 2008	Jan	CFTG
AB		25.5MG	N020356 006	Jan 02, 2008	Jan	CFTG	
AB	+	34MG	N020356 005	Jan 02, 2008	Jan	CFTG	

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+	SHIONOGI INC	25MG/5ML	N009175 001		Apr	CFTG
		NITROFURANTOIN					
AB		AMNEAL PHARMS	25MG/5ML	A201679 001	May 11, 2011	Apr	NEWA

NITROGLYCERIN

OINTMENT; INTRA-ANAL
RECTIV

+ PROSTRAKAN INC 0.4% N021359 001 Jun 21, 2011 Jun NEWA

NIZATIDINE

CAPSULE; ORAL
NIZATIDINE

AB	GLENMARK GENERICS	150MG	A090618 001	Jul 15, 2011	Jul	NEWA
AB		300MG	A090618 002	Jul 15, 2011	Jul	NEWA
AB	MYLAN	150MG	A075934 001	Jul 09, 2002	Feb	CAHN
AB		300MG	A075934 002	Jul 09, 2002	Feb	CAHN

NORETHINDRONE

TABLET; ORAL-28
NORETHINDRONE

AB1 LUPIN LTD 0.35MG A091325 001 Sep 19, 2011 Sep NEWA

NORGESTREL

TABLET; ORAL
OVRETTE

@ WYETH PHARMS 0.075MG N017031 001 Aug CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
PAMELOR

AB	MALLINCKRODT LLC	EQ 10MG BASE	N018013 001		Aug	CAHN
AB		EQ 25MG BASE	N018013 002		Aug	CAHN
AB		EQ 50MG BASE	N018013 004		Aug	CAHN
AB	+	EQ 75MG BASE	N018013 003		Aug	CAHN

SOLUTION; ORAL

PAMELOR

	@ MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012 001		Sep	DISC
AA		EQ 10MG BASE/5ML	N018012 001		Jul	CAHN

NYSTATIN

CREAM; TOPICAL
MYCOSTATIN

@ BRISTOL MYERS SQUIBB 100,000 UNITS/GM A060575 001 Aug DISC

NYSTATIN

AT TARO 100,000 UNITS/GM A064022 001 Jan 29, 1993 Aug CRLD

POWDER; TOPICAL

MYCOSTATIN

@ BRISTOL MYERS SQUIBB 100,000 UNITS/GM A060578 001 Aug DISC

NYSTATIN

>D> AT COASTAL PHARMS 100,000 UNITS/GM A065203 001 Jul 15, 2004 Oct CRLD

>A> AT + 100,000 UNITS/GM A065203 001 Jul 15, 2004 Oct CRLD

AT 100,000 UNITS/GM A065203 001 Jul 15, 2004 Aug CRLD

SUSPENSION; ORAL

NYSTATIN

AA HI TECH PHARMA 100,000 UNITS/ML A064042 001 Feb 28, 1994 Aug CAHN

AA VISTAPHARM 100,000 UNITS/ML A065422 001 Mar 07, 2011 Feb NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@ ACTAVIS MID ATLANTIC 100,000 UNITS/GM;0.1%

A062367 001 May 28, 1985 Aug DISC

OINTMENT; TOPICAL

MYKACET

@ ACTAVIS MID ATLANTIC 100,000 UNITS/GM;0.1%

A062733 001 Mar 09, 1987 Aug DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP WOCKHARDT USA EQ 0.2MG BASE/ML

A090986 001 May 11, 2011 Apr NEWA

AP EQ 1MG BASE/ML

A090986 002 May 11, 2011 Apr NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP BIONICHE PHARMA USA EQ 0.05MG BASE/ML

A079198 001 Feb 10, 2011 Jan NEWA

AP EQ 0.1MG BASE/ML

A079198 002 Feb 10, 2011 Jan NEWA

AP EQ 0.5MG BASE/ML

A079198 003 Feb 10, 2011 Jan NEWA

AP MYLAN INSTITUTIONAL EQ 0.05MG BASE/ML

A079198 001 Feb 10, 2011 Aug CAHN

AP EQ 0.1MG BASE/ML

A079198 002 Feb 10, 2011 Aug CAHN

AP EQ 0.5MG BASE/ML

A079198 003 Feb 10, 2011 Aug CAHN

AP WOCKHARDT USA EQ 0.05MG BASE/ML

A090985 001 May 11, 2011 Apr NEWA

AP EQ 0.1MG BASE/ML

A090985 002 May 11, 2011 Apr NEWA

AP EQ 0.5MG BASE/ML

A090985 003 May 11, 2011 Apr NEWA

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

>A> AT FERA PHARMS 0.3%

A076830 001 Aug 31, 2004 Oct CAHN

>D> AT LUITPOLD 0.3%

A076830 001 Aug 31, 2004 Oct CAHN

SOLUTION/DROPS; OTIC

OFLOXACIN

>A> AT FERA PHARMS 0.3%

A090395 001 Aug 11, 2009 Oct CAHN

>D> AT LUITPOLD 0.3%

A090395 001 Aug 11, 2009 Oct CAHN

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

>A> OLANZAPINE

>A> AP INNOPHARMA LLC 10MG/VIAL

A201588 001 Oct 24, 2011 Oct NEWA

ZYPREXA

>D> + LILLY 10MG/VIAL

N021253 001 Mar 29, 2004 Oct CFTG

>A> AP + 10MG/VIAL

N021253 001 Mar 29, 2004 Oct CFTG

TABLET; ORAL

>A> OLANZAPINE

>A> AB DR REDDYS LABS LTD 20MG

A076133 002 Oct 24, 2011 Oct NEWA

>A> AB TEVA PHARMS 2.5MG

A076000 001 Oct 24, 2011 Oct NEWA

>A> AB 5MG

A076000 002 Oct 24, 2011 Oct NEWA

>A> AB 7.5MG

A076000 003 Oct 24, 2011 Oct NEWA

>A> AB 10MG

A076000 004 Oct 24, 2011 Oct NEWA

>A> AB 15MG

A076000 005 Oct 24, 2011 Oct NEWA

ZYPREXA

>D> LILLY 2.5MG

N020592 001 Sep 30, 1996 Oct CFTG

>A> AB 2.5MG

N020592 001 Sep 30, 1996 Oct CFTG

>D> + 5MG

N020592 002 Sep 30, 1996 Oct CFTG

>A> AB + 5MG

N020592 002 Sep 30, 1996 Oct CFTG

>D> 7.5MG

N020592 003 Sep 30, 1996 Oct CFTG

TABLET; ORAL

ZYPREXA

>A>	AB	LILLY	7.5MG	N020592 003	Sep 30, 1996	Oct	CFTG
>D>			10MG	N020592 004	Sep 30, 1996	Oct	CFTG
>A>	AB		10MG	N020592 004	Sep 30, 1996	Oct	CFTG
>D>			15MG	N020592 005	Sep 09, 1997	Oct	CFTG
>A>	AB		15MG	N020592 005	Sep 09, 1997	Oct	CFTG
>D>			20MG	N020592 006	Sep 09, 1997	Oct	CFTG
>A>	AB		20MG	N020592 006	Sep 09, 1997	Oct	CFTG

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

>A>	AB	APOTEX INC	5MG	A091265 001	Oct 24, 2011	Oct	NEWA
>A>	AB		10MG	A091265 002	Oct 24, 2011	Oct	NEWA
>A>	AB		15MG	A091265 003	Oct 24, 2011	Oct	NEWA
>A>	AB		20MG	A091265 004	Oct 24, 2011	Oct	NEWA
>A>	AB	DR REDDYS LABS LTD	5MG	A076534 001	Oct 24, 2011	Oct	NEWA
>A>	AB		10MG	A076534 002	Oct 24, 2011	Oct	NEWA
>A>	AB		15MG	A076534 003	Oct 24, 2011	Oct	NEWA
>A>	AB		20MG	A076534 004	Oct 24, 2011	Oct	NEWA
>A>	AB	PAR PHARM	5MG	A078109 001	Oct 24, 2011	Oct	NEWA
>A>	AB		10MG	A078109 002	Oct 24, 2011	Oct	NEWA
>A>	AB		15MG	A078109 003	Oct 24, 2011	Oct	NEWA
>A>	AB		20MG	A078109 004	Oct 24, 2011	Oct	NEWA
>A>	AB	TORRENT PHARMS LLC	5MG	A091415 001	Oct 25, 2011	Oct	NEWA
>A>	AB		10MG	A091415 002	Oct 25, 2011	Oct	NEWA
>A>	AB		15MG	A091415 003	Oct 25, 2011	Oct	NEWA
>A>	AB		20MG	A091415 004	Oct 25, 2011	Oct	NEWA

ZYPREXA ZYDIS

>D>	+	LILLY	5MG	N021086 001	Apr 06, 2000	Oct	CFTG
>A>	AB	+	5MG	N021086 001	Apr 06, 2000	Oct	CFTG
>D>			10MG	N021086 002	Apr 06, 2000	Oct	CFTG
>A>	AB		10MG	N021086 002	Apr 06, 2000	Oct	CFTG
>D>			15MG	N021086 003	Apr 06, 2000	Oct	CFTG
>A>	AB		15MG	N021086 003	Apr 06, 2000	Oct	CFTG
>D>			20MG	N021086 004	Apr 06, 2000	Oct	CFTG
>A>	AB		20MG	N021086 004	Apr 06, 2000	Oct	CFTG

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB	RANBAXY	4MG	A078602 001	Feb 24, 2011	Feb	NEWA
AB		8MG	A078602 002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	PFIZER	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008	May	CAHN
AP	TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006	Jan	CMFD

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	+	HOSPIRA	EQ 0.64MG BASE/ML	A077348 001	Feb 01, 2007	Apr	CRLD
AP		TEVA PHARMS	EQ 0.64MG BASE/ML	A077480 001	Nov 22, 2006	Aug	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	PFIZER	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008	May	CAHN
AP	TEVA	EQ 2MG BASE/ML	A076759 001	Nov 22, 2006	Sep	CMFD

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483 001	Jan 31, 2011	Jan	NEWA
AA	SILARX	EQ 4MG BASE/5ML	A091342 001	Jan 27, 2011	Jan	NEWA

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB	TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011	Mar	NEWA
AB		EQ 8MG BASE	A077729 002	Mar 28, 2011	Mar	NEWA
AB		EQ 24MG BASE	A077729 003	Mar 28, 2011	Mar	NEWA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

AP	SAGENT PHARMS	30MG/ML	A090585 001	Aug 30, 2011	Aug	NEWA
----	---------------	---------	-------------	--------------	-----	------

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE

@

EQ 6MG BASE/ML

EQ 12MG BASE/ML

N021246 002 Mar 21, 2011 Jun NEWA

N021246 001 Dec 14, 2000 Jul DISC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	SANDOZ	50MG/10ML (5MG/ML)	A078817 001	Jan 24, 2011	Jan	NEWA
AP		50MG/VIAL	A090849 001	Apr 28, 2011	Apr	NEWA
AP		100MG/VIAL	A090849 002	Apr 28, 2011	Apr	NEWA
AP		100MG/20ML (5MG/ML)	A078817 002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@ ACTAVIS ELIZABETH

MYLAN

600MG

600MG

A075843 001 Oct 03, 2001 Aug DISC

A075847 001 Feb 28, 2001 Feb CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE

KING PHARMS R AND D

OXYCODONE

5MG

7.5MG

N202080 001 Jun 17, 2011 Jun NEWA

N202080 002 Jun 17, 2011 Jun NEWA

OXYCODONE HYDROCHLORIDE

AB	COASTAL PHARMS	5MG	A091313 001	Feb 18, 2011	Feb	NEWA
AB		15MG	A091313 002	Feb 18, 2011	Feb	NEWA
AB		30MG	A091313 003	Feb 18, 2011	Feb	NEWA
AB	RHODES PHARMS	5MG	A091490 001	Mar 09, 2011	Feb	NEWA
AB		10MG	A091490 002	Mar 09, 2011	Feb	NEWA
AB		15MG	A091490 003	Mar 09, 2011	Feb	NEWA
AB		20MG	A091490 004	Mar 09, 2011	Feb	NEWA
AB		30MG	A091490 005	Mar 09, 2011	Feb	NEWA

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+ MEDA PHARMS

50MG

N016848 001

May CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	TEVA	5MG	A091443 002	Feb 15, 2011	Jan	NEWA
AB		10MG	A091443 001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@	ENDO PHARMS	7.5MG	N021610 005	Feb 29, 2008	Feb	DISC
@		15MG	N021610 006	Feb 29, 2008	Feb	DISC

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	ONCO THERAPIES LTD	6MG/ML	A091540 001	Sep 29, 2011	Sep	NEWA
----	--------------------	--------	-------------	--------------	-----	------

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

	JANSSEN PHARMS	1.5MG	N021999 006	Aug 26, 2008	Jul	CAHN
		3MG	N021999 001	Dec 19, 2006	Jul	CAHN
+		6MG	N021999 002	Dec 19, 2006	Jul	CAHN
		9MG	N021999 003	Dec 19, 2006	Jul	CAHN
@		12MG	N021999 004	Dec 19, 2006	Jul	CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001	Jul 31, 2009	Jun	CAHN
		78MG/0.5ML (78MG/0.5ML)	N022264 002	Jul 31, 2009	Jun	CAHN
+		117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009	Aug	CRLD
		117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009	Jun	CAHN
		156MG/ML (156MG/ML)	N022264 004	Jul 31, 2009	Jun	CAHN
		234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Aug	CRLD
+		234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Jun	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

>D>	AP	+	NOVARTIS	90MG/VIAL	N020036 004	May 06, 1993	Oct	DISC
>A>		@		90MG/VIAL	N020036 004	May 06, 1993	Oct	DISC

PAMIDRONATE DISODIUM

AP	MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373 001	Dec 23, 2008	May	CAHN
AP		90MG/10ML (9MG/ML)	A078373 002	Dec 23, 2008	May	CAHN
AP	PFIZER	30MG/10ML (3MG/ML)	A078520 001	Oct 31, 2008	Aug	CAHN
AP		90MG/10ML (9MG/ML)	A078520 002	Oct 31, 2008	Aug	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

	JANSSEN PHARMS	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523 001	Apr 12, 2010	Jun	CAHN
		43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523 002	Apr 12, 2010	Jun	CAHN
		70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523 004	Apr 12, 2010	Jun	CAHN

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

	+	JANSSEN PHARMS	61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523 003	Apr 12, 2010 Jun	CAHN
--	---	----------------	---	-------------	------------------	------

ZENPEP

>A>		APTALIS PHARMA US	27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210 001	Aug 27, 2009 Oct	CAHN
>A>			55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210 002	Aug 27, 2009 Oct	CAHN
>A>			82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210 003	Aug 27, 2009 Oct	CAHN
>A>	+		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009 Oct	CAHN
>D>		EURAND	27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210 001	Aug 27, 2009 Oct	CAHN
>D>			55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210 002	Aug 27, 2009 Oct	CAHN
>D>			82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210 003	Aug 27, 2009 Oct	CAHN
>D>	+		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009 Oct	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB		ACTAVIS TOTOWA	EQ 20MG BASE	A090797 001	Feb 07, 2011 Jan	NEWA
AB			EQ 40MG BASE	A090797 002	Feb 07, 2011 Jan	NEWA
AB		DR REDDYS LABS LTD	EQ 20MG BASE	A077619 001	Jan 19, 2011 Jan	NEWA
AB			EQ 40MG BASE	A077619 002	Jan 19, 2011 Jan	NEWA
AB		JUBILANT ORGANOSYS	EQ 20MG BASE	A090901 001	Aug 30, 2011 Aug	NEWA
AB			EQ 40MG BASE	A090901 002	Aug 30, 2011 Aug	NEWA
AB		KUDCO IRELAND	EQ 20MG BASE	A078281 001	Jan 20, 2011 Jan	NEWA
AB			EQ 40MG BASE	A078281 002	Jan 20, 2011 Jan	NEWA
AB		MATRIX LABS LTD	EQ 20MG BASE	A090970 001	Jan 19, 2011 Jan	NEWA
AB			EQ 40MG BASE	A090970 002	Jan 19, 2011 Jan	NEWA
AB		TORRENT PHARMS	EQ 20MG BASE	A090074 001	Jan 19, 2011 Jan	NEWA
AB			EQ 40MG BASE	A090074 002	Jan 19, 2011 Jan	NEWA
AB		WOCKHARDT	EQ 20MG BASE	A091231 001	Jan 19, 2011 Jan	NEWA
AB			EQ 40MG BASE	A091231 002	Jan 19, 2011 Jan	NEWA

PARICALCITOL

INJECTABLE; INJECTION

PARICALCITOL

AP		SANDOZ CANADA INC	0.002MG/ML	A091108 001	Jul 27, 2011 Jul	NEWA
AP			0.005MG/ML	A091108 002	Jul 27, 2011 Jul	NEWA
		ZEMPLAR				
AP	+	ABBOTT	0.002MG/ML	N020819 002	Feb 01, 2000 Jul	CFTG
AP	+		0.005MG/ML	N020819 001	Apr 17, 1998 Jul	CFTG

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

		@ KING PFIZER	EQ 250MG BASE	A062310 001		Aug CAHN
		@ MONARCH PHARMS	EQ 250MG BASE	A062310 001		May CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

		@ ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010 Aug	DISC
--	--	---------------------	--------------	-------------	------------------	------

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

@ ACTAVIS ELIZABETH EQ 20MG BASE
 @ EQ 30MG BASE
 @ EQ 40MG BASE

A076968 002 Jun 21, 2010 Aug DISC
 A076968 003 Jun 21, 2010 Aug DISC
 A076968 004 Jun 21, 2010 Aug DISC

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB MYLAN EQ 37.5MG BASE
 PAXIL CR
 AB + GLAXOSMITHKLINE EQ 37.5MG BASE

A091427 001 Apr 14, 2011 Apr NEWA
 N020936 003 Dec 06, 2000 Apr CTEC

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB VALEANT INTL 400MG

A075028 001 Jul 20, 1998 Apr CAHN

PHENDIMETRAZINE TARTRATETABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA EMCURE PHARMS USA 35MG
 AA MIKAH PHARMA 35MG

A040762 001 Jan 28, 2008 Jul CAHN
 A040762 001 Jan 28, 2008 Aug CAHN

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@ ACTAVIS TOTOWA 15MG
 @ 30MG
 @ 30MG
 @ 37.5MG
 AA LANNETT HOLDINGS INC 37.5MG

A040460 001 Jan 14, 2003 Jul DISC
 A040227 001 Jun 18, 1997 Jul DISC
 A040448 001 Jan 22, 2003 Jul DISC
 A040228 001 Jun 19, 1997 Jul DISC
 A201961 001 Jul 20, 2011 Jul NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@ ACTAVIS TOTOWA 37.5MG
 AA ELITE LABS 37.5MG
 AA EPIC PHARMA LLC 37.5MG

A040190 001 May 30, 1997 Jul DISC
 A200272 001 Jan 31, 2011 May CAHN
 A200272 001 Jan 31, 2011 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

CITIUS PHARMS 15MG
 + 30MG

N202088 001 Jun 13, 2011 Jun NEWA
 N202088 002 Jun 13, 2011 Jun NEWA

PHENTERMINE RESIN COMPLEXCAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

LANNETT HOLDINGS INC EQ 15MG BASE
 EQ 30MG BASE

A040872 001 Jul 28, 2011 Jul NEWA
 A040872 002 Jul 28, 2011 Jul NEWA

PHENTOLAMINE MESYLATEINJECTABLE; INJECTION

ORAVERSE

+ SEPTODONT HOLDING 0.4MG/1.7ML

N022159 001 May 09, 2008 Aug CAHN

PHENYTOIN SODIUMINJECTABLE; INJECTION

PHENYTOIN SODIUM

AP X-GEN PHARMS 50MG/ML

A040573 001 Sep 13, 2006 May CAHN

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

@ BIOVAIL TECHNOLOGIES 1MG/0.5ML

N012223 002

Aug CAHN

@ 10MG/ML

N012223 001

Aug CAHN

TABLET; ORAL

MEPHYTON

+ BIOVAIL TECHNOLOGIES 5MG

N010104 003

Aug CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

ALCON RES 1%

N200890 001 Jun 22, 2010 May CTNA

2%

N200890 002 Jun 22, 2010 May CTNA

+ 4%

N200890 003 Jun 22, 2010 May CTNA

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

+ VALEANT INTL 1%

N021302 001 Dec 13, 2001 Jul CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP AUROBINDO PHARMA LTD EQ 2GM BASE/VIAL;EQ 250MG
BASE/VIAL

A065498 001 May 23, 2011 May NEWA

AP EQ 3GM BASE/VIAL;EQ 375MG
BASE/VIAL

A065498 002 May 23, 2011 May NEWA

AP EQ 4GM BASE/VIAL;EQ 500MG
BASE/VIAL

A065498 003 May 23, 2011 May NEWA

AP HOSPIRA INC EQ 2GM BASE/VIAL;EQ 250MG
BASE/VIAL

A065386 001 Sep 15, 2009 Jan CAHN

AP EQ 3GM BASE/VIAL;EQ 375MG
BASE/VIAL

A065386 002 Sep 15, 2009 Jan CAHN

AP EQ 4GM BASE/VIAL;EQ 500MG
BASE/VIAL

A065386 003 Sep 15, 2009 Jan CAHN

AP EQ 36GM BASE/VIAL;EQ 4.5GM
BASE/VIAL

A065446 001 Sep 15, 2009 Jan CAHN

AP INSTITUTO BIOCHEMICO EQ 2GM BASE/VIAL;EQ 250MG
BASE/VIAL

A065523 001 May 31, 2011 May NEWA

AP EQ 3GM BASE/VIAL;EQ 375MG
BASE/VIAL

A065523 002 May 31, 2011 May NEWA

AP EQ 4GM BASE/VIAL;EQ 500MG
BASE/VIAL

A065523 003 May 31, 2011 May NEWA

AP EQ 36GM BASE/VIAL;EQ 4.5GM
BASE/VIAL

A090498 001 May 31, 2011 May NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@ MYLAN 10MG

A074043 001 Sep 22, 1992 Feb CAHN

@ 20MG

A074043 002 Sep 22, 1992 Feb CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

KOWA CO EQ 1MG BASE

N022363 001 Aug 03, 2009 Jul CAHN

EQ 2MG BASE

N022363 002 Aug 03, 2009 Jul CAHN

+ EQ 4MG BASE

N022363 003 Aug 03, 2009 Jul CAHN

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

AT	PRECISION DERMAT	0.5%	A090184	001	Jul 21, 2010	Jun	CAHN
----	------------------	------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

AA	KREMERS URBAN PHARMS	17GM/SCOOPFUL	A076652	001	Jul 02, 2004	Sep	CAHN
----	----------------------	---------------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

@ MEDA PHARMS

120GM/PACKET;1.49GM/PACKET;3.36GM	N018983	005	Oct 26, 1984	Jun	CAHN
/PACKET;2.92GM/PACKET;11.36GM/PAC					
KET					

@

227.1GM/PACKET;2.82GM/PACKET;6.36	N018983	004	Oct 26, 1984	Jul	DISC
GM/PACKET;5.53GM/PACKET;21.5GM/PA					
CKET					

AA	+	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT	N018983	010	Jan 31, 1989	Jun	CAHN
		;5.53GM/BOT;21.5GM/BOT					

227.1GM/PACKET;2.82GM/PACKET;6.36	N018983	004	Oct 26, 1984	Jun	CAHN
GM/PACKET;5.53GM/PACKET;21.5GM/PA					
CKET					

AA	+	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5	N018983	007	Jun 12, 1987	Jun	CAHN
		.84GM/BOT;22.72GM/BOT					

@

360GM/PACKET;4.47GM/PACKET;10.08G	N018983	006	Oct 26, 1984	Jun	CAHN
M/PACKET;8.76GM/PACKET;34.08GM/PA					
CKET					

COLYTE WITH FLAVOR PACKS

AA	+	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5	N018983	012	Oct 08, 1998	Jun	CAHN
			.84GM/BOT;22.72GM/BOT					

COLYTE-FLAVORED

AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT	N018983	008	Nov 14, 1991	Jun	CAHN
			;5.53GM/BOT;21.5GM/BOT					

AA	+	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5	N018983	009	Nov 14, 1991	Jun	CAHN
		.84GM/BOT;22.72GM/BOT					

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLMYCIN B SULFATE

AP	SAGENT STRIDES	EQ 500,000 UNITS BASE/VIAL	A090110	001	Jun 29, 2011	Jun	NEWA
----	----------------	----------------------------	---------	-----	--------------	-----	------

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

PINNACLE BIOLGS

75MG/VIAL

N020451	001	Dec 27, 1995	Aug	CMFD
---------	-----	--------------	-----	------

@

75MG/VIAL

N020451	001	Dec 27, 1995	Jun	DISC
---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

AB	NESHER PHARMS	8MEQ	N018238	001		Aug	CAHN
----	---------------	------	---------	-----	--	-----	------

MICRO-K 10

AB	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Aug	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

AB	PADDOCK LABS	8MEQ	A200185	001	May 18, 2011	May	NEWA
----	--------------	------	---------	-----	--------------	-----	------

AB		10MEQ	A200185	002	May 18, 2011	May	NEWA
----	--	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

>D>	BC	UPSHER SMITH	10MEQ	N019123 002	Apr 17, 1986	Oct	CRLD
>A>	BC	+ UPSHER-SMITH LABS	10MEQ	N019123 002	Apr 17, 1986	Oct	CRLD

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

>D>	@	MISSION PHARMA	10MEQ/PACKET	N019647 002	Oct 13, 1988	Oct	CAHN
>D>	@		20MEQ/PACKET	N019647 001	Oct 13, 1988	Oct	CAHN
>A>	@	UNIV TX SW MEDCTR	10MEQ/PACKET	N019647 002	Oct 13, 1988	Oct	CAHN
>A>	@		20MEQ/PACKET	N019647 001	Oct 13, 1988	Oct	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

	BOEHRINGER INGELHEIM	2.25MG	N022421 006	Jun 17, 2011	Jun	NEWA
		3.75MG	N022421 007	Jun 17, 2011	Jun	NEWA

PRAZICQUANTEL

TABLET; ORAL

BILTRICIDE

+	BAYER PHARMA AG	600MG	N018714 001	Dec 29, 1982	Sep	CAHN
---	-----------------	-------	-------------	--------------	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

@	VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416 001	Oct 31, 2007	May	DISC
---	----------------	-----------------	-------------	--------------	-----	------

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	JUBILANT CADISTA	1MG	A040611 001	Jun 06, 2005	Jan	CAHN
AB		5MG	A040362 002	Aug 29, 2001	Jan	CAHN
AB		10MG	A040362 001	Aug 29, 2001	Jan	CAHN
AB		20MG	A040362 003	Jun 29, 2005	Jan	CAHN

PREGABALIN

CAPSULE; ORAL

LYRICA

CPPI CV	25MG	N021446 001	Dec 30, 2004	Sep	CAHN
	50MG	N021446 002	Dec 30, 2004	Sep	CAHN
	75MG	N021446 003	Dec 30, 2004	Sep	CAHN
	100MG	N021446 004	Dec 30, 2004	Sep	CAHN
	150MG	N021446 005	Dec 30, 2004	Sep	CAHN
	225MG	N021446 007	Dec 30, 2004	Sep	CAHN
+	300MG	N021446 008	Dec 30, 2004	Sep	CAHN

SOLUTION; ORAL

LYRICA

+	CPPI CV	20MG/ML	N022488 001	Jan 04, 2010	Sep	CAHN
---	---------	---------	-------------	--------------	-----	------

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

>A>	@	NURO PHARMA	250MG/5ML	N010401 001		Oct	CAHN
>D>	@	XCEL PHARMS	250MG/5ML	N010401 001		Oct	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268 002	Feb 27, 1998	Jan	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	X-GEN PHARMS	25MG/ML	A040737 001	Apr 24, 2008	May	CAHN
AP		50MG/ML	A040737 002	Apr 24, 2008	May	CAHN

SUPPOSITORY; RECTAL

PHENERGAN

@	SHIONOGI INC	12.5MG	N010926 002		Aug	CAHN
@		25MG	N010926 001		Aug	CAHN
@		50MG	N011689 001		Aug	CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB	EMCURE PHARMS USA	12.5MG	A040673 001	Mar 05, 2008	Jul	CAHN
AB		25MG	A040673 002	Mar 05, 2008	Jul	CAHN
AB		50MG	A040673 003	Mar 05, 2008	Jul	CAHN
AB	MYLAN	12.5MG	A091054 001	Aug 30, 2011	Aug	NEWA
AB		25MG	A091054 002	Aug 30, 2011	Aug	NEWA
AB		50MG	A091054 003	Aug 30, 2011	Aug	NEWA

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927 002		Jan	CMFD
---	--------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@	XANODYNE PHARM	65MG	N010997 003		Jan	DISC
---	----------------	------	-------------	--	-----	------

DOLENE

@	HERITAGE PHARMS INC	65MG	A080530 001		Aug	DISC
---	---------------------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

@	MYLAN	65MG	A040569 001	Dec 16, 2004	Aug	DISC
@	TEVA	65MG	A088615 001	Oct 22, 1984	Mar	DISC
@	VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009	Mar	DISC
@	WEST WARD	65MG	A083501 001		Jan	DISC

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N

@	XANODYNE PHARM	100MG	N016862 002		Jan	DISC
---	----------------	-------	-------------	--	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	GLAXOSMITHKLINE	60MG	A078703 001	Jul 15, 2011	Jul	NEWA
AB		80MG	A078703 002	Jul 15, 2011	Jul	NEWA
AB		120MG	A078703 003	Jul 15, 2011	Jul	NEWA
AB		160MG	A078703 004	Jul 15, 2011	Jul	NEWA
AB	ZYDUS PHARMS USA INC	60MG	A090321 001	Mar 25, 2011	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	80MG	A090321	002	Mar 25, 2011	Mar	NEWA
AB		120MG	A090321	003	Mar 25, 2011	Mar	NEWA
AB		160MG	A090321	004	Mar 25, 2011	Mar	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG	A070213	005	Apr 08, 2011	Mar	NEWA
----	-------	------	---------	-----	--------------	-----	------

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+	COREPHARMA	25MG	N008578	001		Jun	CAHN
---	------------	------	---------	-----	--	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@ ACTAVIS TOTOWA	EQ 5MG BASE	A076459	001	Dec 22, 2004	Jul	DISC
	@	EQ 10MG BASE	A076459	002	Dec 22, 2004	Jul	DISC
	@	EQ 20MG BASE	A076459	003	Dec 22, 2004	Jul	DISC
	@	EQ 40MG BASE	A076459	004	Dec 22, 2004	Jul	DISC
AB	MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Feb	CAHN
AB		EQ 10MG BASE	A076036	002	Jan 28, 2005	Feb	CAHN
AB		EQ 20MG BASE	A076036	003	Jan 28, 2005	Feb	CAHN
AB		EQ 40MG BASE	A076036	004	Jan 28, 2005	Feb	CAHN

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

	@ ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008	Aug	DISC
	@	2.5MG	A077513	002	Jun 18, 2008	Aug	DISC
	@	5MG	A077513	003	Jun 18, 2008	Aug	DISC
	@	10MG	A077513	004	Jun 18, 2008	Aug	DISC
AB	AUROBINDO PHARMA LTD	1.25MG	A091604	001	Jun 08, 2011	May	NEWA
AB		2.5MG	A091604	002	Jun 08, 2011	May	NEWA
AB		5MG	A091604	003	Jun 08, 2011	May	NEWA
AB		10MG	A091604	004	Jun 08, 2011	May	NEWA

TABLET; ORAL

RAMIPRIL

AB	MATRIX LABS LTD	1.25MG	A090650	001	Jun 30, 2011	Jun	NEWA
AB		2.5MG	A090650	002	Jun 30, 2011	Jun	NEWA
AB		5MG	A090650	003	Jun 30, 2011	Jun	NEWA
AB		10MG	A090650	004	Jun 30, 2011	Jun	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

@	MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000	Feb	CAHN
@		EQ 300MG BASE	A075564	002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007	Sep	CAHN
AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	Mar	NEWA
AA	SUN PHARM INDS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Sep	NEWA
AA	TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011	May	NEWA

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023 001	Aug 22, 1997	Feb	CAHN
AB		EQ 300MG BASE	A074023 002	Aug 22, 1997	Feb	CAHN

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

>D>	BIONICHE TEORANTA	EQ 1MG BASE/VIAL	N020630 001	Jul 12, 1996	Oct	CAHN
>D>		EQ 2MG BASE/VIAL	N020630 002	Jul 12, 1996	Oct	CAHN
>D>	+	EQ 5MG BASE/VIAL	N020630 003	Jul 12, 1996	Oct	CAHN
>A>	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630 001	Jul 12, 1996	Oct	CAHN
>A>		EQ 2MG BASE/VIAL	N020630 002	Jul 12, 1996	Oct	CAHN
>A>	+	EQ 5MG BASE/VIAL	N020630 003	Jul 12, 1996	Oct	CAHN

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

@	ACTAVIS TOTOWA	300MG	N050429 001		Jul	DISC
---	----------------	-------	-------------	--	-----	------

INJECTABLE; INJECTION

RIFAMPIN

AP	PFIZER	600MG/VIAL	A065421 001	May 22, 2008	May	CAHN
----	--------	------------	-------------	--------------	-----	------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+	SALIX PHARMS	550MG	N022554 001	Mar 24, 2010	Feb	CRLD
---	--------------	-------	-------------	--------------	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	TIBOTEC	EQ 25MG BASE	N202022 001	May 20, 2011	May	NEWA
---	---------	--------------	-------------	--------------	-----	------

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	100MG	A076375 001	Jan 14, 2003	Jul	DISC
---	----------------	-------	-------------	--------------	-----	------

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346 004	Apr 12, 2007	Jun	CAHN
+		25MG/VIAL	N021346 001	Oct 29, 2003	Jun	CAHN
		37.5MG/VIAL	N021346 002	Oct 29, 2003	Jun	CAHN
		50MG/VIAL	N021346 003	Oct 29, 2003	Jun	CAHN

SOLUTION; ORAL

RISPERDAL

AA	+	JANSSEN PHARMS	1MG/ML	N020588 001	Jun 10, 1996	Jun	CAHN
----	---	----------------	--------	-------------	--------------	-----	------

RISPERIDONE

AA	AMNEAL PHARMS	1MG/ML	A091384 001	May 25, 2011	May	NEWA
AA	TARO	1MG/ML	A090347 001	Feb 07, 2011	Jan	NEWA

TABLET; ORAL

RISPERDAL

AB	JANSSEN PHARMS	0.25MG	N020272 008	May 10, 1999	Jun	CAHN
AB		0.5MG	N020272 007	Jan 27, 1999	Jun	CAHN
AB	+	1MG	N020272 001	Dec 29, 1993	Jun	CAHN

TABLET; ORAL

RISPERDAL

AB	JANSSEN PHARMS	2MG	N020272 002	Dec 29, 1993	Jun	CAHN
AB		3MG	N020272 003	Dec 29, 1993	Jun	CAHN
AB		4MG	N020272 004	Dec 29, 1993	Jun	CAHN
	@	5MG	N020272 005	Dec 29, 1993	Jun	CAHN

RISPERIDONE

	@ ACTAVIS TOTOWA	0.25MG	A078071 001	Jun 17, 2009	Jul	DISC
	@	0.5MG	A078071 002	Jun 17, 2009	Jul	DISC
	@	1MG	A078071 003	Jun 17, 2009	Jul	DISC
	@	2MG	A078071 004	Jun 17, 2009	Jul	DISC
	@	3MG	A078071 005	Jun 17, 2009	Jul	DISC
	@	4MG	A078071 006	Jun 17, 2009	Jul	DISC
AB	AJANTA PHARMA LTD	0.25MG	A201003 001	Aug 24, 2011	Aug	NEWA
AB		0.5MG	A201003 002	Aug 24, 2011	Aug	NEWA
AB		1MG	A201003 003	Aug 24, 2011	Aug	NEWA
AB		2MG	A201003 004	Aug 24, 2011	Aug	NEWA
AB		3MG	A201003 005	Aug 24, 2011	Aug	NEWA
AB		4MG	A201003 006	Aug 24, 2011	Aug	NEWA
	@ CADISTA PHARMS	0.25MG	A078828 001	Mar 23, 2009	Sep	DISC
	@	0.5MG	A078828 002	Mar 23, 2009	Sep	DISC
	@	1MG	A078828 003	Mar 23, 2009	Sep	DISC
	@	2MG	A078828 004	Mar 23, 2009	Sep	DISC
	@	3MG	A078828 005	Mar 23, 2009	Sep	DISC
	@	4MG	A078828 006	Mar 23, 2009	Sep	DISC
AB	CIPLA	0.25MG	A077543 001	May 18, 2011	May	NEWA
AB		0.5MG	A077543 002	May 18, 2011	May	NEWA
AB		1MG	A077543 003	May 18, 2011	May	NEWA
AB		2MG	A077543 004	May 18, 2011	May	NEWA
AB		3MG	A077543 005	May 18, 2011	May	NEWA
AB		4MG	A077543 006	May 18, 2011	May	NEWA
	@ RATIOPHARM	0.25MG	A077784 001	Jun 08, 2010	Feb	DISC
	@	0.5MG	A077784 002	Jun 08, 2010	Feb	DISC
	@	1MG	A077784 003	Jun 08, 2010	Feb	DISC
	@	2MG	A077784 004	Jun 08, 2010	Feb	DISC
	@	3MG	A077784 005	Jun 08, 2010	Feb	DISC
	@	4MG	A077784 006	Jun 08, 2010	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

AB	JANSSEN PHARMS	0.5MG	N021444 001	Apr 02, 2003	Jul	CAHN
AB	+	1MG	N021444 002	Apr 02, 2003	Jul	CAHN
AB		2MG	N021444 003	Apr 02, 2003	Jul	CAHN
AB		3MG	N021444 004	Dec 23, 2004	Jul	CAHN
AB		4MG	N021444 005	Dec 23, 2004	Jul	CAHN

RISPERIDONE

>A>	AB	JUBILANT ORGANOSYS	0.5MG	A090839 001	Nov 04, 2011	Oct	NEWA
>A>	AB		1MG	A090839 002	Nov 04, 2011	Oct	NEWA
>A>	AB		2MG	A090839 003	Nov 04, 2011	Oct	NEWA
>A>	AB		3MG	A090839 004	Nov 04, 2011	Oct	NEWA
>A>	AB		4MG	A090839 005	Nov 04, 2011	Oct	NEWA
	AB	MYLAN	0.5MG	A091537 001	Mar 30, 2011	Mar	NEWA
	AB		1MG	A091537 002	Mar 30, 2011	Mar	NEWA
	AB		2MG	A091537 003	Mar 30, 2011	Mar	NEWA
	AB		3MG	A091537 004	Mar 30, 2011	Mar	NEWA
	AB		4MG	A091537 005	Mar 30, 2011	Mar	NEWA
	AB	WATSON LABS FLORIDA	0.5MG	A076996 001	Apr 19, 2011	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	WATSON LABS FLORIDA	1MG	A076996 002	Apr 19, 2011	Apr	NEWA
AB		2MG	A076996 003	Apr 19, 2011	Apr	NEWA
AB		3MG	A076996 004	Apr 19, 2011	Apr	NEWA
AB		4MG	A076996 005	Apr 19, 2011	Apr	NEWA

RIVAROXABAN

TABLET; ORAL

XARELTO

+	JOHNSON AND JOHNSON	10MG	N022406 001	Jul 01, 2011	Jul	NEWA
---	---------------------	------	-------------	--------------	-----	------

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458 001	Jul 28, 2010	Jan	CAHN
AP		100MG/10ML (10MG/ML)	A091458 002	Jul 28, 2010	Jan	CAHN

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG	N022522 001	Feb 28, 2011	Feb	NEWA
---	---------------------	--------	-------------	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	PRINSTON INC	EQ 0.25MG BASE	A078110 001	May 05, 2008	Aug	CAHN
AB		EQ 0.5MG BASE	A078110 002	May 05, 2008	Aug	CAHN
AB		EQ 1MG BASE	A078110 003	May 05, 2008	Aug	CAHN
AB		EQ 2MG BASE	A078110 004	May 05, 2008	Aug	CAHN
AB		EQ 3MG BASE	A078110 005	May 05, 2008	Aug	CAHN
AB		EQ 4MG BASE	A078110 006	May 05, 2008	Aug	CAHN
AB	PRINSTON PHARM LLC	EQ 0.25MG BASE	A078110 001	May 05, 2008	May	CAHN
AB		EQ 0.5MG BASE	A078110 002	May 05, 2008	May	CAHN
AB		EQ 1MG BASE	A078110 003	May 05, 2008	May	CAHN
AB		EQ 2MG BASE	A078110 004	May 05, 2008	May	CAHN
AB		EQ 3MG BASE	A078110 005	May 05, 2008	May	CAHN
AB		EQ 4MG BASE	A078110 006	May 05, 2008	May	CAHN

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+	EISAI INC	40MG/ML	N201367 001	Mar 03, 2011	Mar	NEWA
---	-----------	---------	-------------	--------------	-----	------

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+	MARATHON PHARMS	50MG	A086101 001	Oct 03, 1983	Jan	CAHN
+		100MG	A086101 002	Oct 03, 1983	Jan	CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

@	ACTAVIS MID ATLANTIC	2.5%	A084394 001		Aug	DISC
---	----------------------	------	-------------	--	-----	------

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	ORTHO JANSSEN	2%	N021385	001	Dec 10, 2003	Jul	CAHN
---	---------------	----	---------	-----	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@	ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	DISC
---	--------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	EQ 25MG BASE	A078175	001	Jul 21, 2010	Jul	DISC
---	----------------	--------------	---------	-----	--------------	-----	------

@		EQ 50MG BASE	A078175	002	Jul 21, 2010	Jul	DISC
---	--	--------------	---------	-----	--------------	-----	------

@		EQ 100MG BASE	A078175	003	Jul 21, 2010	Jul	DISC
---	--	---------------	---------	-----	--------------	-----	------

@	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC
---	----------------------	--------------	---------	-----	--------------	-----	------

@		EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
---	--	--------------	---------	-----	--------------	-----	------

@		EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
---	--	---------------	---------	-----	--------------	-----	------

AB	MYLAN	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN
----	-------	--------------	---------	-----	--------------	-----	------

AB		EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
----	--	---------------	---------	-----	--------------	-----	------

@	PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299	001	Feb 06, 2007	Jul	DISC
---	--------------------	--------------	---------	-----	--------------	-----	------

@		EQ 50MG BASE	A077299	002	Feb 06, 2007	Jul	DISC
---	--	--------------	---------	-----	--------------	-----	------

@		EQ 100MG BASE	A077299	003	Feb 06, 2007	Jul	DISC
---	--	---------------	---------	-----	--------------	-----	------

@	ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
---	--------	--------------	---------	-----	--------------	-----	------

@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
---	--	--------------	---------	-----	--------------	-----	------

@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC
---	--	---------------	---------	-----	--------------	-----	------

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

@	ACTAVIS TOTOWA	5MG	A078735	001	Aug 30, 2010	Jul	DISC
---	----------------	-----	---------	-----	--------------	-----	------

@		10MG	A078735	002	Aug 30, 2010	Jul	DISC
---	--	------	---------	-----	--------------	-----	------

@		20MG	A078735	003	Aug 30, 2010	Jul	DISC
---	--	------	---------	-----	--------------	-----	------

@		40MG	A078735	004	Aug 30, 2010	Jul	DISC
---	--	------	---------	-----	--------------	-----	------

@		80MG	A078735	005	Aug 30, 2010	Jul	DISC
---	--	------	---------	-----	--------------	-----	------

AB	MICRO LABS LTD	5MG	A090383	001	Sep 16, 2011	Sep	NEWA
----	----------------	-----	---------	-----	--------------	-----	------

AB		10MG	A090383	002	Sep 16, 2011	Sep	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		20MG	A090383	003	Sep 16, 2011	Sep	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		40MG	A090383	004	Sep 16, 2011	Sep	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		80MG	A090383	005	Sep 16, 2011	Sep	NEWA
----	--	------	---------	-----	--------------	-----	------

>A> SIMVASTATIN; SITAGLIPTIN PHOSPHATE

>A> TABLET; ORAL

>A> JUVISYNC

>A>	MERCK SHARP DOHME	10MG;EQ 100MG BASE	N202343	001	Oct 07, 2011	Oct	NEWA
-----	-------------------	--------------------	---------	-----	--------------	-----	------

>A>		20MG;EQ 100MG BASE	N202343	002	Oct 07, 2011	Oct	NEWA
-----	--	--------------------	---------	-----	--------------	-----	------

>A>	+	40MG;EQ 100MG BASE	N202343	003	Oct 07, 2011	Oct	NEWA
-----	---	--------------------	---------	-----	--------------	-----	------

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+	MEDIGENE AG	15%	N021902	001	Oct 31, 2006	May	CAHN
---	-------------	-----	---------	-----	--------------	-----	------

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@ MALLINCKRODT LLC	460MG/GM; 420MG/GM	N018509 001	Aug 07, 1985	Aug	CAHN
--------------------	--------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ HOSPIRA	450MG/100ML	N018380 001		Aug	DISC
-----------	-------------	-------------	--	-----	------

@	450MG/100ML	N017670 001		Aug	DISC
---	-------------	-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955 001	Feb 18, 1999	Mar	CFTG
----	---	-------------------	------------	-------------	--------------	-----	------

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		GENERAMEDIX	62.5MG/5ML	A078215 001	Mar 31, 2011	Mar	NEWA
----	--	-------------	------------	-------------	--------------	-----	------

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F 18

@ NIH NCI DCTD	10-200mCi/ML	N022494 001	Jan 26, 2011	Apr	DISC
----------------	--------------	-------------	--------------	-----	------

+	10-200mCi/ML	N022494 001	Jan 26, 2011	Jan	NEWA
---	--------------	-------------	--------------	-----	------

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Feb	CTNA
---	-------------	--	-------------	--------------	-----	------

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Jan	NEWA
---	-------------	--	-------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LABS	15GM/60ML	A090590 001	May 13, 2011	May	NEWA
----	--	--------------	-----------	-------------	--------------	-----	------

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

@ PFIZER	EQ 2GM BASE/VIAL	N050347 001		Jun	DISC
----------	------------------	-------------	--	-----	------

@	EQ 4GM BASE/VIAL	N050347 002		Jun	CAHN
---	------------------	-------------	--	-----	------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO PHARMS	0.9%	N022408 001	Jan 18, 2011	Jan	NEWA
---	----------------	------	-------------	--------------	-----	------

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

@ PFIZER	EQ 1GM BASE/2.5ML	A060111 001		Jul	DISC
----------	-------------------	-------------	--	-----	------

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

>A>	+	APTALIS PHARMA US	1GM/10ML	N019183 001	Dec 16, 1993	Oct	CAHN
>D>	+	AXCAN	1GM/10ML	N019183 001	Dec 16, 1993	Oct	CAHN

TABLET; ORAL

CARAFATE

>A>	AB	+	APTALIS PHARMA US	1GM	N018333 001		Oct	CAHN
>D>	AB	+	AXCAN	1GM	N018333 001		Oct	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

	+	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Aug	CAHN
--	---	----------------	-------------------------------------	-------------	--------------	-----	------

IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 003	Dec 23, 1996	Jun	CFTG
----	---	-----------------	-------------------------------------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AB		SUN PHARM INDS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358 001	Jun 21, 2011	Jun	NEWA
		@ TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318 001	Feb 06, 2009	Aug	DISC
		@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318 002	Feb 06, 2009	Aug	DISC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

	@	ROXANE	EQ 25MG BASE	A078241 001	Aug 10, 2009	Mar	DISC
	@		EQ 50MG BASE	A078241 002	Aug 10, 2009	Mar	DISC
	@		EQ 100MG BASE	A078241 003	Aug 10, 2009	Mar	DISC

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

	@	SHIONOGI INC	EQ 10MG BASE	N020070 001	Sep 09, 1993	Jun	DISC
	@		EQ 20MG BASE	N020070 002	Sep 09, 1993	Jun	DISC
	@		EQ 30MG BASE	N020070 003	Sep 09, 1993	Jun	DISC
	@		EQ 40MG BASE	N020070 004	Sep 09, 1993	Jun	DISC

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB		ACCORD HLTHCARE	0.5MG	A091195 001	Aug 31, 2011	Aug	NEWA
AB			1MG	A091195 002	Aug 31, 2011	Aug	NEWA
AB			5MG	A091195 003	Aug 31, 2011	Aug	NEWA

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

AB		APOTEX	EQ 10MG BASE	A090878 001	Sep 23, 2011	Sep	NEWA
AB			EQ 20MG BASE	A090878 002	Sep 23, 2011	Sep	NEWA

TAPENTADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NUCYN TA ER

		ORTHO MCNEIL JANSSEN	EQ 50MG BASE	N200533 001	Aug 25, 2011	Aug	NEWA
			EQ 100MG BASE	N200533 002	Aug 25, 2011	Aug	NEWA

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

	ORTHO MCNEIL JANSSEN	EQ 150MG BASE	N200533 003	Aug 25, 2011	Aug	NEWA
		EQ 200MG BASE	N200533 004	Aug 25, 2011	Aug	NEWA
+		EQ 250MG BASE	N200533 005	Aug 25, 2011	Aug	NEWA

TELAPREVIR

TABLET; ORAL

INCIVEK

+	VERTEX PHARMS	375MG	N201917 001	May 23, 2011	May	NEWA
---	---------------	-------	-------------	--------------	-----	------

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

@	NOVARTIS	100MG/5ML	N022154 001	Apr 28, 2009	Jun	DISC
---	----------	-----------	-------------	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	JUBILANT CADISTA	EQ 1MG BASE	A075317 001	Dec 20, 2004	Jan	CAHN
AB		EQ 2MG BASE	A075317 002	Dec 20, 2004	Jan	CAHN
AB		EQ 5MG BASE	A075317 003	Dec 20, 2004	Jan	CAHN
AB		EQ 10MG BASE	A075317 004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE	A077136 001	Jul 02, 2007	Feb	CAHN
	@ ROXANE	EQ 250MG BASE	A077223 001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL

TERBUTALINE SULFATE

AB	+	IMPAX LABS	5MG	A075877 002	Jun 26, 2001	Jan	CRLD
----	---	------------	-----	-------------	--------------	-----	------

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

>A>	+	WATSON LABS	2MG/24HR	N020489 003	Oct 20, 2011	Oct	NEWA
>D>	+		2.5MG/24HR	N020489 001	Sep 29, 1995	Oct	DISC
>A>	@		2.5MG/24HR	N020489 001	Sep 29, 1995	Oct	DISC
>A>	+		4MG/24HR	N020489 004	Oct 20, 2011	Oct	NEWA
>D>	+		5MG/24HR	N020489 002	May 02, 1997	Oct	DISC
>A>	@		5MG/24HR	N020489 002	May 02, 1997	Oct	DISC

GEL; TRANSDERMAL

ANDROGEL

BX	+	ABBOTT LABS	1% (5GM/PACKET)	N021015 002	Feb 28, 2000	Aug	CAHN
			1% (2.5GM/PACKET)	N021015 001	Feb 28, 2000	Aug	CAHN

GEL, METERED; TRANSDERMAL

ANDROGEL

+	ABBOTT LABS	1% (1.25GM/ACTIVATION)	N021015 003	Sep 26, 2003	Aug	CAHN
+		1.62% (20.25MG/1.25GM ACTIVATION)	N022309 001	Apr 29, 2011	Aug	CAHN
+	ABBOTT PRODS	1.62% (20.25MG/1.25GM ACTIVATION)	N022309 001	Apr 29, 2011	Apr	NEWA

FORTESTA

+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463 001	Dec 29, 2010	Mar	CPOT
---	-------------	-----------------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; BUCCAL
STRIANT

+ ACTIENT PHARMS 30MG N021543 001 Jun 19, 2003 Jun CAHN

TETRABENAZINE

TABLET; ORAL

XENAZINE

VALEANT INTL 12.5MG N021894 001 Aug 15, 2008 Jun CAHN

+ 25MG N021894 002 Aug 15, 2008 Jun CAHN

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

@ SCHIFF AND CO 12.7MG/FIBER N050653 001 Mar 25, 1994 Jun CAHN

SUSPENSION; ORAL

SUMYCIN

@ PAR PHARM 125MG/5ML A060400 001 Jul DISC

TABLET; ORAL

SUMYCIN

@ PAR PHARM 250MG A061147 001 Jul DISC

@ 500MG A061147 004 Jul DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

BC ACTIENT PHARMS 100MG A087942 001 Aug 22, 1983 Jun CAHN

BC 200MG A087943 001 Aug 22, 1983 Jun CAHN

BC 300MG A087944 001 Aug 22, 1983 Jun CAHN

400MG A081034 001 Feb 28, 1992 Jun CAHN

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 80MG/100ML N019211 002 Dec 14, 1984 Aug DISC

@ 200MG/100ML N019211 004 Dec 14, 1984 Aug DISC

@ 400MG/100ML N019211 005 Dec 14, 1984 Aug DISC

SOLUTION; ORAL

THEOPHYLLINE

+ SILARX 80MG/15ML A091156 001 Apr 13, 2011 Mar NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

@ HOSPIRA 100MG/ML A040079 001 May 03, 1996 May DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

>D> CEPHALON 2MG N020646 005 Apr 16, 1999 Oct CFTG

>A> AB 2MG N020646 005 Apr 16, 1999 Oct CFTG

>D> + 4MG N020646 001 Sep 30, 1997 Oct CFTG

>A> AB + 4MG N020646 001 Sep 30, 1997 Oct CFTG

>A> TIAGABINE HYDROCHLORIDE

>A> AB SUN PHARM INDS 2MG A077555 001 Nov 04, 2011 Oct NEWA

>A> AB 4MG A077555 002 Nov 04, 2011 Oct NEWA

TICAGRELOR

TABLET; ORAL

BRILINTA

+	ASTRAZENECA LP	90MG	N022433	001	Jul 20, 2011	Jul	NEWA
---	----------------	------	---------	-----	--------------	-----	------

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

	@ ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999	Aug	DISC
AB	MYLAN	250MG	A075161	001	Sep 13, 1999	Feb	CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT	APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000	Jun	CAHN
AT		EQ 0.5% BASE	A075412	001	Sep 08, 2000	Sep	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	EQ 2MG BASE	A076283	001	Jul 12, 2002	Aug	DISC
@		EQ 4MG BASE	A076283	002	Jul 12, 2002	Aug	DISC
@	ACTAVIS TOTOWA	EQ 2MG BASE	A076281	001	Oct 20, 2003	Jul	DISC
@		EQ 4MG BASE	A076281	002	Oct 20, 2003	Jul	DISC

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	FERA PHARMS	0.3%	A065026	001	Sep 11, 2001	Mar	CAHN
----	-------------	------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

	@ HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991	Aug	DISC
AP	+	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991	Aug	CRLD

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARM INTL	100MG	N020697	001	Jan 29, 1998	Jun	CRLD
@		200MG	N020697	002	Jan 29, 1998	Jun	DISC

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@	ACTAVIS ELIZABETH	EQ 400MG BASE	A073308	001	Jan 24, 1992	Aug	DISC
---	-------------------	---------------	---------	-----	--------------	-----	------

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191	001	Mar 09, 2011	Feb	NEWA
AP	SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284	001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS

TOPOTECAN

AP	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582	001	Feb 02, 2011	Feb	NEWA
----	-------------	----------------------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

TOPOTECAN

SANDOZ

		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011	Feb	NEWA
		EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011	Feb	NEWA
AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	VINTAGE PHARMS	5MG	A090613 001	Mar 22, 2011	Mar	NEWA
AB		10MG	A090613 002	Mar 22, 2011	Mar	NEWA
AB		20MG	A090613 003	Mar 22, 2011	Mar	NEWA
AB		100MG	A090613 004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

	+	CIPHER PHARMS INC	100MG	N022370 001	May 07, 2010	Aug	CTNA
			150MG	N022370 004	Aug 01, 2011	Aug	NEWA
			200MG	N022370 002	May 07, 2010	Aug	CTNA
			300MG	N022370 003	May 07, 2010	Aug	CTNA

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

@ ACTAVIS ELIZABETH

		50MG	A075960 001	Jun 19, 2002	Aug	DISC
AB	ZYDUS PHARMS USA INC	50MG	A090404 001	Jan 31, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB	LUPIN LTD	100MG	A200503 001	Aug 29, 2011	Aug	NEWA
AB		200MG	A200503 002	Aug 29, 2011	Aug	NEWA
AB		300MG	A200503 003	Aug 29, 2011	Aug	NEWA
AB	PAR PHARM	300MG	A078783 003	Sep 20, 2011	Sep	NEWA

ULTRAM ER

AB	+	VALEANT INTL	100MG	N021692 001	Sep 08, 2005	Jun	CAHN
AB			200MG	N021692 002	Sep 08, 2005	Jun	CAHN
AB			300MG	N021692 003	Sep 08, 2005	Aug	CTEC
BC			300MG	N021692 003	Sep 08, 2005	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

	+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Aug	CAHN
--	---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

AP	+	PHARMACIA AND UPJOHN	100MG/ML	N019281 001	Dec 30, 1986	Aug	CFTG
----	---	----------------------	----------	-------------	--------------	-----	------

TRANEXAMIC ACID

>A>	AP	BIONICHE PHARMA	100MG/ML	A091657 001	Nov 03, 2011	Oct	NEWA
	AP	PHARMAFORCE	100MG/ML	A201885 001	Aug 10, 2011	Aug	NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

@ ALCON

0.004%

N021257 001	Mar 16, 2001	May	DISC
-------------	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OLEPTRO

+	ANGELINI LABOPHARM	150MG	N022411 001	Feb 02, 2010	Jun	CAHN
		300MG	N022411 002	Feb 02, 2010	May	CAHN
+	ANGELINI LLC	150MG	N022411 001	Feb 02, 2010	Aug	CAHN
		300MG	N022411 002	Feb 02, 2010	Aug	CAHN

TRETINOIN

CREAM; TOPICAL
RENOVA

	+	ORTHO JANSSEN	0.02%	N021108 001	Aug 31, 2000	Jul	CAHN
AB2	+		0.05%	N019963 001	Dec 29, 1995	Jul	CAHN

RETIN-A

AB	+	ORTHO JANSSEN	0.025%	N019049 001	Sep 16, 1988	Jul	CAHN
AB1	+		0.05%	N017522 001		Jul	CAHN
AB	+		0.1%	N017340 001		Jul	CAHN

GEL; TOPICAL

RETIN-A

AB	+	ORTHO JANSSEN	0.01%	N017955 001		Jul	CAHN
AB	+		0.025%	N017579 002		Jul	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	ORTHO JANSSEN	0.05%	N016921 001		Jul	CAHN
----	---	---------------	-------	-------------	--	-----	------

SWAB; TOPICAL

RETIN-A

	@	ORTHO JANSSEN	0.05%	N016921 002		Jul	CAHN
--	---	---------------	-------	-------------	--	-----	------

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

	@	ACTAVIS MID ATLANTIC	0.1%	A087798 001	Jun 04, 1982	Aug	DISC
--	---	----------------------	------	-------------	--------------	-----	------

TRIDERM

AT		CROWN LABS	0.1%	A088042 001	Mar 19, 1984	Sep	CAHN
----	--	------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

	@	ACTAVIS MID ATLANTIC	0.1%	A087799 001	Jun 07, 1982	Aug	DISC
--	---	----------------------	------	-------------	--------------	-----	------

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

AT	+	TARO	0.1%	A070730 001	Oct 01, 1986	Aug	CTNA
----	---	------	------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

AB		TEVA BRANDED PHARM	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Aug	CAHN
----	--	--------------------	---------------	-------------	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP		LUITPOLD	100MG/ML	A091330 001	Mar 08, 2011	May	CAHN
----	--	----------	----------	-------------	--------------	-----	------

AP		PHARMAFORCE	100MG/ML	A091330 001	Mar 08, 2011	Feb	NEWA
----	--	-------------	----------	-------------	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP		LUITPOLD	100MG/ML	A091329 001	Mar 08, 2011	May	CAHN
----	--	----------	----------	-------------	--------------	-----	------

AP		PHARMAFORCE	100MG/ML	A091329 001	Mar 08, 2011	Feb	NEWA
----	--	-------------	----------	-------------	--------------	-----	------

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	NOVEL LABS INC	100MG	A091437 001	Jun 15, 2011	May	NEWA
----	----------------	-------	-------------	--------------	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361 001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361 002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361 003	Aug 02, 2006	Feb	CAHN

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	WATSON LABS	EQ 3.75MG BASE/VIAL	N020715 001	Jun 15, 2000	Sep	CTNA
+		EQ 11.25MG BASE/VIAL	N021288 001	Jun 29, 2001	Sep	CTNA

URSODIOL

TABLET; ORAL

URSO 250

>A>	AB	APTALIS PHARMA US	250MG	N020675 001	Dec 10, 1997	Oct	CAHN
>D>	AB	AXCAN	250MG	N020675 001	Dec 10, 1997	Oct	CAHN

URSO FORTE

>A>	AB	+	APTALIS PHARMA US	500MG	N020675 002	Jul 21, 2004	Oct	CAHN
>D>	AB	+	AXCAN	500MG	N020675 002	Jul 21, 2004	Oct	CAHN

URSODIOL

AB	GLENMARK GENERICS	250MG	A090801 001	Jul 12, 2011	Jul	NEWA
AB		500MG	A090801 002	Jul 12, 2011	Jul	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370 001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370 002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	PFIZER	EQ 500MG BASE/VIAL	A065397 001	Dec 30, 2008	May	CAHN
AP		EQ 1GM BASE/VIAL	A065397 002	Dec 30, 2008	May	CAHN
AP		EQ 5GM BASE/VIAL	A065432 001	Dec 30, 2008	May	CAHN
AP		EQ 10GM BASE/VIAL	A091469 001	Jul 01, 2011	Jun	NEWA
AP	STRIDES ARCOLAB LTD	EQ 10GM BASE/VIAL	A091554 001	Sep 19, 2011	Sep	NEWA

VANDETANIB

TABLET; ORAL

VANDETANIB

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Apr	NEWA
+		300MG	N022405 002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	PFIZER	10MG/VIAL	A090243 001	May 11, 2010	May	CAHN
----	--------	-----------	-------------	--------------	-----	------

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	PFIZER	20MG/VIAL	A090243	002	May 11, 2010	May	CAHN
----	--------	-----------	---------	-----	--------------	-----	------

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)

VPRIV

>D>	+	SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575	002	Feb 26, 2010	Oct	DISC
-----	---	---------------------	----------------	---------	-----	--------------	-----	------

>A>	@		200 UNITS/VIAL	N022575	002	Feb 26, 2010	Oct	DISC
-----	---	--	----------------	---------	-----	--------------	-----	------

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011	Aug	NEWA
---	-------------------	-------	---------	-----	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834	001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A200834	002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A200834	003	Apr 14, 2011	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421	001	May 06, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078421	002	May 06, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078421	003	May 06, 2011	Apr	NEWA
AB	MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A078789	002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A078789	003	Jun 01, 2011	May	NEWA
AB	ORCHID HLTHCARE	EQ 37.5MG BASE	A091123	001	Jul 11, 2011	Jun	NEWA
AB		EQ 75MG BASE	A091123	002	Jul 11, 2011	Jun	NEWA
AB		EQ 150MG BASE	A091123	003	Jul 11, 2011	Jun	NEWA
AB	TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A090899	002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A090899	003	Jun 01, 2011	May	NEWA
AB	VALEANT INTL	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Apr	NEWA
AB	WOCKHARDT	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078865	002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078865	003	Apr 14, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174	001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090174	002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090174	003	Apr 14, 2011	Apr	NEWA

TABLET; ORAL

EFFEXOR

@	WYETH PHARMS INC	EQ 25MG BASE	N020151	002	Dec 28, 1993	Aug	DISC
@		EQ 37.5MG BASE	N020151	006	Dec 28, 1993	Aug	DISC
@		EQ 50MG BASE	N020151	003	Dec 28, 1993	Aug	DISC
@		EQ 75MG BASE	N020151	004	Dec 28, 1993	Aug	DISC
@		EQ 100MG BASE	N020151	005	Dec 28, 1993	Aug	DISC

VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A078932	001	Dec 14, 2010	Jul	CAHN
AB		EQ 37.5MG BASE	A078932	002	Dec 14, 2010	Jul	CAHN
AB		EQ 50MG BASE	A078932	003	Dec 14, 2010	Jul	CAHN
AB		EQ 75MG BASE	A078932	004	Dec 14, 2010	Jul	CAHN
AB		EQ 100MG BASE	A078932	005	Dec 14, 2010	Jul	CAHN
@	PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008	Aug	DISC

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

	@ PLIVA HRVATSKA DOO	EQ 37.5MG BASE	A078517 002	Jun 13, 2008	Aug	DISC
	@	EQ 50MG BASE	A078517 003	Jun 13, 2008	Aug	DISC
	@	EQ 75MG BASE	A078517 004	Jun 13, 2008	Aug	DISC
	@	EQ 100MG BASE	A078517 005	Jun 13, 2008	Aug	DISC
AB	+	TEVA	EQ 50MG BASE	A076690 003	Aug 03, 2006	Aug CRLD

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

AB	ALKERMES GAINESVILLE	120MG	N019614 001	May 29, 1990	Sep	CAHN
AB		180MG	N019614 003	Jan 09, 1992	Sep	CAHN
AB		240MG	N019614 002	May 29, 1990	Sep	CAHN
	+	360MG	N019614 004	May 10, 1996	Sep	CAHN

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

@	HOSPIRA	2.5MG/ML	A070577 001	Feb 02, 1987	Aug	DISC
---	---------	----------	-------------	--------------	-----	------

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

@	ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986	Aug	DISC
@		120MG	A070468 001	Sep 24, 1986	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

AB	GLENMARK GENERICS	120MG	A090700 001	Aug 03, 2011	Jul	NEWA
AB		180MG	A090700 002	Aug 03, 2011	Jul	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	May	CAHN
		20MG	N022567 002	Jan 21, 2011	May	CAHN
	+	40MG	N022567 003	Jan 21, 2011	May	CAHN
	TROVIS PHARMS	10MG	N022567 001	Jan 21, 2011	Jan	NEWA
		20MG	N022567 002	Jan 21, 2011	Jan	NEWA
	+	40MG	N022567 003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

@	APP PHARMS	1MG/ML	A076401 001	Oct 28, 2003	Jan	DISC
---	------------	--------	-------------	--------------	-----	------

VINCRISTINE SULFATE PFS

AP	+	HOSPIRA	1MG/ML	A071484 001	Apr 19, 1988	Sep CRLD
----	---	---------	--------	-------------	--------------	----------

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	INVAGEN PHARMS	1MG	A090935 001	May 25, 2011	May	NEWA
AB		2MG	A090935 002	May 25, 2011	May	NEWA
AB		2.5MG	A090935 003	May 25, 2011	May	NEWA
AB		3MG	A090935 004	May 25, 2011	May	NEWA
AB		4MG	A090935 005	May 25, 2011	May	NEWA
AB		5MG	A090935 006	May 25, 2011	May	NEWA
AB		6MG	A090935 007	May 25, 2011	May	NEWA
AB		7.5MG	A090935 008	May 25, 2011	May	NEWA
AB		10MG	A090935 009	May 25, 2011	May	NEWA

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN
----	----------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

ZIDOVUDINE

AB	HEC PHARM INC	300MG	A202058	001	Oct 07, 2011	Sep	NEWA
	@ MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011	Feb	NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+	NOVARTIS	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Jun	NEWA
---	----------	-------------------	---------	-----	--------------	-----	------

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016	001	Apr 23, 2007	Feb	CAHN
AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB	ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	Apr	NEWA
AB	SANDOZ	6.25MG	A090107	001	Jul 01, 2011	Jun	NEWA
AB		12.5MG	A090107	002	Jul 01, 2011	Jun	NEWA
AB	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr	NEWA
AB		12.5MG	A078483	002	Jun 06, 2011	Jul	NEWA
	ZOLPIDEM TARTRATE						
AB	ACTAVIS S ATLANTIC	12.5MG	A078179	001	Jun 06, 2011	Sep	NEWA

OTC DRUG PRODUCT LIST - 31ST EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

2-1

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	@ ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008	Aug	DISC
	SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA
	SUN PHARM INDS INC	5MG/5ML	A091327	001	Oct 17, 2011	Oct	NEWA
	TARO	5MG/5ML	A201546	001	May 20, 2011	May	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>	@ ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008	Aug	DISC
	SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA
	SUN PHARM INDS INC	5MG/5ML	A091327	002	Oct 17, 2011	Oct	NEWA
	TARO	5MG/5ML	A201546	002	May 20, 2011	May	NEWA

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011	Aug	NEWA
		10MG	A090142	002	Aug 30, 2011	Aug	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011	Aug	NEWA
		10MG	A090142	004	Aug 30, 2011	Aug	NEWA

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

PHARMASEAL SCRUB CARE

+	CAREFUSION	4%	N019793	001	Dec 02, 1988	Aug	CAHN
---	------------	----	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
---	---------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+	CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
---	---------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+	CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA
---	---------------	-----------------	---------	-----	--------------	-----	------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	APOTEX	100MG	A074948	001	Jun 19, 1998	Sep	CMFD
		200MG	A074948	002	Jul 26, 2002	Sep	CMFD

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

@	ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001	Aug	DISC
---	----------------------	-------------	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

	MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN
--	-------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA
---	-------------------	----------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA
---	-------------------	----------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

+		180MG	N020872	010	Jan 24, 2011	Jan	NEWA
---	--	-------	---------	-----	--------------	-----	------

ALLEGRA HIVES

SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

+		180MG	N020872	009	Jan 24, 2011	Jan	NEWA
---	--	-------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

MYLAN	30MG	A077081	004	Jul 21, 2011	Jul	NEWA
-------	------	---------	-----	--------------	-----	------

TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

MYLAN	30MG	A077081	005	Jul 21, 2011	Jul	NEWA
-------	------	---------	-----	--------------	-----	------

TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

	180MG	A076502	008	Apr 12, 2011	Mar	NEWA
--	-------	---------	-----	--------------	-----	------

MYLAN	60MG	A077081	006	Jul 21, 2011	Jul	NEWA
-------	------	---------	-----	--------------	-----	------

	180MG	A077081	008	Jul 21, 2011	Jul	NEWA
--	-------	---------	-----	--------------	-----	------

TEVA	60MG	A076447	006	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

	180MG	A076447	008	Apr 13, 2011	Mar	NEWA
--	-------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

	180MG	A076502	009	Apr 12, 2011	Mar	NEWA
--	-------	---------	-----	--------------	-----	------

MYLAN	60MG	A077081	007	Jul 21, 2011	Jul	NEWA
-------	------	---------	-----	--------------	-----	------

	180MG	A077081	009	Jul 21, 2011	Jul	NEWA
--	-------	---------	-----	--------------	-----	------

TEVA	60MG	A076447	007	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

	180MG	A076447	009	Apr 13, 2011	Mar	NEWA
--	-------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011	Jan	NEWA
---	-------------------	------------	---------	-----	--------------	-----	------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011	Jan	NEWA
---	-------------------	-------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011	Jun	NEWA
--------------------	-------------	---------	-----	--------------	-----	------

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

AMNEAL PHARMS	100MG/5ML	A200457	001	Aug 18, 2011	Aug	NEWA
---------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

IBUPROFEN

ADVENT PHARMS	200MG	A076460	001	Nov 26, 2003	Jul	CAHN
AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003	Aug	CAHN
	200MG	A076460	001	Nov 26, 2003	May	CAHN
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	Jan	NEWA
	200MG	A091239	001	Feb 01, 2011	Jan	NEWA
MERRO PHARM	200MG	A070985	001	Oct 02, 1987	Jan	CAHN
SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011	Mar	NEWA
	200MG	A091355	001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+ NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991	Jan	CRLD
--------------------	--------------	---------	-----	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

+ TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN
---------------	--------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011	May	NEWA
-----------------	-----------	---------	-----	--------------	-----	------

LORATADINE

TABLET; ORAL

LORATADINE

MYLAN	10MG	A078447	001	Aug 12, 2011	Aug	NEWA
-------	------	---------	-----	--------------	-----	------

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

@ ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997	Aug	DISC
------------------------	----------	---------	-----	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL

PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011	Apr	NEWA
----------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

THEROXIDIL

>A>	EI INC	2%	A078176	001	Nov 09, 2007	Oct	CAHN
>A>		5%	A076239	001	Aug 24, 2004	Oct	CAHN
>D>	HARMONY LABS	2%	A078176	001	Nov 09, 2007	Oct	CAHN
>D>		5%	A076239	001	Aug 24, 2004	Oct	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

GRANULES INDIA	EQ 200MG BASE	A091353 001	Sep 20, 2011	Sep	NEWA
MARKSANS PHARMA	EQ 200MG BASE	A090545 001	Mar 16, 2011	Feb	NEWA
RANBAXY LABS LTD	EQ 200MG BASE	A091183 001	May 20, 2011	May	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

PERRIGO R AND D	EQ 2MG BASE	A091349 001	Jul 20, 2011	Jul	NEWA
	EQ 4MG BASE	A091354 001	Jul 20, 2011	Jul	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID OTC

+ MSD CONSUMER	20MG;1.1GM	N022281 001	Dec 01, 2009	Sep	CAHN
----------------	------------	-------------	--------------	-----	------

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

+ BAYER HLTHCARE	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000	Aug	CAHN
------------------	------------------	-------------	--------------	-----	------

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

ANBEX	65MG	N018664 002	May 12, 2011	Apr	NEWA
-------	------	-------------	--------------	-----	------

PURIFIED WATER

SOLUTION; OPHTHALMIC

PUR-WASH

+ NIAGARA PHARMS	98.3%	N022305 001	Sep 01, 2011	Sep	NEWA
------------------	-------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN	EQ 75MG BASE	A075497 001	Jan 14, 2000	Feb	CAHN
PERRIGO R AND D	EQ 150MG BASE	A091429 001	May 11, 2011	Apr	NEWA
	EQ 150MG BASE	A091429 002	May 11, 2011	Apr	NEWA
SVADS HOLDINGS SA	EQ 150MG BASE	A200536 001	Jun 28, 2011	Jun	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2011

NO OCTOBER 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379 001	5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7868044	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N022502 001	7998467	May 31, 2028	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	7964202	Sep 01, 2024	DP U-1078			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N021747 001	>A> 5405084	Apr 11, 2012	DP		>A> NP	Oct 07, 2014
	>A> 5472143	Sep 29, 2013	DP			
	>A> 5497944	Mar 12, 2013	DP			
	>A> 5662271	Sep 02, 2014	DP			
	>A> 5911851	Sep 29, 2013	DP			
	>A> 5964416	Oct 04, 2016	DP			
	>A> 6007676	Sep 29, 2013	DP			
	>A> 6149054	Dec 19, 2016	DP			
	>A> 6176442	Oct 04, 2016	DP			
	>A> 6453795	Dec 05, 2016	DP			
	>A> 6503362	Sep 29, 2013	DP			
	>A> 6726124	Oct 04, 2016	DP			
	>A> 6846413	Aug 28, 2018	DP			
	>A> 6977042	Aug 28, 2018	DP			
	>A> 6988496	Feb 23, 2020	DP			
	>A> 7104470	Oct 04, 2016	DP			
	>A> 7246615	May 31, 2016	DP			
	>A> 7284474	Aug 26, 2024	DP			
	>A> 7396341	Oct 10, 2026	DP			
	>A> 7802568	Feb 26, 2019	DP			
	>A> 7837235	Mar 13, 2028	DP			
	>A> 7896264	May 26, 2025	DP			
	>A> 7988001	Apr 06, 2021	DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N021762 001	>A> 5994329	Jul 17, 2018	U-647	Y		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2016	DS DP U-878			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 001	RE42462	Oct 07, 2015	DS			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 002	RE42462	Oct 07, 2015	DS			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 005					PC	Jul 02, 2011
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 006					PC	Jul 02, 2011
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N022434 001	>A> 7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 004					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 005					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 006					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021713 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021866 001					I-633	Feb 16, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004					D-130	Feb 04, 2014
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZITHROMYCIN - ZMAX</u>						
N050797 001	7887844	Feb 14, 2024	DP			
<u>AZTREONAM - CAYSTON</u>						
N050814 001					ODE	Feb 22, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8017655	Nov 27, 2012	DS DP			
	>A> 8038988	Aug 25, 2023	DP			
<u>BIMATOPROST - LUMIGAN</u>						
N021275 001	8017655	Nov 27, 2012	DS DP			
<u>BIMATOPROST - LUMIGAN</u>						
N022184 001	8017655	Nov 27, 2012	DS DP			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Aug 13, 2012	DS DP U-1040			
	5196404*PED	Feb 13, 2013				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	7012066	Feb 22, 2022	DS DP U-1128		NCE	May 13, 2016
	7772178	Nov 11, 2027	DP U-1128			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021262 001	>A> 5424078	Jun 13, 2012		Y		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021770 001	>A> 5424078	Jun 13, 2012	DP	Y		
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	7967011	Aug 11, 2021	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001					>A> NP	Oct 28, 2014
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002					>A> NP	Oct 28, 2014
<u>BUPRENORPHINE; NALOXONE - SUBOXONE</u>						
N022410 001	>A> 8017150	Sep 10, 2023	DP			
<u>BUPRENORPHINE; NALOXONE - SUBOXONE</u>						
N022410 002	>A> 8017150	Sep 10, 2023	DP			
<u>CARBAMAZEPINE - CARBAMAZEPINE</u>						
A076697 003					>A> PC	Nov 16, 2011
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 001	5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 002	5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 003	5326570	Jul 23, 2011	U-215			
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5760068	Jun 02, 2015	U-672			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5760068	Jun 02, 2015	U-672			
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7935093	Oct 02, 2027	DP U-1022			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N021441 001	7863287	Feb 28, 2027	DP			
<u>CICLOPIROX - LOPROX</u>						
N020519 001	>A> 7026337	Nov 21, 2016	U-714			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	7981909	Sep 16, 2017	U-1162			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CLOBAZAM - ONFI</u>						
N202067 001					>A> NCE	Oct 21, 2016
<u>CLOBAZAM - ONFI</u>						
N202067 002					>A> NCE	Oct 21, 2016
<u>CLOBAZAM - ONFI</u>						
N202067 003					>A> NCE	Oct 21, 2016
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP		M-61	May 06, 2014
	4847265*PED	May 17, 2012			PED	Nov 06, 2014
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP		M-61	May 06, 2014
	4847265*PED	May 17, 2012			PED	Nov 06, 2014
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Feb 17, 2029	U-1161			
	7981938	Oct 06, 2028	U-1166			
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	7230098	Feb 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027	U-1179		>A> ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	7230098	Feb 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027	U-1179		>A> ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	7879349	Jun 01, 2024	DP U-1152			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 001	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 002	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	>A> 8007826	May 26, 2027	U-1030			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8003673	Sep 04, 2028	U-1180			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		D-118	Oct 21, 2011
	5843946*PED	Jun 01, 2016			I-578	Oct 21, 2011
	6037157	Jun 26, 2016	U-935		NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			PED	Jun 13, 2014
	6248775	Aug 13, 2014	DS		PED	Jun 18, 2012
	6248775*PED	Feb 13, 2015			PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DASATINIB - SPRYCEL</u>						
N021986 005	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
<u>DASATINIB - SPRYCEL</u>						
N021986 006	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
<u>DEFERIPRONE - FERRIPROX</u>						
N021825 001					>A> NCE	Oct 14, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 007	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 008	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005 001	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001	>A> 6114319	May 18, 2019	DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	7915307	Aug 24, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	7915307	Aug 24, 2027	U-620			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2012	DS DP U-992			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5922695	Jul 25, 2017	DS U-750			
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP U-750			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-750			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-750			
	6043230*PED	Jan 25, 2018				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> NCE	Nov 20, 2013
	>A> 7160870	Dec 08, 2021	DS DP U-930		>A> ODE	Nov 20, 2015
	>A> 7332481	May 24, 2021	U-930			
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-930			
<u>EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS U-257			
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP U-257			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP			
	5977089*PED	Jan 25, 2018	U-257			
	6043230	Jul 25, 2017	U-257			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-257			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-248			
	6043230	Jul 25, 2017	DP U-541			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-248			
<u>EPINASTINE HYDROCHLORIDE - EPINASTINE HYDROCHLORIDE</u>						
A090870 001					PC	Oct 29, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101 001					M-86 PED	Jun 18, 2012 Dec 18, 2012
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
A078965 001					>A> PC	Sep 21, 2011
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019				
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Dec 13, 2020	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
					>A> ODE	May 05, 2018
					ODE	Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
					>A> ODE	May 05, 2018
					ODE	Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019			I-638	May 05, 2014
					NCE	Mar 30, 2014
					>A> ODE	May 05, 2018
					ODE	Oct 29, 2017
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>EZETIMIBE - ZETIA</u>						
N021445 001	5846966	Sep 21, 2013	U-474			
	5846966	Sep 21, 2013	U-473			
	5846966	Sep 21, 2013	U-1172			
	7612058	Jan 25, 2022	U-1173			
	7612058	Jan 25, 2022	U-1027			
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-1173			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZOABINE - POTIGA</u>						
N022345 001					NCE	Jun 10, 2016
<u>EZOABINE - POTIGA</u>						
N022345 002					NCE	Jun 10, 2016
<u>EZOABINE - POTIGA</u>						
N022345 003					NCE	Jun 10, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZOGBINE - POTIGA</u>						
N022345	004				NCE	Jun 10, 2016
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001				M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	002				M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	003				M-98	Jan 31, 2014
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519	001				NC	Apr 23, 2014
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695	001	7863331	Aug 08, 2020	U-1107		
		7863331	Aug 08, 2020	U-1106		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695	003	7863331	Aug 08, 2020	U-1107		
		7863331	Aug 08, 2020	U-1106		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418	001	7915247	Aug 20, 2027	U-1061		
		7915247	Aug 20, 2027	U-1059		
		7915247	Aug 20, 2027	U-1000		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418	002	7915247	Aug 20, 2027	U-1061		
		7915247	Aug 20, 2027	U-1059		
		7915247	Aug 20, 2027	U-1000		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	001	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	002	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	003	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	004	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510	005	6759059	Sep 24, 2019	DP U-767		
		6761910	Sep 24, 2019	DP U-767		
		7910132	Sep 24, 2019	DP U-767		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002					NDF	Jun 30, 2014
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	7384980	May 11, 2019	DS DP U-913			
	>A> 7807715	Jun 07, 2027	DP U-913			
	7855230	May 11, 2019	U-913			
	7985772	May 11, 2019	DS DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	7384980	May 11, 2019	DS DP U-913			
	>A> 7807715	Jun 07, 2027	DP U-913			
	7855230	May 11, 2019	U-913			
	7985772	May 11, 2019	DS DP U-913			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 007	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 010	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 008	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 009	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N020872 005	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N021909 002	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N201373 001	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N020872 006	5578610	Nov 26, 2013	DS DP			U-1160
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015		DP		
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015		DP		
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017				U-1160
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015		DP		
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012				U-1160
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012				U-1160
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS			U-1160
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N021909 003	5578610	Nov 26, 2013	DS DP			U-1158
	5738872	Feb 28, 2015		DP		
	6037353	Mar 14, 2017				U-1158
	6187791	May 11, 2012				U-1158
	6399632	May 11, 2012				U-1158
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N201373 002	5578610	Nov 26, 2013	DS DP			U-1157
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017				U-1157
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012				U-1157
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012				U-1157
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N020786 002	5578610	Nov 26, 2013	DS DP U-1159			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1159			
	6037353*PED	Sep 14, 2017	U-138			
	6039974	Jul 31, 2018	DP			
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1159			
	6187791*PED	Nov 11, 2012	U-138			
	6399632	May 11, 2012	U-1159			
	6399632*PED	Nov 11, 2012	U-468			
	7135571	May 18, 2014	DS U-1159			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N021704 002	5578610	Nov 26, 2013	DS DP U-1159			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1159			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1159			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1159			
	6399632*PED	Nov 11, 2012				
	6613357	Dec 25, 2020	DP U-1159			
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N201699 001	7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027	U-319			
<u>FINGOLIMOD - GILENYA</u>						
N022527 001					>A> M-106	Jul 20, 2014
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	>A> 6315173	Dec 23, 2017	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 001	>A> 7446090	Aug 23, 2019	DP		D-133	Aug 22, 2014
	>A> 7563763	Aug 23, 2019	U-993			
	>A> 7563763	Aug 23, 2019	U-1183			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 002	>A> 7446090	Aug 23, 2019	DP		D-133	Aug 22, 2014
	>A> 7563763	Aug 23, 2019	U-993			
	>A> 7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 003	>A> 5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	>A> 5929028	Jan 14, 2018	DP U-567			
	>A> 7446090	Aug 23, 2019	DP			
	>A> 7563763	Aug 23, 2019	U-993			
	>A> 7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 004	>A> 5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	>A> 5929028	Jan 14, 2018	DP U-567			
	>A> 7446090	Aug 23, 2019	DP			
	>A> 7563763	Aug 23, 2019	U-993			
	>A> 7563763	Aug 23, 2019	U-1183			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 001	5691336	Mar 04, 2019	DS DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5691336	Mar 04, 2019	DS DP			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	>A> 6204257	Aug 07, 2018	DS DP U-945			
	>A> 6872838	Aug 07, 2018	DS			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			M-103	May 17, 2014
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	7456160*PED	Jul 09, 2021			PED	Mar 09, 2014
<u>GABAPENTIN - GABAPENTIN</u>						
A078974 001					PC	Aug 22, 2011
<u>GABAPENTIN - GRALISE</u>						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	6818787	Nov 06, 2022	DS DP		NCE	Apr 06, 2016
	>A> 8026279	Nov 10, 2016	DS DP			
<u>GADOBUTROL - GADAVIST</u>						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015			U-1112	
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015			U-1112	
	>A> 8017105	May 26, 2015	DS			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015			U-1112	
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015			U-1112	
	>A> 8017105	May 26, 2015	DS			
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 001					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 002					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A079183 001					PC	May 14, 2011
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 001					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 002					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 003					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 004					M-102	Apr 29, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 001					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002					I-635	Feb 25, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004					I-635	Feb 25, 2014
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N022076 001	7981877	Jan 23, 2025	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945 001					ODE	Feb 03, 2018
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N022150 001	>A> 5648333	Jul 15, 2014	DS DP U-1187		NCE >A> ODE	Aug 25, 2016 Aug 25, 2018
<u>ILOPERIDONE - FANAPT</u>						
N022192 001	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 002	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 003	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 004	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 005	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 006	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 007	RE39198	Nov 15, 2016	DS DP U-971			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001					I-636	Mar 24, 2014
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002					NS	Jul 15, 2014
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N020314 001	5384113	Jan 24, 2012	DP			
	5753627	May 19, 2015		U-1125		
	5776894	Jul 07, 2015	DS DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	7918833	Sep 23, 2027	DP			
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780 001					NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780 005					NR	Mar 25, 2014
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001					NCE	Jan 14, 2016
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6670384	Jan 23, 2022	DP U-960		>A> M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-959		NCE	Oct 16, 2012
	6670384*PED	Jul 23, 2022			>A> PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958		PED	Apr 16, 2013
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP U-960		>A> M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-959		NCE	Oct 16, 2012
	6670384*PED	Jul 23, 2022			>A> PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958		PED	Apr 16, 2013
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>KETOCONAZOLE - KETOCONAZOLE</u>						
A091550 001					>A> PC	Feb 21, 2012
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338	May 24, 2027	U-1181			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 001	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 002	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 003	7919115	Jan 04, 2029	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 004	7919115	Jan 04, 2029	DS DP			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1165	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1165	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	7968569	Oct 07, 2023			U-1165	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1165	
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 003	6036976	Dec 13, 2016	DP		D-132	Jun 17, 2014
	7429559	Dec 13, 2016	DP		NS	Jun 17, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 002					>A> M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 005					>A> M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 006					>A> M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 007	5575987	Sep 02, 2013	DP		NP	Aug 15, 2014
	5631020	May 20, 2014	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 008	5480656	Jan 02, 2013	DP		NP	Aug 15, 2014
	5575987	Sep 02, 2013	DP			
	5631020	May 20, 2014	DP			
	5643607	Jul 01, 2013	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091093 001					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091093 002					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091261 002					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091285 001					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091285 002					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091291 002					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091399 001					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091399 002					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091430 001					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091430 002					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091557 001					>A> PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091557 002					>A> PC	Mar 10, 2012
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001					I-637 >A> ODE	Apr 29, 2014 Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Dec 31, 2019	DS DP		I-637 >A> ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Dec 31, 2019	DS DP		I-637 >A> ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017		U-774	NCE	May 02, 2016
	6890898	Feb 02, 2019		U-493		
	7078381	Feb 02, 2019		U-493		
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019		U-493		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	>A> 8025899	Sep 26, 2027	DP			
	>A> 8025899*PED	Mar 26, 2028				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	>A> 8025899	Sep 26, 2027	DP			
	>A> 8025899*PED	Mar 26, 2028				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N200738 001					NDF PED	Apr 15, 2014 Oct 15, 2014
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 001	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	>A> 8026393	Oct 25, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	>A> 8026393	Oct 25, 2027	DP			
<u>MALATHION - OVIDE</u>						
N018613 001	7977324	Aug 14, 2026	DP			
<u>MESALAMINE - LIALDA</u>						
N022000 001					I-640	Jul 14, 2014
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A090692 001					>A> PC	Mar 28, 2012
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A090692 002					>A> PC	Mar 28, 2012
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	>A> 6559158	Nov 03, 2017	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	>A> 6559158	Nov 03, 2017	U-1185		>A> NCE	Apr 24, 2013
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806 001	7456207	Sep 22, 2024	DP			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	7919483	Feb 28, 2027	U-1078			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001					M-99	Jan 19, 2014
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001	>A> 8007830	Oct 24, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	7671070*PED	Mar 29, 2020				
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	6025389	Oct 20, 2014	DP U-1122			
<u>NALTREXONE - VIVITROL</u>						
N021897 001	7919499	Oct 15, 2029	U-1124			
	7919499	Oct 15, 2029	U-1123			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N021926 001	>A> 8022095	Aug 14, 2017	DP U-867			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 002	>A> 6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 003	>A> 6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 004	>A> 6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 005	>A> 6545040	Dec 17, 2021	DP U-3			
<u>NELARABINE - ARRANON</u>						
N021877 001	>A> 5424295	Jun 13, 2017	DS DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 002	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7998506	Sep 20, 2013	U-1141			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 003	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7998506	Sep 20, 2013	U-1141			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 004	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7998506	Sep 20, 2013	U-1141			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	>A> 7169791	Jul 04, 2023	DS DP U-836		I-627 NCE ODE	Jun 17, 2014 Oct 29, 2012 Oct 29, 2014
<u>NITROGLYCERIN - RECTIV</u>						
N021359 001					NP	Jun 21, 2014
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 001					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 002					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 003					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 004					NPP PED	Dec 04, 2012 Jun 04, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861 001	7977376	Feb 02, 2023	DP			
	7977376*PED	Aug 02, 2023	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	DS		U-376	
	5763483	Dec 27, 2016	DS		U-1113	
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 002	>A> 5763483	Dec 27, 2016	DS DP		U-1113	
	>A> 5763483*PED	Jun 27, 2017				
	>A> 5866601	Feb 02, 2016	DS DP			
	>A> 5866601*PED	Aug 02, 2016				
	>A> 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	7923536	Dec 09, 2023			U-1117	
	RE41884	Aug 14, 2016			U-1117	
<u>PALIPERIDONE - INVEGA</u>						
N021999 001					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 002					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 003					NPP	Apr 06, 2014
					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 004					NPP	Apr 06, 2014
					PED	Oct 06, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE - INVEGA</u>						
N021999	006				NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	001	>A> 5254556	Oct 27, 2012	DS DP U-543		
		>A> 5254556*PED	Apr 27, 2013			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	002	>A> 5254556	Oct 27, 2012	DS DP U-543		
		>A> 5254556*PED	Apr 27, 2013			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	003	>A> 5254556	Oct 27, 2012	DS DP U-543		
		>A> 5254556*PED	Apr 27, 2013			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	004	>A> 5254556	Oct 27, 2012	DS DP U-543		
		>A> 5254556*PED	Apr 27, 2013			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	005	>A> 5254556	Oct 27, 2012	DS DP U-543		
		>A> 5254556*PED	Apr 27, 2013			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372	001	7947724	Jan 30, 2024	DP		
		7947725	Jan 30, 2024	DP		
		7960424	Jan 30, 2024	DP		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372	002	7947724	Jan 30, 2024	DP		
		7947725	Jan 30, 2024	DP		
		7960424	Jan 30, 2024	DP		
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A091427	001				PC	Nov 01, 2011
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462	001				M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462	002				M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PERFLUTREN - DEFINITY</u>						
N021064	001	5527521	Feb 22, 2015	DP U-665		
		5585112	Dec 17, 2013	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088	001	6149938	Jul 23, 2018	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088	002	6149938	Jul 23, 2018	DP		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684	001	6900184	Apr 14, 2023	DP U-282		
		7915229	Apr 14, 2023	DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 001					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 002					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 003					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 005					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 006					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 007					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 006	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 007	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 001	>A> 5288726	Apr 14, 2017	DS DP U-991			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 002	>A> 5288726	Apr 14, 2017	DS DP U-991			
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N020815 001	>A> 8030330	Mar 10, 2017	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP			
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6369062	May 27, 2019	DP	Y		
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
<u>RIBAVIRIN - COPEGUS</u>						
N021511 001					NPP	Aug 09, 2014
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-1153			
	7638522	Apr 14, 2023	DP			
<u>RITONAVIR - NORVIR</u>						
N020659 001	>A> 5635523	Jul 30, 2013	U-190			
	>A> 5635523*PED	Jan 30, 2014				
	>A> 5674882	Jul 30, 2013	U-688			
	>A> 5674882*PED	Jan 30, 2014				
<u>RITONAVIR - NORVIR</u>						
N020945 001	>A> 5635523	Jul 30, 2013	U-347			
	>A> 5635523*PED	Jan 30, 2014				
	>A> 5674882	Jul 30, 2013	U-895			
	>A> 5674882*PED	Jan 30, 2014				
<u>RITONAVIR - NORVIR</u>						
N022417 001	>A> 5635523	Jul 30, 2013	U-688			
	>A> 5635523*PED	Jan 30, 2014				
	>A> 5674882	Jul 30, 2013	U-688			
	>A> 5674882*PED	Jan 30, 2014				
<u>RIVAROXABAN - XARELTO</u>						
N022406 001	7157456	Feb 08, 2021	DS DP		NCE	Jul 01, 2016
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	>A> 5298520	Jun 29, 2012	U-240			
	>A> 5298520*PED	Dec 29, 2012				
	>A> 5602162	Feb 11, 2014		Y		
	>A> 5602162*PED	Aug 11, 2014				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	>A> 5298520	Jun 29, 2012	U-240			
	>A> 5298520*PED	Dec 29, 2012				
	>A> 5602162	Feb 11, 2014		Y		
	>A> 5602162*PED	Aug 11, 2014				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	>A> 5298520	Jun 29, 2012	U-240			
	>A> 5298520*PED	Dec 29, 2012				
	>A> 5457895	Oct 01, 2013				
	>A> 5457895*PED	Apr 01, 2014				
	>A> 5602162	Feb 11, 2014	U-240	Y		
	>A> 5602162*PED	Aug 11, 2014				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	>A> 5298520	Jun 29, 2012	U-240			
	>A> 5298520*PED	Dec 29, 2012				
	>A> 5457895	Oct 01, 2013				
	>A> 5457895*PED	Apr 01, 2014				
	>A> 5602162	Feb 11, 2014	U-240	Y		
	>A> 5602162*PED	Aug 11, 2014				
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Jul 06, 2012	DS DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 001	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 002	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 003	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 004	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 005	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	7927624	Dec 02, 2021	DP U-20			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 002	7030152	Apr 02, 2018	U-1032			
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
ROSUVASTATIN CALCIUM - CRESTOR								
N021366 003	7030152*PED	Oct	02, 2018	U-1032				
	7964614	Apr	02, 2018					
	7964614*PED	Oct	02, 2018					
ROSUVASTATIN CALCIUM - CRESTOR								
N021366 004	7030152*PED	Oct	02, 2018	U-1032				
	7964614	Apr	02, 2018					
	7964614*PED	Oct	02, 2018					
ROSUVASTATIN CALCIUM - CRESTOR								
N021366 005	7030152*PED	Oct	02, 2018	U-1032				
	7964614	Apr	02, 2018					
	7964614*PED	Oct	02, 2018					
ROTIGOTINE - NEUPRO								
N021829 001	6699498	Nov	27, 2020	DP				
	>A> 6884434	Mar	30, 2021	DP				
ROTIGOTINE - NEUPRO								
N021829 002	6699498	Nov	27, 2020	DP				
	>A> 6884434	Mar	30, 2021	DP				
ROTIGOTINE - NEUPRO								
N021829 003	6699498	Nov	27, 2020	DP				
	>A> 6884434	Mar	30, 2021	DP				
RUFINAMIDE - BANZEL								
N021911 001	6740669	Nov	14, 2022	DS DP				
RUFINAMIDE - BANZEL								
N021911 002	6740669	Nov	14, 2022	DS DP				
RUFINAMIDE - BANZEL								
N021911 003	6740669	Nov	14, 2022	DS DP				
RUFINAMIDE - BANZEL								
N201367 001	6740669	Aug	17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015	
SAPROPTERIN DIHYDROCHLORIDE - KUVAN								
N022181 001	7947681	Nov	17, 2024	U-1156				
	8003126	Nov	16, 2025					
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA								
N022350 001	7951400	Nov	30, 2028	DP				
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA								
N022350 002	7951400	Nov	30, 2028	DP				
SEVELAMER CARBONATE - RENVELA								
N022127 001	7985418	Oct	27, 2025	DP				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	>A> 6303661	Apr 24, 2017	U-1188			
	>A> 6699871	Jul 26, 2022	DS DP			
	>A> 6890898	Feb 02, 2019	U-1191			
	>A> 6890898	Feb 02, 2019	U-1190			
	>A> 6890898	Feb 02, 2019	U-1189			
	>A> 7078381	Feb 02, 2019	U-1188			
	>A> 7125873	Jul 26, 2022	DP U-1193			
	>A> 7125873	Jul 26, 2022	DP U-1192			
	>A> 7125873	Jul 26, 2022	DP U-1190			
	>A> 7125873	Jul 26, 2022	DP U-1189			
	>A> 7326708	Apr 11, 2026	DS DP U-1188			
	>A> 7459428	Feb 02, 2019	U-1189			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	>A> 6303661	Apr 24, 2017	U-1188			
	>A> 6699871	Jul 26, 2022	DS DP			
	>A> 6890898	Feb 02, 2019	U-1191			
	>A> 6890898	Feb 02, 2019	U-1190			
	>A> 6890898	Feb 02, 2019	U-1189			
	>A> 7078381	Feb 02, 2019	U-1188			
	>A> 7125873	Jul 26, 2022	DP U-1193			
	>A> 7125873	Jul 26, 2022	DP U-1192			
	>A> 7125873	Jul 26, 2022	DP U-1190			
	>A> 7125873	Jul 26, 2022	DP U-1189			
	>A> 7326708	Apr 11, 2026	DS DP U-1188			
	>A> 7459428	Feb 02, 2019	U-1189			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	>A> 6303661	Apr 24, 2017	U-1188			
	>A> 6699871	Jul 26, 2022	DS DP			
	>A> 6890898	Feb 02, 2019	U-1191			
	>A> 6890898	Feb 02, 2019	U-1190			
	>A> 6890898	Feb 02, 2019	U-1189			
	>A> 7078381	Feb 02, 2019	U-1188			
	>A> 7125873	Jul 26, 2022	DP U-1193			
	>A> 7125873	Jul 26, 2022	DP U-1192			
	>A> 7125873	Jul 26, 2022	DP U-1190			
	>A> 7125873	Jul 26, 2022	DP U-1189			
	>A> 7326708	Apr 11, 2026	DS DP U-1188			
	>A> 7459428	Feb 02, 2019	U-1189			
<u>SINECATECHINS - VEREGEN</u>						
N021902 001	7858662	Oct 02, 2026	DP U-172			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N201444 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7897623	Jan 12, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPINOSAD - NATROBA</u>						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 28, 2026	DP			
	7901385	Jul 31, 2026	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003	7125905	Feb 15, 2021	DS DP		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>TADALAFIL - CIALIS</u>						
N021368 001	>A> 6140329	Jul 11, 2016	DP U-155		>A> I-642	Oct 07, 2014
	>A> 6140329	Jul 11, 2016	DP U-1184		>A> I-641	Oct 07, 2014
	>A> 6821975	Nov 19, 2020	DS DP U-614			
	>A> 6821975	Nov 19, 2020	DS DP U-533			
	>A> 6821975	Nov 19, 2020	DS DP U-1184			
	>A> 6943166	Apr 26, 2020	U-614			
	>A> 6943166	Apr 26, 2020	U-155			
	>A> 6943166	Apr 26, 2020	U-1184			
	>A> 7182958	Apr 26, 2020	DP U-155			
	>A> 7182958	Apr 26, 2020	DP U-1184			
<u>TADALAFIL - CIALIS</u>						
N021368 002					>A> I-642	Oct 07, 2014
					>A> I-641	Oct 07, 2014
<u>TADALAFIL - CIALIS</u>						
N021368 003					>A> I-642	Oct 07, 2014
					>A> I-641	Oct 07, 2014
<u>TADALAFIL - CIALIS</u>						
N021368 004					>A> I-642	Oct 07, 2014
					>A> I-641	Oct 07, 2014
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 001	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 002	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 003	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	>A> 6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	>A> 6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	>A> 6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	>A> 6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	>A> 6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3</u>						
N019882 001	5573748	Nov 12, 2013	DP			
<u>TELAPREVIR - INCIVEK</u>						
N201917 001					NCE	May 23, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TELMISARTAN - MICARDIS</u>						
N020850 002	7998953	Jun 06, 2020	U-1177			
	8003679	Oct 06, 2022	U-1176			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	>A> 8026276	Jan 20, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS U-250		I-569	Aug 11, 2011
	5922695	Jul 25, 2017	DS U-256		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-250		PED	Feb 11, 2012
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TESTOSTERONE - ANDRODERM</u>						
N020489 003					>A> NS	Oct 20, 2014
<u>TESTOSTERONE - ANDRODERM</u>						
N020489 004					>A> NS	Oct 20, 2014
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 001	6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
<u>TESTOSTERONE - FORTESTA</u>						
N021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	7935690	Apr 21, 2023	U-1009			
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>TICAGRELOR - BRILINTA</u>						
N022433 001	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	6908928	Sep 24, 2021	DS DP U-762			
	6908928	Sep 24, 2021	DS DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
	>A> 8022082	Jan 19, 2026	DP U-1186			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 001	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 002	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 003	7988998	Oct 27, 2023	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 001	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 002	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 003	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 004	7999007	Mar 29, 2029	DP U-1174			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIAMCINOLONE ACETONIDE - NASACORT AQ</u>						
N020468 001	7977045	Jul 03, 2016	DP U-896			
<u>VANDETANIB - VANDETANIB</u>						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VANDETANIB - VANDETANIB</u>						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 001					M-105	Jul 22, 2014
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 002					M-105	Jul 22, 2014
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	7504509	Oct 22, 2026	DS DP		NCE	Aug 17, 2016
	7863288	Jun 20, 2029	DS DP		>A> ODE	Aug 17, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	>A> 7652069	Mar 04, 2023	DP			
	>A> RE38506	Nov 29, 2012	DS DP			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	7932241	Feb 05, 2028	DP			
	7932241*PED	Aug 05, 2028				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 003	4939130	Sep 02, 2012	DS DP U-53			
	4939130*PED	Mar 02, 2013				
	7932241	Feb 05, 2028	DP			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>